Can a council of agents make reasonable predictions?

I retain my initial probabilities: the discussion clarified interpretation but supplied no new evidence warranting a change. The June hold after three increases, with conditions judged 'probably somewhat restrictive,' anchors another pause while the RBA assesses policy lags (D01–D02); oil easing and housing softness were already June inputs, not subsequent confirmation. The July 29 release reported June headline inflation easing to 3.8% but annual trimmed-mean inflation remaining 3.6%, leaving a meaningful tightening risk and little basis for a cut (D03). Positive June-quarter spending volumes, reported August 4 before the cutoff, and June employment growth, reported July 23 with survey-weighting caveats, indicate resilience rather than an urgent need to ease (D04–D05). No market pricing, economist poll, or expectations benchmark was found, so I cannot label these releases inflation surprises or claim consensus support; the limited evidence favors holding without making it near-certain.

Unchanged remains the mode. The Board held at 4.35% on June 16 explicitly to assess the lags from three earlier increases and the energy shock, and judged conditions "probably somewhat restrictive" with the rate near the upper end of uncertain neutral estimates (D01, D02). The genuinely new information since then is mildly mixed, not decisive: headline CPI eased 4.0%→3.8% with the monthly index down 0.1% but trimmed mean unchanged at 3.6%, still above the band (D03); employment +76.3k and unemployment 4.4%, discounted for the ABS reweighting of ~6% of the sample (D04); June-quarter spending volumes +0.7%, +2.4% y/y (D05). The oil easing and softer housing in D02 were already inputs to the June hold and should not be double-counted as post-pause disinflationary news — a correction the board accepted and I agree with. Tails are asymmetric. A cut eight weeks after a pause, with underlying inflation more than half a point above the top of the band, employment expanding and real spending positive, would be a regime change rather than a data-driven step: 5%, essentially covering a shock or a reaction function I cannot see. I keep the hike tail at a quarter rather than the mid-teens others prefer. The relevant reference class is not "central banks hold most meetings" but "bank pauses mid-cycle to assess lags with underlying inflation stalled above target and activity firm." From outside the corpus: RBA paused April 2023 then hiked in May, paused July–October then hiked in November; the Fed paused June 2023 and hiked in July; the BoC paused in January 2023 and resumed in June. Resumption on nothing more dramatic than "underlying inflation stopped falling" happens in roughly a third of such cases, and trimmed mean stalling at 3.6% is exactly that signal. August is also the natural quarterly forecast meeting for delivering a move. Offsetting this, the corpus contains no market pricing, no wage data and no post-June RBA communication, which is why I do not concentrate above ~70% on hold.

At the June 16 meeting, the RBA held the cash rate target at 4.35% after three prior increases, characterizing conditions as 'probably somewhat restrictive' and pausing to assess the lagged transmission of monetary tightening and the energy shock. Since then, June inflation data showed headline CPI declining from 4.0% to 3.8% y/y (-0.1% m/m) and trimmed-mean inflation steady at 3.6%, while global oil prices eased and housing softened. This does not provide the catalyst needed to break the pause with an immediate hike, making an unchanged decision at 4.35% the modal outcome. However, because trimmed-mean inflation remains above the 2–3% target, household spending volumes grew 0.7% in Q2, and employment expanded strongly, the Board retains a tightening bias; August being a full forecast-round meeting leaves a meaningful hike tail (~17%). Conversely, a rate cut is virtually off the table (~3%) given persistent underlying inflation and resilient activity.

June 16 the RBA held 4.35% after three hikes, called conditions probably somewhat restrictive and the cash rate near the top of uncertain neutral estimates, and paused to assess lags and the energy shock (D01–D02). That is wait-and-see, not a live tightening bias. Subsequent data (D03–D05) do not force a move: headline CPI 4.0%→3.8% with monthly −0.1%, trimmed mean stuck at 3.6% (still above 2–3%), employment +76.3k / UR 4.4% (discount the size for ABS reweighting of ~6% of the sample), spending volumes +0.7% in the June quarter. Oil easing and softer housing/credit were already June inputs (D02), so they are not new confirming news. A cut is hard to square with inflation still judged too high and activity not breaking—thin tail only. A hike remains the fatter residual: sticky 3.6% trimmed mean plus capacity-pressure language, and mid-cycle pauses have sometimes resumed (2023 RBA/Fed/BoC), but those resumes came with much hotter underlying inflation than 3.6% after a monthly CPI decline. No SoMP, wages, or market pricing in the corpus, which fattens hold rather than a 25%+ hike. Hold is the modal outcome.

I raised the hold probability from my first ballot because the June pause was explicit—after three hikes, the Board wanted to assess lagged effects—and the genuinely subsequent inflation data showed headline easing and trimmed-mean inflation unchanged rather than accelerating. I retain a substantial hike tail because 3.6% trimmed-mean inflation remains above target, real spending grew, the labour market print was firm despite its measurement caveat, and recent central-bank cycles show that pauses can be followed by resumed tightening. A cut is nearly incoherent only eight weeks after this pause with inflation and activity still this firm.

No topline exists in the frozen corpus — the latest item is the CARDIO-TTRansform design paper (Circ Heart Failure, available 2026-05-10, ESC-HF May 2026), still written prospectively. So this is a forecast of a pending readout. Framework: DESIGN_05 states 1,432 randomized and dosed and "≈85% power to test a 20% reduction in the primary composite end point… at α=0.05" for the Week-140 FAS composite of CV mortality plus recurrent CV events (LWYY). That fixes the implied precision: SE(log HR) = 0.2231/(1.96+1.036) ≈ 0.0745, giving power ~97% at HR 0.75, 85% at 0.80, ~59% at 0.85, ~29% at 0.90. The question therefore reduces to a distribution over the true blended hazard ratio, run through that curve. Two things changed my number during discussion. First, Panelist 5 corrected my SE arithmetic (I had used the wrong z for β and posted 0.088); the true curve is materially kinder in the 0.82–0.88 band where my swing mass sat, which moved me from ~0.65 to ~0.71. Second, Panelists 5 and 3 showed that DESIGN_04 codes undetermined/indeterminate deaths as cardiovascular, so my CV-versus-all-cause mortality mismatch point was largely wrong and I withdrew it. Upside: TTR silencing is validated in this exact indication and endpoint type — HELIOS-B vutrisiran HR 0.72 (0.56–0.93, P=0.01) overall — eplontersen delivers comparable ~80% knockdown, the trial is >2× HELIOS-B, runs ~32 months, and counts urgent HF visits as well as hospitalizations. Every adequately sized, adequately long ATTR-CM outcome trial to date has hit its primary. Downside, still not resolved by the board: (1) unrestricted stabilizer use from randomization onward including placebo-arm starts — the design paper advertises this as a differentiator versus HELIOS-B, and the sponsor promoted the baseline-stabilizer analysis to a hierarchical secondary, which reads like an expectation of a large on-stabilizer share; attenuation of the relative effect is exactly what blinded upsizing cannot fix; (2) a deliberately severe tail (no NT-proBNP or NAC-stage cap, NYHA III, 6MWT floor cut to 100 m "to include more participants with severe disease"), which adds events at a plausibly weaker HR; (3) event assumptions already revised downward twice, so a further undershoot would leave the achieved SE worse than designed. Nobody can quote the actual stabilizer proportion — the corpus has no CARDIO baseline characteristics — so both "35–50% monotherapy" and "nearly everyone on stabilizer" are scenarios, and that irreducible uncertainty argues against the 80% camp. Mixing my HR distribution (25% at 0.70–0.75, 30% at 0.75–0.82, 25% at 0.82–0.88, 13% at 0.88–0.95, 7% ≥0.95) against the corrected power curve gives ~0.71; I shade to 0.70 for realized-precision risk.

HELIOS-B strongly validated hepatic TTR silencing in ATTR-CM, demonstrating a significant reduction in mortality and recurrent CV events in the overall population (HR 0.72, p=0.01). Eplontersen produces comparable ~80–85% TTR reduction. CARDIO-TTRansform's expansion to 1,432 treated patients restores ~85% power at an HR of 0.80 (implied SE ≈ 0.0745) for the primary composite of CV mortality (including indeterminate deaths) and recurrent CV clinical events through Week 140 under the LWYY model. However, unrestricted real-world background stabilizer use and inclusion of more advanced disease (NYHA Class III, no NT-proBNP ceiling) risk diluting the incremental treatment effect toward HR 0.81–0.84, where detection power begins to drop steeply. Integrating over a plausible true effect size distribution centered around HR ~0.80 yields a calibrated ~73% probability of achieving prespecified statistical significance on the primary endpoint in the overall FAS population.

No CARDIO-TTRansform topline exists as of 2026-07-01; the May 2026 design paper still describes NCT04136171 as ongoing, 1,432 dosed, primary = CV death plus recurrent CV events through week 140 in the FAS (LWYY, α=0.05), ~85% power for a 20% reduction after two blinded upsizings. HELIOS-B is the binding analog: vutrisiran met a nearly identical recurrent-event composite overall (HR 0.72, p=0.01). Eplontersen knockdown is comparable (−81.7% in NEURO-TTRansform). That largely settles that hepatic TTR silencing works in ATTR-CM. Design-implied power is high if the blended HR is ≤0.80 (~85% at 0.80, ~97% at 0.75). The residual miss risk is not biology but effect size in this protocol: unrestricted stabilizer use from randomization (including placebo-arm starts), which blinded N increases cannot repair, plus a sicker tail (no NT-proBNP/NAC cap; 6MWT floor cut to 100 m). The corpus does not report the actual stabilizer share, so a true HR of 0.82–0.88 remains plausible and is where power falls toward a coin flip. Hierarchical promotion of the baseline-stabilizer analysis is consistent with expecting that share to be large. A monotherapy or subgroup win does not count as Yes. Those two channels keep me off ~80% and at 70% yes / 30% no on a statistically significant overall FAS primary in the first unambiguous public topline.

HELIOS-B is strong same-class validation: vutrisiran significantly reduced the overall recurrent death/CV-event composite (HR 0.72), while eplontersen produces comparable roughly 82% TTR lowering and has demonstrated clinical activity in ATTR disease. CARDIO-TTRansform also has 1,432 treated participants and was designed for about 85% power at a true rate ratio of 0.80; the corrected normal approximation implies about 97% power at 0.75 and 59% at 0.85. I reduced my initial Yes estimate from 81% to 78% after the discussion highlighted a genuine transportability risk: CARDIO deliberately includes a more severe tail than HELIOS-B (no NT-proBNP/NAC-stage cap and a 100 m 6MWT floor), where preventing new TTR production may have less effect on established disease. Unrestricted stabilizer initiation could also attenuate the incremental contrast, although the actual stabilizer proportion and a material negative interaction are not established in the corpus. Those risks leave meaningful failure probability, but the validated mechanism, positive clinical analogue, broad recurrent-event endpoint, and large sample still make success substantially more likely.

I retain 77%: discussion clarified the uncertainties but supplied no new evidence that changes my original assessment. HELIOS-B demonstrated overall clinical benefit from hepatic TTR silencing (HR 0.72, 95% CI 0.56–0.93; HELIOS_B_01), while CARDIO-TTRansform enrolled 1,432 treated participants and specifies approximately 85% power for a 20% reduction in its overall Week-140 composite (DESIGN_05). That conditional power implies roughly 59% power at a true rate ratio of 0.85, so a modestly attenuated effect still has a reasonable chance of significance. My 23% failure probability reflects uncertain transfer from vutrisiran to eplontersen, unrestricted stabilizer use, broader severe-disease eligibility, and possible event-count shortfalls; actual stabilizer proportions were not established in the corpus. Indeterminate deaths count as cardiovascular deaths (DESIGN_04), so uncertain death attribution is not an additional major penalty. This forecast concerns only the first reported prespecified overall FAS primary result, not polyneuropathy, biomarkers, subgroup wins, or later mortality analyses.

Across EoE Phase 3 trials, histologic remission (peak eosinophils <=6/HPF) is reliably achieved against a low placebo baseline (~5-6%), making histologic response the most probable individual endpoint success. However, achieving statistically significant DSQ improvement at Week 24 has repeatedly proven difficult due to high placebo response, permissive symptom inclusion criteria, background PPI/STC maintenance, and the lag in clinical remodeling. Dupilumab achieved DSQ only with intensive weekly dosing, failing at Q2W; benralizumab in AstraZeneca's MESSINA trial achieved 87.4% histologic response but failed DSQ (P=0.18). While tezepelumab's upstream TSLP inhibition targets broader Type 2 inflammation beyond eosinophils alone, its Q4W dosing and an estimated minimum detectable effect of ~5.7 points leave DSQ clearance around a ~44% conditional probability given histology. Procedural precedent from MESSINA indicates that failing DSQ does not invalidate a reportable high-dose histologic win. Accounting for residual hierarchical and target-validation risks, 'histology_only' is the modal outcome (47%), followed by 'both' (38%), 'neither' (13%), and 'symptoms_only' (2%).

No CROSSING topline or SAP in the freeze. Same co-primaries as MESSINA and TREET: peak eos ≤6/hpf and DSQ at Week 24, 420 mg Q4W vs placebo, ~120/arm. Histology: every type-2 biologic tried in EoE has driven large ≤6/hpf gaps vs ~5–6% placebo; TSLP sits upstream of IL-5/eotaxin-3 and is the strongest EoE GWAS locus. 420 mg should separate eos with high probability. Residual misses are incomplete tissue coverage, the strict ≤6 bar, or a DSQ-first hierarchy that leaves a numerical eos win unclaimable (dupilumab Q2W pattern). AZ’s own MESSINA reported histology as significant while DSQ failed, so I treat histology_only as the default public classification, with only a small hierarchy haircut into neither. DSQ: bimodal-ish but not strictly so. Weekly dupilumab moved DSQ by about −10 to −12; Q2W and benralizumab were ~0 despite histology. Scaled TREET CIs imply CROSSING needs ~6 points at 80% power. TSLP blockade is mechanistically in the IL-13/mast-cell class that can hit symptoms, but Q4W vs weekly, no EoE PoC, no DSQ floor, and allowed PPI/STC all push toward an intermediate or null delta that misses. P(DSQ | claimable histology) ~0.42; P(DSQ | no histology) very small. That yields histology_only as the mode, both second, neither in the high teens, symptoms_only residual.

I moved 5 points from both to histology-only after the discussion’s correction of DSQ power. The dupilumab Part B confidence interval implies an SE near 2.5 at about 80 per group, or about 2.0 at CROSSING’s roughly 120 per arm, so a placebo-adjusted DSQ benefit likely needs to be around 5.5–6 points even before multiplicity. That widens the range of biologically real but statistically unsuccessful symptom effects. Histology remains about 79% likely: TSLP blockade at the deliberately high 420-mg dose should suppress type-2 esophageal inflammation, but there is no direct tezepelumab EoE proof-of-concept in the frozen corpus, so I do not treat it as a near-certainty. MESSINA supports a formally reportable histology win despite DSQ failure, while the unknown CROSSING hierarchy leaves some procedural risk. Symptoms-only remains structurally unlikely. Overall, the upstream mechanism gives tezepelumab a credible chance to resemble weekly dupilumab and hit both, but the fragile Week-24 DSQ endpoint now makes histology-only my slight mode.

I retain my initial probabilities: the discussion supplied useful procedural comparisons but no direct tezepelumab EoE efficacy or target-engagement evidence that resolves my main uncertainty. MESSINA showed 87.4% versus 6.5% histologic response yet failed DSQ (P=0.18); weekly dupilumab achieved both, supporting broader inflammatory blockade but not proving that upstream TSLP inhibition will reproduce it. CROSSING plans about 120 participants per arm, and scaling the dupilumab Part B confidence interval suggests roughly a 5.7-point DSQ effect is needed for 80% power at unadjusted two-sided 5% significance, leaving intermediate symptom effects vulnerable. I give histologic success 73% probability, not near 90%, because eosinophil reduction need not yield sufficient stringent remission and established inflammation may persist despite alarmin blockade. MESSINA supports a formally reportable histology-only outcome, while dupilumab's hierarchy-blocked every-two-weeks histology result cautions against assuming significance without CROSSING's unavailable testing plan; this procedural uncertainty is secondary to target-validation risk. Both narrowly leads because effective high-dose TSLP blockade could address broader disease biology, whereas symptoms-only remains unlikely.

No CROSSING topline exists in the frozen corpus (only JRCT_01 registry record, MESSINA_01, DUPILUMAB_01), so this is a prior-based joint forecast built from two components. P(histologic remission formally claimable) ≈ 0.88. Placebo histologic remission is ~5-6% in both EoE Phase 3s in the corpus (5% in TREET Part A, 6.5% in MESSINA), and every type-2 biologic tested in EoE has cleared esophageal eosinophils; TSLP sits upstream of IL-5 and eotaxin-3 and is EoE's strongest genetic locus. The haircut from ~0.93 to ~0.88 reflects two things: no tezepelumab EoE proof-of-concept anywhere in the corpus, and a residual ~10-15% chance that CROSSING's unretrieved testing graph sequences DSQ ahead of histology within the 420 mg arm — the trap Panelist 4 identified, evidenced by dupilumab q2w's 56-point histologic separation being "not significant per hierarchical testing". I weight AZ's own MESSINA precedent (histology reported P<0.001 while DSQ failed at P=0.18, same sponsor, same co-primaries) more heavily, which keeps histology_only reportable. P(DSQ | histology) ≈ 0.44. Historical DSQ effects cluster at the extremes — dupilumab weekly -12.32 and -9.92 (both P<0.001), dupilumab q2w -0.51, benralizumab about +3 (P=0.18) — but Panelist 4 correctly noted this is three regimens, not a demonstrated bimodal law, and correctly recomputed the minimum detectable effect: back-solving the Part B CI gives SE ≈ 2.5 at ~80/group, ~2.0 at 120/group, so ~5.7 points detectable before multiplicity. An intermediate tezepelumab effect of -3 to -5 points therefore loses. Mechanism favors a hit (TSLP is upstream of IL-13, mast cells, ILC2s, and the IL-13-axis agents are the ones that moved symptoms); design cuts against it (Q4W versus weekly dupilumab, 24 weeks short for remodeling, entry requiring only ">=2 episodes of dysphagia per week" with no stated DSQ floor, and permitted background PPI/topical steroids, all of which raise the placebo arm and compress the delta). Multiplying: both 0.88 x 0.44 ≈ 0.39, histology_only 0.88 x 0.56 ≈ 0.49, rounded to 0.40/0.47 to leave symptoms_only 0.02 (a symptom win with a histology miss is near-impossible for an upstream type-2 blocker and would additionally require the unlikely DSQ-first sequence) and neither 0.11 (essentially the histology-failure mass).

No HARBOR efficacy is in the corpus; this is a forward call on a still-blinded 54-week trial. MARINA de-risked muscle delivery (~37–46% DMPK knockdown vs +0.9% placebo) and makes vHOT a mechanistically proximate primary, which is why I am near even rather than in the low 30s. It does not de-risk the confirmatory test: functional measures were exploratory and unpowered, composite missplicing separation was modest and noisy with no clean dose response, and there is no quantified vHOT effect or HARBOR N/power. I dropped an earlier extra penalty for “no significant phase 2” (that was absence, not a failed powered trial) and I do not read the Q2→H2 2026 slip as a failure signal. Remaining failure modes—partial splice rescue, site variance, practice effects on a timed task, and winner’s-curse endpoint choice—keep me slightly under 50%.

I retain a modest lean to success. Del-desiran produced clear randomized target engagement, with DMPK RNA reductions of roughly 37–46% versus essentially none on placebo, and vHOT is an objective measure relatively close to the myotonia mechanism. However, MARINA was a small safety/PD study with only 10 placebo patients; functional outcomes were exploratory, and the active-placebo separation in composite splice correction was only about 9–10 percentage points with no clean dose response. With no quantified randomized vHOT effect, HARBOR sample size, or powering assumptions in the corpus, regression to the mean, practice effects, and multisite variability keep failure risk substantial. The Q2-to-H2 readout shift is consistent with completing 54-week follow-up after July 2025 enrollment and carries little efficacy information.

I retain 63% Yes: the discussion clarified source errors but provided no new evidence changing my initial assessment. My general late-stage prior is modestly favorable, though the corpus supplies no matched base rate; substantial randomized DMPK reduction, some splice correction, and exploratory functional improvements support a plausible effect on myotonia. Confidence remains limited because MARINA included only 28 active participants and 10 placebo participants, functional outcomes were explicitly exploratory and underpowered, and higher-dose composite missplicing improved only 9–10 percentage points more than placebo. We lack numerical randomized vHOT effects, variability, and current HARBOR power assumptions, so these findings are not confirmatory efficacy evidence. The H2 2026 readout expectation supersedes older Q2 guidance without implying failure, and the older week-30 primary assessment cannot be assumed amended merely because later guidance describes a 54-week readout. Resolution still requires researcher verification of the first unambiguous disclosure and prespecified primary vHOT success; secondary benefits alone do not count.

This is a pure forward forecast: the frozen corpus (D01–D05 is the whole set) has no HARBOR efficacy data, and the latest source (Novartis, 28 Apr 2026) still puts the readout in H2 2026, after the cutoff. For yes: del-desiran's target engagement is unambiguous (muscle DMPK RNA −37% to −46% vs +0.9% placebo), and the primary endpoint is a timed myotonia measure whose pathophysiology (CLCN1 missplicing) sits one step downstream of that biomarker — a much shorter causal chain than the composite function/disability scales that usually sink neuromuscular phase 3s. DM1 is progressive, so the placebo arm should be flat-to-worsening on vHOT rather than improving. The trial is fully enrolled, the sponsor kept guiding to a readout, and no evidence in the corpus indicates a failure, a futility stop, or an endpoint change. For no: MARINA was a safety-first phase 1/2 (28 active across three cohorts, 10 placebo) whose functional results were explicitly exploratory and unpowered, so the primary was plausibly chosen off the best small-sample signal — winner's curse. I corrected my own reading during discussion: D05 reports missplicing fell 3%/17%/16% versus 7% on placebo, i.e. ~9–10 points of separation with a non-monotonic low dose and a placebo arm that moved nearly as much as the drug. That means the pharmacodynamic step nearest myotonia is partial and noisy, not near-normalizing. Entering phase 3 without a statistically significant randomized functional result is the modal setup for a miss, and neurology runs below the all-indication phase 3 primary-success rate. Live failure modes: effect attenuation across many sites, practice effects on a repeated timed task, dropout over a long study. The Q2→H2 2026 timing shift I treat as evidentially empty: enrollment completed July 2025, so 54 weeks of follow-up plus lock lands in H2 2026 arithmetically. Net: modestly above even, down from my first ballot's 60% because of the missplicing correction. 56/44.

Following panel discussion, I have adjusted my estimate from 63% to 57% for the primary endpoint being achieved: 1. Mechanistic rationale remains favorable: Del-desiran demonstrated target engagement in MARINA (NEJM 2026), achieving ~40% DMPK knockdown and modest splice correction across cohorts. Because myotonia (measured via vHOT) is directly caused by ClC-1 missplicing, the endpoint is mechanistically proximate to target engagement, distinguishing it from downstream degenerative disability scores. 2. Translation and statistical risks: MARINA was a safety/PD study with only 28 active participants across three dose cohorts (and 10 placebo). Functional outcomes were exploratory and unpowered. Designing and powering HARBOR from small exploratory signals exposes the trial to effect-size attenuation, site-to-site variability on timed motor tests, and practice/placebo effects. 3. Operational timing: The timeline shift from Q2 2026 to H2 2026 is consistent with completing 54 weeks of follow-up after the July 2025 enrollment completion rather than an efficacy signal. Balancing biological plausibility against the lack of prior confirmatory clinical data and Phase 3 trial variance supports a modest lean toward success at 57%.

The causal-genetic case and large expected absolute Lp(a) reduction make a clinically meaningful benefit slightly more likely than not. With 993 events, however, the result is highly sensitive to effect size: approximate power is about 38% at a true HR of 0.90 and 73% at 0.85 before any multiplicity tightening. I did not materially update from my first vote: the discussion correctly rejected double-discounting genetic-to-trial calibration, but HORIZON's baseline Lp(a) distribution, achieved lowering on the monthly regimen, adherence dilution, and alpha allocation are absent from the frozen evidence. Phase 2 proves biomarker lowering, not event reduction, and success confined to the >=90 mg/dL subgroup would still resolve No.

I retain 65%: causal genetic support, substantial demonstrated target engagement, and a 993-event trial favor success, but clinical benefit from this mechanism remains unproven (D01–D02). With 993 events, approximate power before multiplicity is 94% for HR 0.80, 73% for 0.85, and 38% for 0.90; uncertainty about the actual effect therefore warrants substantial failure probability. Discussion did not establish a better effect-size estimate: the claimed CVOT base rate was unsupported, baseline Lp(a) and the exact testing allocation are missing, and one pessimistic genetic calculation explicitly double-counted the lifetime-to-treatment discount. I retain a broad effect-size distribution rather than adopting recalled numerical calibrations as established evidence. Phase 2 biomarker lowering is not clinical efficacy, its highest-response schedule differs from HORIZON's, and neither H2 2026 filing guidance nor delayed event accrual demonstrates benefit. Yes requires multiplicity-valid benefit in the overall ≥70 mg/dL population; benefit confined to ≥90 mg/dL does not suffice, and ambiguous disclosure must await clarification rather than be counted as success.

No result exists in the frozen corpus — only the AHJ design paper (D01), the phase 2 biomarker study (D02), and Novartis's April 2026 slide placing the readout in H2 2026 (D03). So this is a pure forward forecast, and it reduces to one comparison: the effect HORIZON can detect versus the effect Lp(a) lowering plausibly delivers. Detection: 993 adjudicated events give SE(log HR) ≈ 0.064, so significance needs an observed HR below roughly 0.88, with power ~95% at a true HR of 0.80, ~73% at 0.85, ~38% at 0.90. Alpha shared with the Lp(a)>=90 analysis tightens this somewhat. Delivery: I moved up from my first ballot because of the double-discount argument Panelist 2 raised and Panelist 1 endorsed, which Panelist 5 later accepted too. Mapping Lp(a) to LDL-equivalent units on the genetic scale and then applying the observed CTT trial effect already embeds the lifetime-to-trial adjustment; my initial 0.88-0.92 centre applied that haircut twice. Done cleanly, an ~80 mg/dL absolute Lp(a) reduction over 4-5 years in a secondary-prevention population implies a true HR nearer 0.83, and secondary-prevention calibrations (Madsen-type) point the same way. Against that, Panelist 5's correct catch that D02's 80% figure came from a weekly schedule (highest monthly arm ~72%) trims the exposure contrast, and it roughly offsets my counterpoint that three of the composite's four components respond to lipid lowering at close to the headline rate. Remaining downside: adherence dilution over five years of monthly injections, unknown alpha allocation, first outcomes test of this mechanism, and the rule that a >=90-only win scores No. Integrating a wide HR distribution (meaningful mass from 0.78 to 0.93) against the power curve lands me at 0.62. I will not go higher, because HORIZON's baseline Lp(a) distribution, its testing hierarchy, and every calibration paper cited on this board are outside the frozen corpus.

The forecast hinges on whether pelacarsen's potent Lp(a) reduction (~70–80% in Phase 2) translates into a clinical effect large enough to achieve statistical significance in the overall population (Lp(a) >= 70 mg/dL) with 993 adjudicated primary events. With SE(log HR) ≈ 0.0635, the study has high statistical power (~94%) if the true HR is 0.80, moderate power (~73%) at HR 0.85, and low power (~38%) at HR 0.90, with multiplicity adjustment for the >=90 mg/dL subgroup further tightening required thresholds. Because baseline Lp(a) is right-skewed, the mean absolute reduction across the overall cohort should be meaningful (~75–85 mg/dL), supporting a plausible true HR around 0.85–0.87. However, the trial's dual testing design introduces material risk that significance is achieved exclusively in the >=90 mg/dL stratum, which resolves as 'No' under the rules. Integrating the plausible effect-size distribution against the study's power curve and multiplicity structure yields an updated probability of 58% for overall-population success.

No topline exists as of the cutoff (D03: event-driven H2 2026 readout). Direction of effect is supported by genetics and by large phase 2 Lp(a) lowering (D02), but D01 has not established clinical-event reduction and the question is multiplicity-adjusted significance in the overall ≥70 mg/dL population, not biomarker change or a ≥90-only win. 993 events give SE(log HR)≈0.0635, so the trial is well powered for HR ~0.80 and often misses at HR ~0.90. I had centered too low (0.88–0.92) by stacking a further lifetime-to-trial haircut on a Burgess-style mapping that already uses trial LDL effects; dropping that double count moves the center to about 0.85–0.89. Remaining, non-double-counted discounts still apply: D02’s 80% was 20 mg weekly, not the phase 3 80 mg monthly schedule; HORIZON’s baseline distribution is not in the corpus; the composite includes CV death; unknown alpha split with the ≥90 analysis; first outcomes test of the mechanism. Filing language is not efficacy evidence. Integrated over a wide HR distribution against that power curve, slight lean to no demonstrated overall primary benefit: 48% yes, 52% no.

I retain my first ballot: the discussion supplied no verified remibrutinib-specific efficacy or exposure evidence that changes it. The closest reference class contains three molecules: evobrutinib and tolebrutinib each missed ARR superiority twice, while fenebrutinib succeeded twice with 51.1% and 58.5% reductions (EVOLUTION_01, GEMINI_01, ROCHE_01). That establishes that BTK inhibition can succeed, not that remibrutinib will; covalent binding and occupancy explanations remain insufficiently substantiated predictors here. The approximately 1,000-patient REMODEL trials share the molecule, comparator and endpoint, so I strongly favor concordant outcomes, but three precedent programs cannot rule out an intermediate effect and meaningful sampling-driven discordance. Novartis's 'H2 2026' milestone is guidance, not a result (Q1_01); only first-topline statistically significant ARR superiority counts, and failure to establish it is not proof of no effect.

No REMODEL topline exists in the frozen corpus: Novartis's 28 Apr 2026 pipeline page still lists REMODEL-1 (n=1001) and REMODEL-2 (n=1011), ARR of confirmed relapses primary, remibrutinib vs teriflunomide double-dummy, readouts "H2 2026, publication TBD." So this is a genuine prediction of an unobserved event. Reference class: three molecules, six phase 3 trials of a BTK inhibitor vs teriflunomide on ARR. Evobrutinib RR 1.02 and 1.00; tolebrutinib 0.13 vs 0.12 (RR 1.06) and 0.11 vs 0.11 (RR 1.00); fenebrutinib −51.1% (p<0.001) and −58.5% (p<0.0001) with Gd+ lesions −70.7%/−77.6%. That is 1 of 3 molecules and 2 of 6 trials. Teriflunomide's ARR was a stable 0.11–0.14 in all six, so the comparator bar was identical for winners and losers — the failures were drug failures, not design artifacts. I gave little weight to the covalent/non-covalent story pushed on the board: with n=3 molecules, bond type is confounded with dose and schedule. evolutionRMS used 45 mg BID of the least selective, liver-limited molecule; GEMINI used tolebrutinib 60 mg once daily. Fenebrutinib was dosed BID to continuous occupancy. Remibrutinib is highly selective, irreversible and BID, which on the occupancy axis sits nearer fenebrutinib — but I searched and the corpus contains no REMODEL dose, no remibrutinib MS phase 2 and no CSF/occupancy data, so I hold that as a prior, not evidence, and it does not move me off roughly even odds between the two concordant outcomes. The residual tilt to "neither" is just the 1-in-3 program base rate. P(one): the mixture, not conditional power, governs. Only true effects of about 20–30% leave a ~1000-patient trial genuinely uncertain; ≥40% gives >95% power each (FENhance cleared it at ~750 per trial) and <15% fails both. Panelist 5 and 1 correctly noted the failing trials' CIs (0.74–1.39 etc.) do not exclude modest effects, so I widened my intermediate band from ~20% to ~27% of mass; at ~40% split probability inside it plus tail sampling that gives ~0.14, up from my first ballot's 0.12. Final: 45 / 14 / 41.

Across Phase 3 RMS programs evaluating BTK inhibitors versus teriflunomide on primary annualized relapse rate (ARR), the empirical track record is 1 successful program out of 3 (fenebrutinib succeeded in both FENhance trials; evobrutinib and tolebrutinib failed in both evolutionRMS and GEMINI trials). REMODEL-1 and REMODEL-2 are large (~1,000 patients each), identically designed, active-controlled twin studies with H2 2026 readouts slated by Novartis. High statistical power and identical regimens strongly correlate the trial outcomes, making the split outcome ('one') relatively unlikely (~14%) compared to concordant results. With no direct Phase 2 MS efficacy or exposure data for remibrutinib in the corpus, the 1-in-3 program base rate provides the anchor, slightly moderated by remibrutinib's high selectivity and BID dosing profile, keeping 'neither' as the most probable outcome (54%), 'both' at 32%, and 'one' at 14%.

No REMODEL topline exists; Novartis still listed H2 2026 readouts. The reference class is three BTKi programs vs teriflunomide on ARR: evobrutinib and tolebrutinib each missed both twins (RRs ~1.0), fenebrutinib hit both (ARR −51% and −59%). That is 1/3 programs, fully concordant. Covalent binding is a weak extra penalty—those misses look like molecule/PK failures, and ARR is a peripheral endpoint—so I do not move from ~1/3 toward 60% neither. Fenebrutinib shows a large effect is achievable; REMODEL is larger than FENhance, which concentrates mass on both-or-neither rather than a split. I leave a mid-teens residual on exactly one for an intermediate true effect plus sampling, not the 10% implied by treating class effects as strictly bimodal. Net: neither slightly favored over both, one clearly last.

I moved probability from both toward neither after treating the evidence at the molecule/program level rather than as generic target validation. Of the three closest BTK-inhibitor programs, evobrutinib and tolebrutinib each failed both ARR trials versus teriflunomide, while fenebrutinib alone achieved both, with very large 51.1% and 58.5% reductions. Remibrutinib may resemble fenebrutinib in sustained target coverage, but the frozen evidence contains no remibrutinib MS efficacy or verified REMODEL exposure data to establish that advantage; covalent binding itself is also too confounded to be decisive. The shared drug and near-identical ~1,000-patient designs make concordant outcomes dominant, but I raised exactly one to 17% because three prior molecules are too small a sample to infer a truly bimodal effect distribution, and an intermediate remibrutinib effect would give substantial split probability.

I retain a 93% hold probability. The Bank judged 2.25% appropriate in July and intended to look through direct oil-price effects; July's 3.0% headline CPI was heavily gasoline-driven, inflation excluding gasoline stayed at 2.2%, and wage growth slowed to 2.8%. Strong employment and improving activity make the small residual risk asymmetric toward a hike, but there is little evidence of the broad second-round inflation or capacity pressure that would normally prompt a newly initiated tightening move. The June market survey is stale and the August 28 GDP release remains unknown, limiting confidence, but the survey's entire interquartile range was still 2.25%, and the business price-intention evidence cited for a hike was already available at the July hold and was largely oil-related. A cut is least likely given headline inflation and firm labour data.

I retain my original probabilities: the discussion supplied useful qualifications but no new evidence warranting a change. July's judgment that 2.25% was appropriate and its intention to 'look through direct oil-price effects' remain the strongest anchors (D01–D02). July employment rose 75,000 while wage growth slowed to 2.8%; headline CPI reached 3.0%, but inflation excluding gasoline remained 2.2%, supporting neither an urgent cut nor clear broad-inflation grounds for a hike (D06–D07). The June survey supports a hold baseline, not a current market-implied probability, and neither a historical conditional hold frequency nor updated preferred core measures was established in the evidence. I retain small tails for the unknown August 28 GDP release, recovery disappointments and inflation spillovers, with higher slightly more likely than lower; the advance quarterly GDP figure cannot be compared directly with the annual growth forecast to establish an upside surprise.

Unchanged remains overwhelmingly the modal outcome. The July 15 decision held at 2.25% with Council judging the existing rate appropriate (D01); the market-participant survey showed median, 25th and 75th percentiles all at 2.25% for September through December (D03); and the July deliberations set an explicit rule — look through direct oil effects, act only on persistent broad inflation (D02). Post-July data fit that rule rather than break it: headline CPI 3.0% but ex-gasoline 2.2% for a third month with gasoline +25.7% (D07), wage growth decelerating to 2.8% from 3.3% (D06), and activity firm but not overheating (May GDP +0.3%, advance Q2 +0.8%, D08; weak advance July retail and manufacturing, D09/D12). Tails are thin and asymmetric toward a hike. A cut needs a growth shock that does not appear anywhere in the evidence, and would be perverse with headline inflation at 3%. A hike would be the first tightening after a completed easing cycle, delivered unsignalled at a non-MPR meeting against a market with zero interquartile dispersion — historically rare outside acute shocks. I nudged the hike tail from 4% to 5%. Two board points had force: my "well above 90%" conditional hold rate is outside knowledge, not verifiable in this corpus (Panelist 2), and the August 28 quarterly GDP print is genuinely unseen. Neither changes the direction, but both argue against pricing the tails as tightly as I first did. Panelist 5's 12–18% hike tail I still reject: the D04 selling-price intentions cited for it are explicitly oil pass-through, the same survey reports worsening sentiment, sub-normal hiring intentions and no binding capacity constraints, and that survey was already in the Bank's hands in July.

The discussion reinforces the dominant case for an unchanged overnight rate target of 2.25% at the September 2, 2026 meeting: 1. Policy anchor and communication: At its July 15 meeting, the Governing Council kept the target at 2.25%, stated that the existing stance was appropriate while economic slack remained, and explicitly resolved in deliberations (D02) to look through direct energy price increases while guarding against broader inflation. Furthermore, September is a non-MPR decision; initiating an unsignaled tightening cycle without an updated Monetary Policy Report would be an extraordinary departure from standard central bank practice. 2. Market expectations: The Bank of Canada’s Market Participants Survey (D03) showed zero interquartile dispersion for September, with the 25th percentile, median, and 75th percentile all at 2.25%. 3. Intermeeting economic data: Incoming data between July 15 and August 26 consistently support staying on hold. While July headline CPI ticked up to 3.0% due to a 25.7% spike in gasoline, CPI excluding gasoline held at 2.2% for the third consecutive month (D07). Crucially, average hourly wage growth decelerated from 3.3% to 2.8% (D06), mitigating concerns about persistent second-round wage-price pressures. Early indicators for July demand also softened (advance retail sales -0.8%, manufacturing sales -0.2%). The upcoming August 28 quarterly GDP print presents a slight tail risk, but with the advance industry estimate already projecting Q2 at ~0.8% and slack recognized in the July forecast, a surprise hike remains a small probability (~6%). A rate cut is even less likely (~3%) given headline inflation at 3.0% and steady employment gains (+75k in July). The probability of an unchanged target is estimated at 91%.

July’s hold and the look-through-oil rule remain the baseline. Post-July data (ex-gasoline CPI still 2.2%, wages slowing to 2.8%) fit that script; September is not an MPR meeting, Q2 strength was already in the July growth story, and D04 was known in July, so I cut the hike tail from 18% to 12%. Remaining hike risk is travel/air inflation, jobs strength, and the Aug 28 GDP we do not see. A cut still needs a growth shock that is not in the evidence. Hold is modal; I will not go to 90%+ because those tails are real even if thin.

The band is fixed by the May 5, 2026 release: "approximately $11.2 billion, plus or minus $300 million" (D002) → 10,900/11,500, a half-width of only ±2.7%. Q1'26 came in at $10,253M, and Jean Hu said it was "exceeding the high end of our guidance" (C003). If Q1 used AMD's customary ±$300M band, that forces a Q1 midpoint below $9,953M, i.e. a beat of at least +3.0% — larger, in relative terms, than the 2.7% it takes to clear $11.5B this quarter. That bound is what moved me up from my opening 38% on "above"; it is conditional on the unobserved Q1 band, which is why it does not carry me past ~42%. Holding "within" as modal: the Q2 guide already leans forward (+9% q/q, +46% y/y, double-digit sequential growth in data center and embedded) after a high-end beat, which mechanically shrinks the expected surprise; MI450/Helios volume is Q3/Q4 (C006) and the upsized customer forecasts are 2027 (C005), so the headline AI news is not Q2 revenue; and the quarter is supply-gated (memory "secured enough supply to meet and exceed our targets", C009), which thins the right tail even with demand above supply. A 1–2.5% beat — AMD's modal historical outcome — lands inside the range. "Below" needs a discrete shock or a step-change in one large segment, not routine variance: the closest precedent is Q3 2022, when a client collapse produced a large low-end miss, roughly one event in the last ~16 quarters and in a far more demand-fragile regime than a sold-out backlog. Client and Gaming (~$3.6B) carrying memory-cost risk is the live path, but management placed that hit in H2 and called Q2 Ryzen demand solid. Panelist 3's timing-slippage argument widens both tails symmetrically; it does not explain why the recent realizations have all been on the high side. 6% is my honest number there. The corpus stops on May 6, 2026 — no intra-quarter print, pre-announcement or revision exists to condition on, which I state as a gap rather than fill with inference.

AMD's Q2 2026 guidance is $11.2 billion ± $300 million ($10,900M to $11,500M inclusive), which corresponds to a narrow band of ±2.68% around the midpoint. While historical guidance often lands 'within' the range, the percentage half-width has compressed to 2.7% at AMD's current revenue scale. Furthermore, Q1 2026 revenue of $10,253M explicitly exceeded the high end of guidance (C003), establishing that beats exceeding +2.7% over midpoint are actively occurring in this demand environment. This justifies elevating 'above' from our initial 20% to 33%. Nevertheless, 'within' remains the distinct modal outcome (60%). Q2 guidance already builds in substantial acceleration (+46% YoY, +9% QoQ, double-digit sequential DC and embedded growth), while the next major product ramp (MI450/Helios) does not deliver volume until H2 (C006), and wafer/advanced packaging capacity constraints prevent runaway quarterly shipments. The downside tail ('below', 7%) is bounded by firm data center backlogs and robust server CPU demand (>70% YoY), but preserved for quarter-end shipment timing and execution risks.

Original May 5 guide is $11.2B ± $300M ($10.9–$11.5B). No later document exists in the frozen corpus, so this remains a guidance-time forecast. Within stays modal because the band is only ±2.7% and Q2 already embeds +9% q/q / +46% y/y with double-digit sequential data center and embedded growth. Helios/MI450 volume is Q3/Q4; 2027 customer-forecast upside is not Q2 revenue. A 1–2.5% midpoint beat still prints inside the range. I raised “above” from 29% to 35% because Q1 $10,253M cleared the high end of its (unobserved) guide — if that band was the usual ±$300M, the implied midpoint beat was at least ~3%, larger than this quarter’s half-width — and because management said memory and wafer supply can meet and exceed the growth they are talking about. I did not go to ~42%: after a high-end beat they leaned the Q2 bar forward, so the next error should mean-revert somewhat. “Below” is the thin tail (~10%), not ~5%. A sold-out DC book and 2H-not-Q2 memory commentary make a demand collapse unlikely, but D003’s yield, third-party manufacturing, and shipment-timing risks can still clip $10.9B without an export shock. The 2022 client miss is a weak analog for this mix.

Within remains modal because the ±$300M band permits a roughly 2.7% midpoint beat, and Q2 guidance already embeds strong 9% sequential growth; the much-discussed Helios and MI450 upside begins in Q3/Q4 and is mainly a 2027 story. I raised above from my first ballot because the closest same-regime observation is explicit: Q1 revenue exceeded the high end, while Q2 server CPU and data-center AI were both expected to grow double digits sequentially and supply was improving. I also raised below modestly for ordinary manufacturing and shipment-timing risk, but strong demand, backlog, and no frozen-record evidence of a late demand shock keep that tail thin.

I retain my first ballot: the discussion supplied no verified new operating evidence or historical guidance-hit dataset that changes my estimates. D002 establishes the original $11,200M ± $300M guide; within remains the likeliest outcome, but Q1's explicitly reported high-end beat (C003) and memory supply sufficient to 'meet and exceed our targets' (C009) support a substantial above-range tail. Q2 guidance already incorporates double-digit sequential growth in server CPUs and data-center AI, while Helios initial volume begins in Q3 and the larger customer-forecast upside concerns 2027 (C005–C006); neither those headlines nor hypothetical PC pull-forward should be counted again as Q2 surprises. Strong demand reduces downside risk but does not eliminate ordinary production, acceptance and shipment-timing shortfalls, so I retain 8% below rather than requiring a discrete external shock. These are judgmental probabilities, not fitted frequencies; resolution must use the first Q2 release's precise consolidated table revenue against the inclusive $10,900M–$11,500M bounds.

Salesforce's Q2 FY27 guidance range of $11.27B to $11.35B ($11,270M to $11,350M) implies sequential growth from Q1's $11,133M of only +1.2% to +1.9% (+1.6% at midpoint), well below historical Q1-to-Q2 seasonal increases (+2% to +4%). With >95% predictable subscription revenue and 14% cRPO growth, management's conservative hurdle makes 'above' the clear modal outcome. However, because the guidance band is just $80M wide, the upper bound sits a mere $40M (~0.35%) above midpoint. Across a $3.9B non-US quarterly revenue base, normal post-guidance foreign exchange volatility or lumpy term-license/professional-services timing can easily absorb that cushion, giving the 'within' outcome a substantial 28% likelihood. A print below $11.27B requires an unexpected currency headwind or transaction slippage, warranting a 7% tail.

The only frozen source is the 27 May 2026 Q1 pack: original Q2 guide $11.27–$11.35B, Q1 actual $11,133M, 95% subscription, cRPO +14%/13% CC in line with the Q2 cRPO guide, FY midpoint raised, organic acceleration placed in H2. Implied year-ago Q2 is ~$10.24B, so last year’s Q1→Q2 sequential was ~+4.2%; this year’s midpoint is only +1.6%. Even a weak ~+2% sequential step would print just over $11.35B, so the live contest is a small beat versus an exact hit of an $80M band. I do not treat unmatched historical “65–75% beat the high end” rates as evidence; they are not in the corpus. Some of the sequential slowdown is intended (Agentforce Apps 7% CC; H2, not Q2, is the acceleration call). Unobserved FX after 27 May and term-license timing can independently move a $40M gap to either bound, so below stays a thin but non-zero tail. Above remains the mode; within keeps a large residual. Modest update from 9/38/53 on the sequential arithmetic, not on room averages.

Above remains most likely because the $11.31B midpoint is only 1.6% above Q1's $11.133B, and the upper bound only 1.9% above Q1. The in-file year-ago figures imply roughly 4.2% Q1-to-Q2 sequential growth, while even the historically weak roughly 2.1% seasonal step discussed by the panel would put revenue near $11.367B, just over the upper bound. The recurring subscription base, 14% cRPO growth, and raised full-year midpoint further limit downside. I reduced above from 72% and raised below from 3% because management explicitly expects organic acceleration only in H2, and post-guidance FX moves or variable term-license/complex-transaction timing could independently hold the result within range or cause a miss; the stated $50M FX effect is year-over-year, not an uncertainty bound.

I retain my initial probabilities: the discussion supplied no verified new evidence strong enough to change them. My general knowledge of Salesforce's conservative guidance favors a modest beat, and the original $11,270–$11,350M range is only 0.71% wide; Q1's 95% subscription-and-support mix supports near-term predictability (D004). The midpoint requires 1.6% sequential growth from Q1's $11,133M, but management's explicit expectation of second-half organic acceleration cautions against extrapolating stronger historical seasonality (D001). Acquisition effects and timing of term-license transactions, as well as FX, leave meaningful uncertainty; a below-range result does not require simultaneous execution and currency shocks. Historical beat frequencies and recent beat compression were not verifiable in the frozen corpus, so this remains a judgmental prior-informed forecast, not a measured historical hit rate.

In-file facts (May 27, 2026 Q1 FY27 release, the only corpus document): Q1 FY27 revenue $11,133M (D006); Q2 guide "$11.27 - $11.35 billion, up 10% - 11% Y/Y and 10% in CC, including slightly above 4pts Informatica contribution," with only $50M of assumed Y/Y FX help; cRPO +14% Y/Y (+13% CC); FY27 revenue midpoint raised; professional services $540M vs $532M a year ago (D004). Core reasoning, unchanged by the discussion in its structure: 1) The guided sequential step is soft. Midpoint $11,310M is +1.6% off Q1's $11,133M, and Informatica is roughly flat sequentially (~$444M in Q1 vs ~$420–450M implied by "slightly above 4pts" on a $10,240M year-ago base), so organic Q/Q is also ~+1.7%. Last year's Q1→Q2 step was ~+4.2% (derivable in-file: Q1 FY26 $9,829M and the implied year-ago Q2 ≈$10.24B from the 10–11% guide). 2) The band is $80M wide, so the top end sits only +$40M (0.35%) above midpoint. A beat of even modest size clears it. 3) A print below $11.27B requires an actual shortfall against a 95%-subscription revenue base most of which is already contracted — rare for this company, though Panelist 4 fairly notes FX or term-license timing could each do it alone, so I keep a thin but non-zero tail. What the board changed: Panelist 4 corrected my claim that professional services is shrinking (it grew 1.5% Y/Y), removing one small downside channel, and rightly insisted that the "beats 65–75% of the time" figure is prior, not corpus evidence. My own Q3 FY26 near-top-of-range recollection is also recall, not evidence, so I downweight it. Net effect: a small shift from below and within toward above, to 66/29/5. I stay below the room's ~70% on above because the cushion is genuinely thin ($40M), FX after 27 May is unobserved in this corpus, and management explicitly located organic acceleration in H2 — meaning part of the soft Q2 guide is intended rather than sandbagged. "Within" at 29% is where the honest uncertainty lives.

Original Q2 guide is $13.8–14.8B (midpoint $14.3B). Q1 table revenue was $13,577M, $1.4B above that quarter’s midpoint and above its high end; the “sixth consecutive quarter of exceeding financial expectations” is not, in this corpus, six verified high-end revenue prints, so I do not use it as a base rate of clearing $14.8B. Revenue is still output-gated with unfilled demand, 18A yields running ahead of internal projections, and Q2 guide already embedding sequential CCG growth, double-digit sequential DCAI, improved supply, and a full quarter of pricing. That makes the modal outcome a print inside the $1B band set with knowledge of the H1 output beat. Above $14.8B (~+9% sequential) is the fat right tail from another output surprise of a few percent. Below $13.8B is only ~+1.6% sequential and needs a disruption large enough to eat the unfilled-order cushion and offset a DCAI tailwind; memory/OEM build cuts are a real path but were known at guide and located by management as a 2H PC risk, so I trim that tail from 12% to 10% rather than to high single digits. No post-24 Apr 2026 print or channel check is in the freeze.

The modal outcome is within the deliberately wide $1.0B range, but upside remains substantial. Q1 consolidated revenue was $13.6B and demand exceeded supply; Intel expected Q2 sequential growth in both CCG and DCAI, DCAI up double digits, improved supply, and a full quarter of pricing. Clearing $14.8B requires about 9% sequential growth, so another output/yield surprise is needed. Below $13.8B requires less than roughly 1.6% growth despite those tailwinds and robust orders, making it mainly a component-demand or operational disruption tail. I reduced my initial above probability after the board correctly noted that Intel’s “sixth consecutive quarter” language does not establish six revenue prints above the high end; only Q1’s high-end beat is explicit in the frozen evidence.

I retain my initial probabilities: the discussion clarified evidence but supplied no new verified facts that change my forecast. The original $13.8–14.8B guidance already assumes improved supply, full-quarter pricing actions and double-digit sequential DCAI growth (D002, C003), making within-range the modal outcome. Q1's $13,577M revenue, roughly $1.4B above its guidance midpoint, plus demand exceeding supply and ahead-of-plan yields support substantially more upside than downside risk (D003, C001–C002). The six-quarter 'exceeding expectations' streak is not six verified upper-bound revenue beats. Below remains a 10% tail because component shortages, customer order timing and manufacturing execution can disappoint without a catastrophic outage; the frozen evidence provides no later-quarter update to eliminate those risks.

Verified from the freeze: original Q2'26 guide $13.8-14.8B (D001/D002); Q1'26 revenue $13,577M, described by the CFO as "$1.4 billion above the midpoint of our guide" on better-than-expected available supply, mix and pricing (C002); revenue is output-gated with demand in excess ("Q1 Revenue would have been meaningfully higher, but demand continues to outpace our growing supply"); Q2 guided "up 2 to 9 percent sequentially" with CCG and DCAI both up, DCAI up double digits (C003). No corpus document postdates 2026-04-24, so no June channel data exists to update on. Central case (within, 52%): segment math — DCAI ~+$0.5B, CCG modestly up, All Other/external foundry roughly flat — lands ~$14.4-14.6B. The guide was set with full knowledge of the H1 output beat, the non-repeating reserved-inventory benefit, and the pricing actions, so the obvious upside levers are already embedded. Right tail (above, 42%): the only quarterly forecast error I can actually verify was +11% on the midpoint, driven by factory output and 18A yields running ahead of internal plan (C001). Clearing $14.8B needs only ~3-4% more output than guided. I discount but do not dismiss the "six consecutive quarters" framing, since the board correctly established that C001 documents only Q1'26 as above the high end and calls the streak "exceeding financial expectations." Left tail (below, 6%): $13.8B is just +1.6% sequential off a quarter where Intel shipped everything it could build and left orders unfilled. With DCAI adding ~$0.5B, CCG would have to drop ~5-8% sequentially, through a cushion of rationed backlog, for the total to miss — a component-gated OEM build cut of that speed and size inside 13 weeks. Real (management flags memory/wafer/substrate constraints hitting demand "at some point in the year") but a tail; management places PC weakness in H2 and calls near-term orders very robust. Accounting-scope risk is minimal: the Fab 34 buyout adds economics rather than removing revenue, Mobileye remains consolidated.

Intel's Q1 2026 release established Q2 revenue guidance of $13.8B to $14.8B (midpoint $14.3B). With demand outpacing available fab capacity across DCAI and CCG, along with locked-in pricing actions, revenue is fundamentally output-constrained rather than demand-constrained. The lower bound of $13.8B is only 1.6% sequential growth over Q1 ($13,577M), making a downside miss an improbable tail event (~8%) requiring acute operational or component disruptions. Landing within the $1.0B guidance range remains the modal scenario (~56%), as management already incorporated sequential DCAI growth and supply improvements into the guide without repeating Q1's one-time reserved inventory sales. However, persistent yield improvements on Intel 18A and Intel 3 create a fat upside tail, where a modest 3.5% output surprise above the midpoint pushes revenue above $14.8B (~36%).

I raise above modestly from my first ballot because the corrected historical comparison is eight recent quarters in which reported revenue cleared the top of NVIDIA’s ±2% guidance band, including subsequent quarters at much larger scale; the H20 charge sometimes invoked against that record was a cost item, not a revenue deduction. Here, $92.82B requires 13.7% sequential growth after Q1 grew 20%, while rising inventory and payables are consistent with continued production ramping and the guide already assumes no China Data Center compute revenue. I retain 13% within because rack-delivery timing, supply constraints, and the lack of intra-quarter evidence could limit the habitual beat; below would require a substantially larger adverse shock.

I retain my initial probabilities: discussion supplied useful corrections but no new verified evidence. D001 specifies '$91.0 billion, plus or minus 2%' and no assumed China Data Center compute revenue; the resolution bounds remain $89,180–$92,820 million. NVIDIA's historical tendency to exceed original guidance during the AI boom is my main reason to favor above, supported directionally by Q1's $81,615 million revenue and 20% sequential growth. However, searches yielded only D001–D003, not the recalled historical guidance series or independent intra-quarter tracking, and strong growth is already embedded in guidance. China exclusion is not booked upside, and rising inventory does not establish spare shipment capacity. Ordinary delivery timing and uncertainty about the current guidance cushion justify a meaningful within probability without requiring evidence of a known disruption; supply, policy and customer delays support the smaller below tail.

Anchor (D001, 21 May 2026): Q1 FY27 revenue $81,615M; "Revenue is expected to be $91.0 billion, plus or minus 2%. NVIDIA is not assuming any Data Center compute revenue from China in its outlook." Band = 89,180–92,820, so "above" needs a beat of more than $1.82B over midpoint. The decisive base rate is the size of NVIDIA's beat over its own midpoint, and in the last eight quarters every one cleared +2%: roughly +8.5%, +7.3%, +7.9%, +4.9%, +2.5% (Q1 FY26, the quarter with ~$2.5B of H20 revenue legally blocked), +3.9%, +5.6%, +4.8% (Q4 FY26's $68,127M against a $65.0B guide is confirmed in the release). The beat did not shrink as revenue grew 55% across FY26, which undercuts the "compression at scale" case: the beat is a deliberate guidance posture plus planned-versus-achieved shipments in a backlog-constrained ramp, and neither term scales down with size. D001's balance sheet (inventory $25.8B vs $21.4B, payables $13.1B vs $9.8B) shows a company building ahead, not scraping a ceiling. I accepted two corrections on the board — the H20 charge was a cost item, and "zero China" is optionality rather than booked dollars, so I do not count China as incremental revenue. What it does do is remove the only mechanism that ever compressed a beat to +2.5%. The honest counterweight, and why "within" is 12% rather than 5%: rack-scale deliveries carry $1–2B of site-readiness and acceptance-timing slack, and with observed beats clustering around +4–5% against a 2% hurdle, an adverse timing swing occasionally lands inside the band. But that variance is already embedded in the FY26 sample, which was itself the NVL72 era. Holding 20–30% on "within" requires the central beat to have shifted down to ~+2%, and no one produced evidence of a hard Q2 supply cap or a post-May demand event. "Below" needs a genuine shock against a deep backlog: ~2%. I shade "above" one point off my opener only because my beat series is recalled, not documented in this frozen corpus (which contains only the three parts of the 21 May release).

NVIDIA guided Q2 FY27 revenue to $91.0B ± 2%, setting the resolution thresholds at $89.18B and $92.82B. NVIDIA has exceeded its +2% upper guidance bound in virtually every quarter of the current AI infrastructure cycle, driven by a consistently conservative guidance framework that typically incorporates a 3% to 6% buffer over expected shipments. With China Data Center compute already excluded, the primary risk of landing 'within' (21%) stems from delivery and site-readiness timing on multi-rack systems (where a slight shift of $1.5B–$2B across late-July quarter boundaries can pull reported revenue inside the ±2% band). An outright miss ('below', 5%) remains a low-probability tail risk given strong backlog visibility and inventory ramp.

Original Q2 FY27 guide in the 21 May 2026 release is $91.0B ±2% ($89.18–$92.82B) with zero Data Center compute from China assumed. Q1 printed $81,615m; the corpus is only that release, so there is no verified beat-rate table and no intra-quarter tracking through 1 Jul. Directionally NVIDIA has usually cleared its ±2% cap in the AI cycle, and China-zero plus a still-ramping balance sheet (inventory $25.8B, payables $13.1B) tilt the error to the right—so above remains the mode. I will not condition at 80–87% on a recalled eight-for-eight series that is not in this corpus: that treats a small, possibly non-stationary sample as a known mean beat of ~+4% with tight variance. At $91B a $1.82B overshoot is required; rack-scale acceptance timing and a possible HBM/CoWoS ceiling are enough to put a large share of outcomes inside the band without a demand break. Below is the thin tail (supply shock or a true demand stall) because China is already out of the plan. Modest update from 14/39/47: slightly more above, slightly less below; within stays large.

Evidence from the 78th Emmy announcement confirms that Hacks set an all-time single-year comedy record with 24 nominations, providing Christopher McDonald substantial coattail support. However, Guest Actor races historically favor revered industry legends with poignant guest spots, where Michael J. Fox commands unrivaled Academy goodwill and historic success. Brett Goldstein retains strong recent Emmy-winner favor from the comedy branch, while Rob Reiner holds notable veteran recognition. First-time nominees Hamish Linklater (Widow's Bay) and Connor Storrie (Saturday Night Live) face steep odds against such established icons.

Nominees (from the complete 78th list): Fox as Gerry on Shrinking; Goldstein as Louis on Shrinking; Linklater as Richard Warren on Widow’s Bay; McDonald as Marty Ghilain on Hacks; Reiner as Albert on The Bear; Storrie hosting SNL. Guest-comedy Emmys favor marquee names and shows with overall heat. Fox is the sentimental/high-goodwill favorite (prior wins, visibility). Reiner benefits from The Bear’s awards track record plus his stature. McDonald benefits from Hacks’ record 24 comedy nominations. Goldstein shares the Shrinking slot and is less distinctive here. Linklater (first-time, Widow’s Bay) and Storrie (first-time SNL host) are long shots. No precursor or critic data in the corpus; remaining uncertainty is high.

In Emmy Guest Acting categories, sentimental legacy narratives and industry reverence play an outsized role in swaying Academy voters. Michael J. Fox is an extraordinarily beloved figure whose guest appearance commands unmatched emotional resonance and industry goodwill, giving him the strongest winning probability. Brett Goldstein (a two-time winner and major creative force in comedy) and Rob Reiner (an iconic television legend) are the principal alternatives. Christopher McDonald benefits from Hacks' overall nomination sweep but has repeatedly fallen short in past nominations. Hamish Linklater and first-time nominee Connor Storrie face substantially lower odds against these towering industry heavyweights.

No critic consensus, betting lines, or episode details appear in the frozen evidence. Guest Actor Comedy historically favors high-profile veterans and prior winners over first-timers. Fox has multiple prior guest wins and strong sentimental pull; Reiner is a comparable icon. Goldstein has recent comedy Emmys but is not a classic “guest star.” Linklater and Storrie are explicitly first-time nominees (Widow’s Bay and SNL); McDonald is a working character actor. Residual probability is split among the three less-established names. These remain weakly informed priors.

Nomination and submission analysis from the official records (D01 and D02) shows the category is heavily led by three established contenders: Jonathan Pryce (Slow Horses, 'Scars'), Colman Domingo (Euphoria, 'In God We Trust'), and Bradley Whitford (The Diplomat, 'Amagansett'). Pryce is favored due to an emotionally powerful showcase episode in an acclaimed drama series where he has strong overdue/veteran momentum. Domingo is a formidable competitor having won this exact category for the same role, bolstered by high industry profile and multiple 2026 nominations, though Euphoria as a whole has cooled relative to The Pitt. Whitford remains a strong third with perennial Academy favor and a high-profile turn opposite Allison Janney. The Pitt's 25 nominations provide strong coattails for first-time nominees Ernest Harden Jr. and Jeff Kober, though they likely split the show's voting bloc. Jeff Hiller on Pluribus rounds out the field as an outsider.

Official D01 list (via panel) plus D02/D03 context: Pryce’s Slow Horses “Scars” episode sits in a prestige series that also earned Oldman a lead nod, giving him the clearest showcase-plus-momentum combination. Domingo repeats the exact Euphoria role that already won him this category, so he retains a large but slightly discounted share because the series has cooled. Whitford’s prior win in the category and high-visibility Diplomat pairing keep him third. The Pitt’s 25 nominations lift Harden and Kober above typical character-actor floors, yet they split that coattail vote. Hiller’s recent comedy win and nom-hosting are weaker signals in a drama guest race. No betting markets or critic roundups were in the corpus, so these remain base-rate plus show-heat estimates with remaining uncertainty.

Following review of the submitted episodes and series contexts: 1. Jonathan Pryce (32%): Slow Horses enjoys strong broad Academy support, and Pryce's showcase submission as David Cartwright in the season finale ("Scars") offers an emotionally poignant, high-caliber veteran performance favored by guest category voters. 2. Colman Domingo (27%): A former winner in this exact category for the same role (Ali in Euphoria) and an industry favorite, though Euphoria carries slightly less momentum than in prior cycles. 3. Bradley Whitford (20%): A three-time Emmy winner with perennial Television Academy affection, benefiting from a high-profile pairing with Allison Janney in The Diplomat. 4. Ernest Harden Jr. (8%) & Jeff Kober (8%): The Pitt is a dominant drama contender with 25 nominations, providing substantial coattails, though having two nominees from the same show likely splits the vote between them. 5. Jeff Hiller (5%): While a respected comedic and dramatic presence, Pluribus lacks the institutional backing and voting breadth of the leading contenders.

Submitted episodes and series (board, citing D01): Domingo/Euphoria (prior winner in this category, same role), Pryce/Slow Horses, Whitford/The Diplomat, Harden and Kober splitting The Pitt, Hiller/Pluribus. D02 establishes The Pitt’s 25 drama noms and the two first-timers, plus Domingo’s dual-category presence and Hiller’s recent win/hosting. That lifts Pryce above my first-ballot 18% (Slow Horses + Oldman momentum + veteran showcase) and keeps Domingo close via the 2022 precedent. Whitford’s category history and Diplomat pairing remain a live third. Pitt heat is real in Creative Arts but split and first-time, so ~19% combined rather than a token. Hiller is the remaining long shot. No markets or critic polls retrieved; guest-actor outcomes stay noisy.

Jamie Lee Curtis holds a commanding position as the singular nominee for The Bear in this category, bolstered by top-tier Academy recognition where she was explicitly singled out in the official nominations announcement. Conversely, Hacks—despite earning a record 24 comedy nominations—faces substantial vote dilution across four contenders (Bibb, Olson, Metcalf, and Weedman). With Bibb and Weedman being first-time nominees, Metcalf (a perennial Emmy favorite) and Olson (a prior nominee for the role) lead the Hacks challenge, while Cherry Jones and Betty Gilpin represent respected but lower-momentum outside alternatives.

Hacks has record comedy heat (24 noms) but four of seven guest-actress nominees (Bibb, Metcalf, Olson, Weedman), which splits a plurality vote. Curtis is the only nominee the Academy press release treated as a marquee name, is the sole The Bear entry here, and fits the guest-category pattern of awarding famous prior winners. Metcalf remains the strongest Hacks path as a proven Emmy winner. Gilpin and Jones get a modest lift as the other non-Hacks names. First-timers Bibb and Weedman stay lowest. Still a wide field with no public ballots, so Curtis is favorite not lock.

Official documentation confirms that Hacks earned a record-breaking 24 comedy nominations, fielding four of the seven nominees in this category (Leslie Bibb, Laurie Metcalf, Kaitlin Olson, and Lauren Weedman). In a plurality voting system conducted across the broader Academy membership, this severe four-way split substantially dilutes Hacks support and heavily benefits Jamie Lee Curtis (The Bear), who is prominently spotlighted in the official announcement and commands massive industry reverence. Inside the Hacks contingent, multi-time Emmy winner Laurie Metcalf and longtime favorite Kaitlin Olson have the best chances to consolidate votes, while Cherry Jones serves as a proven external contender. First-time nominees Bibb and Weedman, along with Betty Gilpin, round out the lower probabilities.

Hacks’ record 24 comedy nominations include first-timers Bibb and Weedman plus Metcalf; that concentration can split the guest-actress vote. Curtis (The Bear) is the clearest high-profile singleton. Metcalf’s Emmy history keeps her a close second. Remaining names lack comparable heat in the available nomination documents. No critics’ groups or betting data in the corpus; probabilities rest on star power, show strength, and vote-splitting.

Official nominations confirm that three of the six nominees (Brittany Allen, Tal Anderson, Tina Ivlev) represent single-episode guest spots in HBO Max's The Pitt. In an at-large plurality voting system, three lesser-known performers from the exact same show are almost certain to divide the show's voting bloc, leaving each at a distinct numerical disadvantage. This concentrates frontrunner status on the two widely established names in the category: Merritt Wever (The Gilded Age) and Shailene Woodley (Paradise). Wever has an exceptional track record with Television Academy voters, having already won two Emmys across different genres (Nurse Jackie, Godless) as a perennial critical darling. Woodley represents the biggest marquee star in the field with broad recognition. Miriam Shor (Pluribus) remains a plausible veteran dark horse, but trails the two primary frontrunners in overall momentum.

Official nominees (D01) put three first-time Pitt guest spots against Wever (Gilded Age, two prior Emmys), Woodley (Paradise), and Shor (Pluribus). Guest Actress historically rewards prior winners and marquee names over split ensemble first-timers; The Pitt’s 25 drama noms give its trio some residual heat but not a plurality path. Wever is therefore the modal pick, Woodley the main alternative, Shor a thinner dark horse; remaining mass is split across Allen/Anderson/Ivlev. No performance-specific or betting evidence exists in the corpus, so the distribution stays moderately concentrated rather than extreme.

The category structure heavily advantages established individual contenders outside the multi-nominee split. The Pitt scored 25 nominations overall, but having three separate episodic guest nominees (Brittany Allen, Tal Anderson, Tina Ivlev) substantially dilutes its voting bloc, with none having a clear pre-existing national profile. In contrast, Merritt Wever is an established Academy darling with two prior Emmy wins across comedy and limited series, appearing here in the acclaimed HBO period drama The Gilded Age. Shailene Woodley represents the classic guest-category marquee star winner archetype in Dan Fogelman's high-profile drama Paradise. Miriam Shor remains a credible dark horse from Pluribus. Wever leads our forecast, followed closely by Woodley.

Official 78th Emmy slate (D01 p.36 / D02): three first-time Pitt guests (Allen/Anderson/Ivlev, single-episode patient/case hours) vs Wever (Gilded Age), Woodley (Paradise), Shor (Pluribus). The Pitt’s 25 drama noms create show heat but historically split guest-acting votes when one series takes half the field; Wever’s two prior Emmys and established prestige-drama support give the cleanest plurality. Woodley is the remaining high-name alternative (Fogelman/Brown producing noms). Shor is the other unsplit first-timer without comparable Academy history. No reviews, clips, or campaign coverage in the corpus; final voting had not opened as of the 6 Aug cutoff. Residual mass stays on the Pitt trio; Wever modal.

The evidence confirms that holding the deposit facility rate at 2.25% is by far the most likely outcome at the July 23 meeting. The ECB raised rates by 25 bps on June 11 explicitly adhering to a meeting-by-meeting, data-dependent approach without a commitment to a preset path. Subsequent data releases show that inflation pressures have eased rather than intensified: June flash HICP fell to 2.8% (down from 3.2%), with energy inflation decelerating significantly. Meanwhile, real activity indicators show ongoing weakness (May industrial production down 0.2% m/m, tight credit conditions) while long-term inflation expectations remain anchored at 2%. Given that July is an interim meeting without updated staff macroeconomic projections, there is little justification or urgency for consecutive hikes (21%), and an immediate rate cut is virtually precluded by elevated core inflation and recent hawkish framing (2%).

The June 11 hike already set the DFR at 2.25% with a data-dependent, no-precommitment reaction function. July 23 is a non-projection meeting six weeks later. Post-hike data (June flash HICP 2.8% from 3.2%, energy and services inflation slowing, May IP −0.2%, unemployment stable) do not show a further inflation deterioration that would compel another 25bp move. The 9 July account restates June persistence risks if energy prices fail to fall, but also anchored expectations, no second-round effects yet, and weakening activity; it is not a July vote. A cut so soon after a hike is inconsistent with still-above-target inflation and the June upside-risk language. A second hike remains a modest tail if the energy shock is judged still worsening, which the available prints do not show. Hold is therefore the modal outcome.

The incoming data between the June 11 hike and the July 23 meeting strongly favor a pause: June headline inflation fell sharply to 2.8% (from 3.2% in May), services inflation cooled to 3.2%, and second-round effects have not emerged, while long-term inflation expectations remain anchored at 2%. Simultaneously, growth momentum is sluggish (May industrial production down 0.2% m/m and 1.2% y/y) and bank credit standards have tightened. In the absence of fresh staff projections at this interim July meeting, and consistent with the ECB's data-dependent, meeting-by-meeting framework, the Governing Council is most likely to maintain the deposit facility rate at 2.25% (78%). An immediate follow-up hike remains an upside risk (20%) driven by geopolitical energy concerns, while an immediate rate cut is nearly ruled out (2%).

June 11 already set DFR at 2.25% with an explicit meeting-by-meeting, no-preset-path reaction function. July 23 is a non-projection meeting only six weeks later. Incoming data after the hike (June flash HICP 2.8% from 3.2%, energy inflation slowing from 10.8% to 8.7%, services 3.2% from 3.5%; May IP −0.2%) show cooling rather than a worse energy pass-through. The 9 July account restates June persistence risks and weakening activity but is not a July vote; expectations remain anchored and second-round effects have not appeared. A second hike is possible if they overweight geopolitical energy uncertainty, but the prints do not force it. A cut so soon after a hike, with inflation still 2.8%, is a thin tail. Hold is the modal outcome. Discussion added no new facts, only the same reading of D01–D06.

H.R. 3106 (WINTER Act) is a narrow, non-regulatory measure directing DHS to incorporate extreme cold scenarios into terrorism preparedness exercises. Its placement on the suspension calendar despite Democratic sponsorship indicates committee clearance and bipartisan support. Consistent with historical base rates for non-controversial suspension measures clearing the two-thirds threshold, the likelihood of passage is high, with the residual risk reflecting occasional unexpected procedural or factional objections.

The frozen corpus has only H.R. 3106 IH (30 Apr 2025): a two-section, no-cost DHS bill requiring one terrorism-exercise scenario with extreme cold and cascading critical-infrastructure effects plus a 60-day after-action report. Sponsors Kennedy (NY) and Thompson (MS); referred to Homeland Security. No reported text, markup, cosponsor growth, or 2026 floor record. Conditioning on the identified 13 Jul 2026 suspension motion existing, leadership almost never calls a 2/3 vote it expects to lose, and this profile is classic suspension fodder, so agreed is the modal outcome. Extra-corpus 85–90% pass-rate claims and inferences about GOP control or Thompson as Ranking Member are not established here; residual 27% covers protest votes, unexpected controversy, or a motion that fails or is not completed as a Clerk result.

H.R. 3106 is a narrow, non-appropriating emergency preparedness exercise measure directing DHS to incorporate extreme cold scenarios into terrorism drills. Such bills are classic suspension calendar material, generally brought forward with bipartisan leadership clearance. Motions to suspend the rules succeed around 85% of the time, and there is no evidence of controversy surrounding this specific directive.

Frozen evidence is only H.R. 3106 IH (4/30/2025): a two-section, no-cost DHS exercise-and-report bill referred to Homeland Security, sponsors Kennedy (NY) and Thompson (MS). No reported text, markup, or floor notice. The question identifies a 7/13/2026 suspension-and-pass motion; those are scheduled when leadership expects two-thirds, and this bill is classic noncontroversial fodder, so passage is the modal Clerk outcome. I do not treat GOP control, Ranking Member status, or committee clearance as known. Residual 25% covers protest votes, a failed 2/3, or a motion that does not produce an agreed/failed Clerk result. Slightly above my first 70% because the text itself is even narrower than a typical authorization bill.

H.R. 8897 has bipartisan sponsorship (Mackenzie, Foushee, Vindman) and was reported favorably by the Committee on Homeland Security (H. Rept. 119-735). The reported text removed the regulatory waiver provisions present in the introduced draft, leaving a clean, discretionary TSA pilot program to ease security screening for families with young children. This type of noncontroversial, bipartisan measure routinely clears the two-thirds threshold required under suspension of the rules. The remaining 8% reflects the inherent risks of floor attendance, scheduling delays, or unexpected procedural hitches.

The identified 2026-07-13 suspension is on a committee-reported, bipartisan TSA family-screening pilot (RH 2026-07-09). The reported text is discretionary, two-year, security-constrained, and dropped the introduced APA/CRA waiver—standard low-salience Homeland Security fare. House suspension votes of this type that actually occur pass well above 90% historically; the two-thirds bar and the frozen corpus having no whip count or floor notice as of 10:00 UTC on vote day are the remaining failure modes. Slightly higher than the first ballot because the RH text is cleaner than the IH excerpt implied.

Panelist 1 and I are in agreement regarding the underlying facts: H.R. 8897 has bipartisan sponsorship, was reported out by the House Committee on Homeland Security (Report 119-735), and addresses a non-controversial administrative issue (a TSA pilot program to expedite screening for families with young children). Motions to suspend the rules and pass such consensus measures historically succeed at a rate of 90-95%. A small probability is retained for rare procedural failures or attendance anomalies.

The identified motion is a House suspension of H.R. 8897 as reported 2026-07-09 (Union Cal. 639, H. Rept. 119-735). The RH text is a two-year discretionary TSA pilot to expedite screening for adults with children 12 and under, only if security protocols are not compromised, with Secure Flight/PreCheck limits and a 270-day briefing. The introduced APA/CRA waiver is gone. Original sponsors Mackenzie and Foushee plus Vindman are bipartisan. That is the classic profile of a committee-reported, low-salience process bill brought under suspension; when such a recorded 2/3 vote actually occurs it usually passes. I raise slightly from 82% because the rest of the RH section confirms a short sunset and no new controversy, and the question identifies a specific Clerk motion rather than an unscheduled bill. I do not go to ~92% because the corpus still has no committee roll call, whip count, or floor notice as of 10:00 UTC, and two-thirds can fail on protest or misjudged controversy.

Floor votes in the US House designated specifically as 'On Passage' succeed at a high base rate (>90%) because leadership controls the floor calendar and typically brings bills to final passage only when passage is whips assured under simple majority rules. The Sunshine Protection Act benefits from broad bipartisan support across multiple Congresses, though slight uncertainty remains due to narrow House majorities and cross-cutting regional differences regarding permanent daylight saving time. An 88% probability reflects these factors.

The identified motion is On Passage (regular order, simple majority), not suspension. Conditional on leadership putting that vote on the floor, modern House base rates are very high because the whip operation rarely allows a final-passage roll call without a majority. That is the main update from my first ballot. Offsets that keep this well below 90%: the archive still has only H.R. 139 IH (Buchanan, 2025-01-03, referred to Energy and Commerce)—no reported text or amendment trail—and permanent DST is a regional/public-health split, not a party-line lock, with a prior House stall after the 2022 Senate analogue. Mixing those, 78% agreed / 22% not_agreed.

The bill (H.R. 139, Sunshine Protection Act of 2025) repeals temporary daylight saving time provisions to make DST permanent year-round. In the US House, motions brought to a floor vote 'On Passage' succeed at a high base rate (>90%), as leadership rarely schedules final passage votes without an expected majority. While the archived text reflects only introduced status without a reported committee amendment, and regional/health-policy debates over permanent DST versus standard time could introduce minor floor volatility under narrow House majorities, the procedural context of an On Passage vote makes agreement the overwhelmingly likely outcome.

The resolution names a 2026-07-14 House “On Passage” motion (regular order, simple majority). Conditional on a Clerk result, leadership almost never holds that vote without a majority; modern House passage rates on such votes are ~90%. Haircut for this bill: the frozen archive has only H.R. 139 IH (Buchanan, 2025-01-03, referred Energy & Commerce)—permanent DST via repeal of 15 U.S.C. 260a and Calder Act offset shifts—with no RH/EH or amendment markup; the House sat on analogous Sunshine Protection bills after the 2022 Senate pass; DST vs. standard time is a regional/health split, not a party-line lock. That is enough to reject 90%+ but not to stay below 50%. Mixing the scheduling base rate with those residuals yields about two-to-one for agreed.

The bill is a Republican priority prohibiting firearms merchant category codes, reported out of the Financial Services Committee with extensive Republican cosponsorship across both moderate and conservative caucuses. Floor votes 'On Passage' under the majority party's control succeed at a very high base rate, needing only a simple majority. The 8% residual covers unforeseen attendance disruptions, whip count miscalculations, or rare defections.

The identified motion is ordinary “On Passage,” so a simple majority of those voting is enough. H.R. 1181 was reported with amendment from Financial Services on 25 Feb 2026 (Union Calendar 447, H. Rept. 119-522) with a long, exclusively Republican cosponsor list. That is strong evidence of a Republican House majority treating a core gun-privacy/MCC bill as a party priority. Leadership almost never schedules a final-passage roll call it expects to lose; historical pass rates for such votes are very high. Residual risk (card-network lobbying peeling off some GOP, a last-minute pull, or a narrow-majority attendance miss) is real but modest given the cosponsor breadth and the fact that the motion is already identified for 14 July. I therefore put 86% on agreed.

H.R. 1181 (Protecting Privacy in Purchases Act) is a consensus Republican priority prohibiting payment card networks from requiring firearm-specific merchant category codes. The bill was reported out of the House Committee on Financial Services (H. Rept. 119-522) to the Union Calendar. The scheduled motion is "On Passage", requiring a simple majority rather than a two-thirds suspension threshold. Given near-unanimous Republican caucus backing, potential support from cross-pressured moderate Democrats, and the strong institutional base rate of leadership not bringing party bills to a final passage roll call without whipped support, the likelihood of passage is very high, tempered only by the slim GOP majority and possible attendance volatility.

The bill reached the Union Calendar after a Financial Services markup with an exclusively Republican, very large cosponsor list and is teed up for a named “On Passage” vote (simple majority, not suspension). Leadership almost never schedules such a vote without a whip count showing it will pass; GOP unity on blocking firearms MCCs is historically near-total. The 15% residual covers a last-minute pull, attendance shortfall on a narrow majority, or the (low-probability) possibility that the 119th House is not Republican-controlled. No contrary evidence appears in the bill texts or discussion.

The available record shows H.R. 8595 as the reported FY2027 State/national security appropriations bill (Union Calendar No. 547, Report 119-631) sponsored by Rep. Diaz-Balart. When House leadership schedules and holds a vote on passage for a committee-reported general appropriations bill, passage is the dominant outcome (~80–85% base rate) because leadership generally whips the floor prior to calling final passage. The residual ~18% risk reflects the vulnerability of contentious foreign operations measures to thin majority margins and last-minute defections over policy riders or funding levels.

No new evidence appeared: the freeze still contains only the 30 Apr 2026 reported bill (Diaz-Balart, Appropriations, Union Cal. 547). Other panelists independently used the same base rate—leadership rarely schedules a regular-order appropriations passage vote it expects to lose—plus the observation that SFOPS riders produce near-unanimous minority opposition and occasional majority defections in a narrow House. That shared reasoning slightly raises my earlier 72% without converting the unobserved 119th majority margin or 15 Jul whip into a lock. Residual 26% covers pull, revolt, or unexpected defeat.

Following discussion, the panel is aligned on the core dynamics: scheduled roll call votes on final passage for regular appropriations bills have a high base rate of success (~80-85%), since majority leadership almost exclusively brings them to a vote when whip counts indicate passage. The remaining failure risk (~18-22%) stems from narrow House margins and the partisan nature of foreign operations funding and policy riders, where a handful of intra-party defections can defeat the measure. I slightly adjust my estimate to 78% for agreed and 22% for not_agreed.

Frozen evidence is only H.R. 8595 RH (30 Apr 2026, Diaz-Balart, Approps, Union Cal. 547). Confirmed GOP-typical riders (Helms-style 7018; UN secretariat hold 7049; flag restriction 7067; UNFPA ban 7057) make unified minority opposition likely, so passage depends on the majority holding. An identified “On Passage” roll call is usually called only with a whip count; SFOPS still has a real failure/pull risk in a narrow House. No 119th margin or July 15 floor record exists. That yields ~73% agreed among resolved Clerk outcomes (Passed/Agreed vs Failed/Rejected).

H.R. 5362 designates the VA multispecialty clinic in Marietta, GA, as the Colonel Michael H. Boyce Department of Veterans Affairs Multispecialty Clinic. Introduced by Rep. Loudermilk with the cosponsorship of the entire 14-member bipartisan Georgia House delegation, the bill satisfies the House Veterans' Affairs Committee requirement for facility naming legislation. Motions to suspend the rules and pass noncontroversial naming bills with unanimous home-state delegation support pass with near certainty, either by voice vote or overwhelming supermajority roll call.

H.R. 5362 is a one-purpose, bipartisan VA clinic naming bill with the full Georgia House delegation as original cosponsors and purely laudatory findings about Col. Boyce (who helped establish the clinic). These measures are the classic suspension vehicle and historically clear two-thirds by large margins or voice vote when brought up. Frozen corpus shows only the Sept 2025 introduced text, so committee/calendar confirmation is missing; that is the residual chance the identified 16 July motion is not taken or fails for an unrelated reason. Conditional on the motion occurring, agreement is near-certain. Slight upward revision from 90% after board confirmation of the same facts and the committee convention of unanimous-delegation naming bills.

H.R. 5362 is a standard, noncontroversial VA facility naming bill cosponsored by the entire 14-member bipartisan Georgia delegation. Under suspension of the rules, such measures overwhelmingly clear the necessary two-thirds majority, whether by voice vote or roll call. The residual probability accounts for rare parliamentary irregularities or sudden procedural protests.

The bill is a one-purpose VA clinic naming measure with unanimous bipartisan Georgia-delegation cosponsorship and purely laudatory findings (Boyce’s Marine career, Cobb County chairmanship, role in siting the clinic, death in 2022). Such bills, when brought under suspension, clear two-thirds almost without exception. The frozen corpus contains only the 2025 introduced text and no committee report or 16 July calendar entry, so a modest residual probability remains that the identified motion is not taken (void or not_agreed). Conditional on the motion occurring, passage is near-certain; overall I therefore assign 90 % to agreed.

H.R. 4541 is a consensus, bipartisan reauthorization of the EARLY Act and the National Breast and Cervical Cancer Early Detection Program (SCREENS for Cancer Act), reported out of the Energy and Commerce Committee with broad bipartisan support. Suspension bills of this non-controversial public health nature almost always clear the two-thirds threshold when scheduled by House leadership, leaving only a ~6% residual risk of procedural disruptions, unexpected floor opposition, or scheduling anomalies.

Bipartisan reported bill (E&C Rept. 119-746, Union Cal. 650) combining EARLY Act sunset extension to 2031 with NBCCEDP/SCREENS updates and a $235.5M/year authorization for FY2026–30. Original and additional sponsors include multiple Republicans. Suspension votes on this class of named cancer-program reauthorizations almost always clear two-thirds when leadership calendars them; no minority views or poison-pill text in the RH version. Remaining 16% covers last-minute pull, hawk protest over the dollar figure or “disparities/equity” language, or a failed 2/3 count.

H.R. 4541 reauthorizes key noncontroversial breast cancer education and screening initiatives (the EARLY Act and the National Breast and Cervical Cancer Early Detection Program). With bipartisan sponsorship across party lines (Rep. Wasserman Schultz, Rep. Miller-Meeks, and others) and committee reporting via Energy and Commerce, the bill represents typical consensus public health legislation scheduled under suspension of the rules. Such bills overwhelmingly pass with the required two-thirds majority, bounded only by the baseline risk of hardline conservative opposition to authorizations or broader procedural delays.

Bipartisan reported reauthorization of two established cancer-education and screening programs (EARLY Act date extension plus NBCCEDP updates including modest disparities-reduction language). Original and additional GOP cosponsors, Energy & Commerce report, Union Calendar placement, and use of the suspension vehicle all match the historical pattern of measures that clear two-thirds. Disparities language is consistent with the program’s long-standing targeting of underserved populations and did not prevent Republican sponsorship. No contrary floor or whip information exists in the corpus; remaining risk is only an unanticipated last-minute objection or procedural protest on the day of the motion.

The bill is a straightforward, non-controversial fraud-prevention amendment to the Federal Employees' Compensation Act considered under suspension of the rules. Such bills routinely pass with overwhelming bipartisan majorities exceeding the two-thirds threshold, aligning with historical suspension calendar base rates exceeding 95%.

The identified motion is a suspension of the rules on a four-page committee-reported FECA substitute allowing DOL to suspend payments to providers convicted of specified fraud. The only IH-to-floor change is non-substantive effective-date wording. Conditional on a Clerk result (withdrawn/cancelled is void, not not_agreed), House suspensions of this profile pass well above two-thirds at a high empirical rate; residual mass covers an unexpected objection or whip miss. Frozen corpus has the week-of listing and bill text, not a same-day vote notice or opposition.

The evidence confirms that H.R. 8823 is slated for consideration under suspension of the rules, as amended. The measure grants the Secretary of Labor authority to suspend FECA payments to medical providers convicted of fraud, with technical wording adjustments in the floor substitute that carry no substantial policy changes. Bipartisan consensus on anti-fraud legislation in federal programs is typically very strong, routinely surpassing the two-thirds majority required for suspension motions. While suspension calendar timing carries standard scheduling and procedural contingencies, conditional on a recorded decision, the likelihood of agreement is high at ~93%.

The identified vehicle is a four-page committee-reported FECA substitute on the week-of-July-20 suspension list: DOL may suspend payments to providers convicted of specified fraud, with a 180-day effective date and only a non-substantive wording tweak versus the introduced bill. If the Clerk records that motion, the relevant threshold is two-thirds; noncontroversial anti-fraud suspensions that are actually called pass at a high base rate. A cancelled or slipped vote is void, so scheduling “may be considered” language should not be treated as not_agreed. Residual risk is the supermajority, thin public record (no whip count, no committee tally, incomplete report number), and the small chance of unexpected opposition. Conditioning on a resolving Clerk result, I put 88% on agreed.

All three panelists independently converged on the same read: this is a narrow, technical, bipartisan-sponsored procurement bill placed on the suspension calendar, with the floor substitute further narrowing scope rather than expanding controversy. No evidence of organized opposition or contested provisions in the frozen record. This matches the profile of suspension bills that pass overwhelmingly (well above the 2/3 threshold). I retain a small tail risk for an unforeseen whip-count surprise or procedural objection, keeping my estimate at 96% agreed / 4% not agreed.

I modestly increase agreement to 86%. The floor substitute under consideration is a narrow Title 41 procurement-standard change—replacing “lowest overall cost alternative” with “best value”—and it is a bipartisan Donalds–Moskowitz measure scheduled for suspension. The substitute also removes the introduced bill’s Title 10 component, limiting rather than expanding scope. Those facts favor broad support sufficient for the distinct two-thirds suspension threshold. I do not move to near-certainty because the available record contains neither a whip count nor a committee vote, and suspension scheduling does not guarantee the required supermajority.

No contrary evidence emerged in discussion. Suspension scheduling is the strongest signal because leadership normally brings up measures expected to obtain the required two-thirds vote. The operative floor substitute is especially narrow, changes only the Title 41 multiple-award-schedule standard from “lowest overall cost alternative” to “best value,” drops the introduced Title 10 provision, and follows bipartisan Donalds–Moskowitz sponsorship. I retain 5% failure risk because there is no whip count or documented committee vote and suspension’s threshold is demanding.

The frozen corpus contains only bill text (IH and RH versions), no floor vote tallies. Panelist 3's observation that the bill has ~three dozen apparently all-Republican cosponsors and was reported to the Union Calendar with an amendment indicates this is majority-party-managed legislation heading to an ordinary on-passage vote (simple majority), not a bipartisan suspension bill. That means passage hinges on GOP unity rather than broad cross-party support. Leadership typically does not schedule reported bills for floor passage votes without a reasonable expectation of the votes being there, which supports a lean toward passage. However, the bill's substantive scope (bank merger clarity/process changes, bank-fintech partnership provisions, discount window modernization, community bank tailoring) touches several areas where a handful of majority-party members could defect on ideological grounds, and with typically narrow House majorities in this era, a small number of defections can flip a vote. Balancing the base rate that scheduled majority bills usually pass against the narrow-margin/defection risk, I land at 82% agreed / 18% not_agreed.

I retain my initial assessment. H.R. 6955 had moved from an introduced January version to a reported-House version dated April 20, a meaningful viability signal for a July passage vote. Its community-bank access and regulatory-tailoring focus plausibly has cross-party appeal, while the reported text’s broader bank-deregulatory provisions create real opposition risk. There is no frozen evidence of a whip count, vote rule, suspension threshold, or floor opposition, so a high—but not near-certain—ordinary-passage probability is warranted.

H.R. 6955 was reported with an amendment, assigned Union Calendar No. 535, and has an identified ordinary final-passage vote. Its approximately three dozen apparently Republican cosponsors and bank-regulatory substance suggest a partisan majority bill, not a suspension measure requiring two-thirds. Conditional on leadership actually scheduling final passage, the base rate strongly favors passage because whip checks precede the vote. I trim slightly from 97% because the frozen corpus contains no committee tally or whip count, and a narrow Republican majority leaves some risk of defections or absences; the discussion produced no concrete evidence of such defections.

Panel discussion reinforced the key facts: H.R. 9770 is a conventional, narrowly-scoped CR (funding through Dec 4, 2026 per §106) introduced by Appropriations Chair Cole just three days before the scheduled passage vote — a turnaround that typically signals leadership has already secured a workable vote count before scheduling. The short duration (rather than a full-year lock-in) lowers the substantive stakes and makes hardline defections somewhat less likely than for a more consequential bill. This nudges me slightly above my initial 72%. However, I maintain a meaningful failure tail because: (1) the corpus contains no direct whip count, rule vote outcome, or floor-schedule confirmation beyond the introduced bill text; (2) recent Congresses (including this one) have shown CR floor votes fail even on short "clean" stopgaps when process objections (not just spending-level objections) drive Freedom Caucus or other defections — the Oct 2023 CR failure (198-232) is a precedent for exactly this dynamic; (3) ordinary passage requires only a simple majority, which is an easier bar than suspension, favoring the majority party, but "easier" is not "certain" given recent narrow-margin volatility. Balancing the favorable structural signals (leadership scheduling, short duration, simple-majority threshold) against the residual and non-trivial historical risk of first-attempt CR failures, I settle at 74% agreed.

I remain at 76% agreed. The introduced July 18 text is a conventional FY2026-rate CR through December 4, 2026, sponsored by Appropriations Chair Cole, and the identified passage vote follows only three days later—jointly a meaningful signal that leadership expects an ordinary-majority path. The board adds no contrary scheduling, rule, or whip evidence. The 24% failure risk remains real: a narrow majority and intra-party opposition have defeated CRs before, and the frozen record contains no actual vote count.

H.R. 9770 is a standard short-term CR at FY2026 operating rates, expiring December 4, introduced by Appropriations Chair Cole only three days before the identified passage vote. That rapid scheduling of a must-pass leadership vehicle, under an ordinary simple-majority passage motion, is strong evidence that a winning coalition is expected. I retain a 12% failure chance because the corpus has no whip count or rule/floor reporting, and narrow-majority House CR votes can fail when conservative defections are not offset by Democrats.

Discussion confirmed consensus: the frozen corpus contains only the reported bill text with no floor whip counts, Rules Committee record, or Clerk result for the July 22 vote. All panelists independently converged on relying on the NDAA's exceptionally strong historical base rate—passed every year for 60+ consecutive years, usually by large bipartisan margins even amid contentious amendment fights. No evidence surfaced of a specific floor revolt, leadership withdrawal, or coalition collapse that would threaten passage this cycle. I maintain my estimate at 94% agreed / 6% not_agreed, with the residual accounting for irreducible uncertainty about unobserved 2026 political dynamics.

I retain 91%. The reported May 13 House text is a comprehensive, conventional FY2027 NDAA, and the annual NDAA has an exceptionally strong House-passage base rate. The discussion adds no vote-specific contrary evidence: no whip-count, leadership withdrawal, scheduling issue, or identifiable revolt. The 9% residual covers exactly those unobserved risks, especially a contentious amendment process or narrow-majority/attendance failure.

The board adds no vote-specific contrary evidence: all panelists found only the full reported NDAA text dated May 13 and no whip count, Rules Committee record, or sign of a revolt. Annual NDAAs have an unusually strong House-passage base rate, and leadership normally brings the final bill to passage only after assembling a majority. I keep a small not-agreed probability because a narrow House majority, partisan riders, absences, or a last-minute coalition failure could still defeat an ordinary passage vote.

The frozen corpus provides only the IH and RH bill text — no rule, schedule, or roll-call record for the July 22 vote. The strongest available signal remains procedural: H.R. 7008 was reported out of committee (H. Rept. 119-479) to the Union Calendar with bipartisan original cosponsorship, and the question specifies an "On Passage" motion rather than a suspension vote, consistent with ordinary Rules Committee-governed floor procedure requiring only a simple majority. Bills that reach this stage under a rule are usually brought to the floor because leadership expects to pass them, and banning/restricting congressional stock trading is a salient, broadly popular bipartisan issue. Discussion with the other panelist confirmed no additional corpus evidence exists to pin down the actual vote count, so I'm maintaining my estimate rather than revising it, while retaining meaningful uncertainty since direct confirmation of the outcome is unavailable.

I retain 86% for agreement. The evidence establishes that this was not merely introduced: the reported version is associated with H. Rept. 119–479 and listed on the Union Calendar. Combined with the broadly cross-partisan political appeal of restricting officials’ covered investments and the fact of an identified floor passage motion, that favors passage. Neither the bill documents nor the board supplies a Clerk roll call, rule, threshold, or whip count, so I retain material risk of opposition or a procedural threshold problem.

The reported bill is on the Union Calendar with House Report 119-479 and has sponsors spanning both the conservative and moderate wings of the House Republican conference. The Clerk-style label 'On Passage,' rather than a motion to suspend the rules and pass, points to an ordinary simple-majority threshold. Floor leadership generally does not bring a reported majority-party bill to final passage without expecting it to pass. I retain an 8% failure chance because the frozen evidence contains no rule, whip count, or same-day scheduling detail, and it does not demonstrate Democratic support if the procedural inference is wrong.

H.R. 8884 is a technical, low-controversy reauthorization of an SSA disability-insurance demonstration project, reported favorably (with an amendment) by Ways and Means to the floor via Committee of the Whole. No signals of partisan conflict or organized opposition appear in the bill text or history. Whether decided by simple majority under ordinary order or by suspension, bills of this profile — narrow scope, committee-endorsed, disability/work-incentive subject matter with broad appeal — pass at a high rate. Thin cosponsorship is a minor caution but not enough to significantly lower confidence given the absence of any contrary signal. I maintain my estimate at 93% agreed / 7% not_agreed.

Unchanged at 91% passage. The reported version records that Ways and Means reported the measure with an amendment on June 25, placed it on Union Calendar No. 620, and identifies a narrow reauthorization of disability-insurance demonstration authority through 2030. Those facts favor passage. But the corpus supplies neither the committee roll call nor floor procedure, whip counts, or actual support, so claims of committee consensus or a suspension vote should not be treated as evidence; the remaining 9% covers a procedural or substantive failure.

I remain at 97%. The strongest evidence is procedural: the Clerk motion is labeled “On Passage,” not a suspension motion, and the reported bill was committed to the Committee of the Whole, pointing to ordinary consideration at a simple-majority threshold. Leadership rarely brings reported legislation to a recorded final-passage vote without the votes, and this is a narrow disability-demonstration reauthorization with added guardrails. The corpus does not provide the committee roll call or minority views, so bipartisan support is unproven; thin sponsorship and possible unexpected majority defections account for the residual 3%.

Nothing on the board moved me off 0.95. The key facts stand: H.R. 8884 is a narrow reauthorization of SSA's disability-insurance demonstration authority (42 U.S.C. 434) to 2030/2031, reported by Ways and Means with an amendment, committed to the Committee of the Whole and placed on Union Calendar No. 620 (Report 119-714). The reported text adds guardrails (90→120 day waiver notice, required evaluation metrics, a limitation, trust-fund/administrative-cost clarification), which reads as committee-negotiated language rather than a partisan flashpoint. The motion is identified as "On Passage," which the Clerk distinguishes from "On Motion to Suspend the Rules and Pass" — the resolution rule itself flags that distinction. That points to ordinary consideration at a simple majority, eliminating the two-thirds failure mode that Panelists 1 and 2 priced in. Combined with the base rate that measures reaching a recorded floor passage vote are agreed to well above 90% of the time, I stay at 0.95. The 5% residual is for what the corpus cannot show me: no whip count, no Rules action, no committee roll call or minority views, so a surprise revolt or a mislabeled suspension vote remains possible but unsupported.

Consensus across the panel confirms the core reasoning: S. 307 is a bipartisan bill (Blackburn/Ossoff), addresses a narrow, non-controversial issue (BOP staff protection from sexual harassment/assault per a DOJ IG report), and is being brought via suspension of the rules — a procedural mechanism leadership uses specifically for bills pre-screened to clear the two-thirds threshold. Historical base rates for suspension motions receiving a recorded vote show well over 90-95% pass. No evidence in the frozen corpus suggests partisan controversy, fiscal fights, or opposition. Residual uncertainty reflects unseen floor dynamics, thin attendance, or unexpected objections, but nothing points to likely failure.

I retain my initial assessment. A House suspension motion is ordinarily scheduled only when leadership expects the required two-thirds support. S. 307 was introduced on a bipartisan basis by Sen. Marsha Blackburn and Sen. Jon Ossoff and concerns protections for Bureau of Prisons staff against inmate sexual harassment and assault, a narrow, low-conflict subject. There is no frozen evidence of House whip counts or a floor dispute, so I preserve a 6% chance of failure at the elevated suspension threshold.

I retain 98% agreed. Scheduling under suspension is a strong endogenous signal that House leadership expects the bill to exceed the two-thirds threshold, while the measure is narrow and bipartisan: Blackburn introduced it with Ossoff, and it implements DOJ Inspector General recommendations protecting Bureau of Prisons staff from inmate sexual harassment and assault. The residual 2% covers an unexpected partisan, fiscal, attendance, or procedural obstacle not visible in the limited frozen evidence.

No new evidence emerged in discussion; the panel independently converged on the same two facts I relied on. S. 307 is a narrow, bipartisan Bureau of Prisons staff-protection bill (Blackburn with Ossoff as original cosponsor) implementing responses to a 2023 DOJ IG report — no fiscal or partisan cleavage in the text. Decisive factor is procedural selection: leadership puts measures on the suspension calendar only after counting two-thirds, and historically well above 95% of suspension motions receiving a recorded vote are agreed to; failures cluster on bills with a visible intra-conference fight, which this is not. The frozen corpus contains only bill versions, no floor schedule or whip count, so I keep ~4% for an unseen objection or a thin-attendance shortfall on the two-thirds threshold.

Consensus across all panelists confirms: S 32 is a narrow, technical, bipartisan (Cruz/Padilla) court-venue housekeeping bill with no ideological content, money, or jurisdictional expansion—precisely the profile leadership schedules under suspension only when two-thirds support is already secured. No evidence of objection or floor controversy exists in the corpus. Residual uncertainty is purely generic procedural/scheduling risk, not substantive opposition.

I retain 96% for agreement. The introduced bill is a narrow judicial-administration measure adding federal court sitting locations in Texas and California, sponsored jointly by Cruz and Padilla. That bipartisan, low-cost, nonideological profile strongly fits a House suspension motion and makes clearing its two-thirds threshold highly likely. No frozen evidence provides an actual Clerk result, vote count, or later support record, so I retain a small probability of an unexpected procedural or floor-vote failure.

S. 32 is a narrow judicial-administration measure adding federal court sitting locations in Texas and California, introduced jointly by Republican Ted Cruz and Democrat Alex Padilla. Measures selected for the suspension calendar are generally expected to clear the two-thirds threshold, and neither the text nor the discussion identified a source of organized opposition. The remaining 1% covers an unusual breakdown in bipartisan support or other failure of the motion; cancellation or withdrawal would be void under the resolution rule rather than a not-agreed outcome.

No new evidence emerged in discussion; all four panelists independently read the same corpus and reached the same read. S. 32 is a three-section venue housekeeping bill adding College Station (28 U.S.C. 124(b)(2)) and El Centro (28 U.S.C. 84(d)) as places for holding district court, introduced by Cruz with Padilla — bipartisan, bicameral-friendly, no money, no ideological hook. It cleared the Senate and was scheduled under suspension, which leadership does only when two-thirds is already counted; the historical failure rate for suspension motions is low and concentrated on bills with an identifiable objecting bloc, which this lacks. I keep 3% on not_agreed for what the frozen corpus cannot show: floor conditions on 2026-08-31, a late objection, or an unrelated partisan blow-up converting a routine suspension into a protest vote. That residual is about day-of politics, not the bill.

The corpus shows this is a Senate-passed (already cleared 60-vote threshold), bipartisan-looking CR-plus-extenders package with no evidence of poison-pill provisions or organized opposition. The strongest signal is procedural: the question conditions on the September 1 suspension motion actually being offered, not merely listed as possible. Leadership only proceeds to an actual suspension vote when confident of the 2/3 threshold; if a whip count came up short, the standard response is to pull the item or pivot to a rule (both of which void the vote rather than producing a recorded failure). Historically, suspension motions that reach an actual recorded vote pass roughly 97-98% of the time. The December 2024 counterexample (174-235 failure) followed a highly public, last-minute collapse in negotiations with visible traces in contemporaneous reporting — nothing analogous appears in this frozen corpus. Weighing the strong procedural/base-rate case against the residual risk of an unforecastable controversy not captured in this evidence set, I settle at 0.90 agreed / 0.10 not_agreed, slightly less extreme than the pure base rate to account for the genuine absence of a whip count in our evidence.

I retain my initial view. The floor listing’s possible suspension consideration is a meaningful indicator that leadership anticipated cross-party support for concurrence in the Senate’s complete FY2027 continuing-appropriations and extensions substitute. But suspension needs two-thirds, and the record available by the cutoff contains no vote count, whip notice, or explicit commitments; the listing itself does not establish an outcome. That leaves a nontrivial risk of falling short despite the bipartisan incentive to pass a stopgap.

The August 26 floor listing’s choice of the suspension route is a meaningful revealed-confidence signal: leadership generally schedules a two-thirds motion only when it expects bipartisan support. The Senate replacement is also a broad continuing-appropriations and routine-extenders package, which is structurally likely to attract cross-party votes. I reduce my initial 89% slightly because the frozen evidence contains no whip count, exact coalition evidence, or outcome, and the two-thirds threshold leaves a material risk that partisan or fiscal-conservative defections defeat a package that could pass under ordinary procedure.

Nothing on the board moved me off my prior; if anything the discussion converged toward it. The corpus contains no whip count, no leadership statement, and no sign of a poison-pill division in the Senate engrossed text — only FLOOR_CONTEXT's note that the Aug 26 listing said the item "may be considered under suspension" and "does not establish an exact vote date or outcome." No panelist surfaced contrary evidence. My number rests on three things. First, the empirical base rate: suspension motions that actually reach a recorded vote pass roughly 97-98% of the time, because leadership self-selects into the two-thirds route only when it believes it has the votes. Second, the substance is a Senate-passed FY2027 CR plus routine authorizing, surface transportation and VA extenders — the text already cleared 60 votes in the Senate, the usual precondition for a broad bipartisan House coalition. Third, and most important for this resolution rule: the question conditions on the motion actually being offered on September 1, five days after the tentative listing. A count that comes up short normally produces a pulled or switched-to-a-rule item, which resolves void here, not not_agreed. So the failed-whip-count scenario largely drains out of the not_agreed bucket. The residual 7% covers the December 2024-style path: a late, publicly visible blowup that causes majority hardliners to defect while the minority withholds votes, with leadership choosing to take the recorded loss anyway. That happens, but it is rare and it leaves traces in the record that are absent here. I would not go below ~0.90 on a bipartisan Senate-passed CR under suspension without affirmative evidence of a revolt, and I do not go above ~0.95 given how thin the procedural evidence in this corpus is.

Convergent independent analysis across the panel: H.R. 9436 is a narrow, bipartisan bill (Lawler R-NY lead, Golden D-ME cosponsor) that simply extends an existing right-whale regulatory deadline from 2028 to 2035, protecting the Northeast lobster fishery. It was reported favorably with an amendment by the Natural Resources Committee (Report 119-766, Union Calendar No. 667) and committed to the Committee of the Whole House on the State of the Union — procedural markers indicating ordinary floor consideration under a rule (simple majority threshold) rather than a two-thirds suspension vote. This lowers the bar for passage and, combined with majority-party sponsorship, bipartisan cover, and no evidence in the corpus of organized opposition or controversy, strongly favors passage. The main residual uncertainty is the lack of direct floor vote tallies, whip counts, or confirmation the vote wasn't pulled/withdrawn — but nothing suggests that occurred. I settle slightly above my initial estimate given the corroborating independent readings on the Union Calendar/Committee of the Whole procedural signal.

Final: 84% agreed. The available primary bill record shows a very narrow extension of the existing right-whale provision’s dates from 2028 to 2035, with bipartisan original sponsorship (Lawler and Golden), and reporting to the House with an amendment on August 27, followed by Union Calendar placement (No. 667). Those are strong indicators that a passage vote was deliberately brought forward with a viable coalition. I retain 16% failure risk because the evidence provides neither the motion’s procedure/threshold nor a committee tally or floor whip count, and the policy can attract environmental opposition.

I raised passage from 91% because the reported text says the bill was committed to the Committee of the Whole, and the identified Clerk motion is captioned “On Passage”; suspension votes are ordinarily identified as motions to suspend the rules and pass. That makes a simple-majority threshold substantially more likely. A recently reported, majority-party-sponsored bill with a Democratic cosponsor and an identified final passage vote has a high base rate of passage. Residual risk remains because the corpus provides no special rule, whip count, committee tally, or direct evidence of floor support, and the environmental issue could produce unexpected defections.

Unchanged at 95%. The corpus establishes: H.R. 9436 is a one-line bill (strike "2028", insert "2035" in Sec. 101 of division JJ of the Consolidated Appropriations Act, 2023), sponsored by Lawler (R-NY) with Golden (D-ME), reported with an amendment by Natural Resources on 2026-08-27 as Report 119-766, Union Calendar No. 667, and committed to the Committee of the Whole (confirmed independently by Panelist 3). That routing plus the Clerk caption "On Passage" means a simple-majority vote under a rule, not a two-thirds suspension. The decisive fact is the conditioning: we are told the passage vote happens. Majority leadership controls whether a reported bill reaches the floor and on what terms; the binding constraint is the rule vote, not final passage. House bills reaching an up-or-down passage vote under a rule are agreed to roughly 95-98% of the time, and this one is majority-party-sponsored, narrow, and industry-protective with minority-side cover from Maine. Majority defections should be negligible even if most Democrats and environmental groups oppose. I did not move toward Panelist 2's 84%. The absence of committee tallies or whip counts in a corpus containing only bill texts is uninformative, not bearish; a double-digit failure probability needs an affirmative signal (suspension caption, a pulled vote, minority-forced consideration) and none exists in the record. The residual 5% covers a mislabeled threshold, a surprise floor revolt, or scheduling weirdness I cannot see.

H.R. 1501 was reported by the Natural Resources Committee (Report No. 119-691), placed on the Union Calendar, and picked up an additional cosponsor before floor consideration — signs of orderly majority-party progress rather than controversy. The question's framing as "On Passage" (distinct from a suspension motion) suggests ordinary-order simple-majority passage, which the Republican majority controls. Bills that leadership schedules for a recorded passage vote after committee reporting pass the vast majority of the time, since leadership rarely brings up bills it expects to lose. That said, as Panelist 2 noted, the corpus doesn't give us the actual committee markup vote, cosponsor list, or direct confirmation of the floor procedure, so there's real residual uncertainty about vote margins or whether some unexpected floor dynamic (amendments, whip problems, unrelated poison-pill riders) could sink it. Weighing the strong procedural base rate against that unresolved uncertainty, I land at 90% agreed / 10% not_agreed — essentially unchanged from my opening position, with a small downward adjustment to reflect the legitimate unknowns raised in discussion.

I retain 88%. H.R. 1501 was reported as H. Rept. 119-691 and placed on the Union Calendar, and its mining-permitting/FAST-41 changes fit the House Republican majority's agenda, making a scheduled passage vote likely to succeed. The frozen bill material does not establish the September 2 floor procedure, vote threshold, or whip count; if it were a suspension motion, the two-thirds requirement is the principal downside risk. The discussion supplied no verifiable contrary evidence or procedural record that warrants a change.

I remain at 97%. The verified procedural record shows a majority-party bill reported as House Report 119-691 and placed on the Union Calendar, while the identified Clerk question is “On Passage,” indicating ordinary passage by simple majority rather than a two-thirds suspension vote. Its mining-permitting deregulation aligns with the Republican House majority, and leadership rarely schedules final passage of its own reported bill without the votes. The discussion added no contrary whip or procedural evidence; I do not count the added cosponsor as evidence of bipartisanship because party support was not established. The 3% tail covers absences, defections in a narrow majority, or a mistaken procedural inference.

Unchanged at 95/5. The verifiable facts: H.R. 1501 is a majority-party (Shreve, R) FAST-41 permitting bill reported by Natural Resources on 2026-06-09 (Rept. 119-691, Union Calendar) and brought to the floor 2026-09-02 on a motion the question labels "On Passage" — the Clerk's wording for ordinary simple-majority passage, distinct from "On Motion to Suspend the Rules and Pass," which the resolution rule itself flags as a different thing. So the two-thirds scenario that would carry real failure risk is mostly excluded by the question stem, not just by my inference. Leadership schedules regular-order passage votes it expects to win, and bills reaching that stage pass at roughly 95-98%; Democratic opposition alone cannot defeat it under a rule. The remaining 5% covers thin-majority absences, an unexpected intra-majority revolt, or my reading of the motion label being wrong. No panelist produced evidence on the committee roll call or whip count, so this stays a base-rate call.

Consistent with the board discussion: H.R. 4795 has bipartisan sponsorship (Foxx-R, Gottheimer-D), was reported out of committee (Report 119-780), and placed on the Union Calendar just a week before this vote — strong procedural signals that leadership scheduled it for passage under regular order. No panelist found evidence of controversy, opposition, or a two-thirds suspension threshold that would meaningfully raise failure risk. The corpus lacks the actual roll call or whip count, which caps my confidence short of certainty, but the totality of procedural evidence supports a high probability of passage.

I retain 82% for agreement. The reported version shows bipartisan original sponsorship by Foxx and Gottheimer and that the bill was reported on Aug. 27, assigned Report 119-780, and placed on Union Calendar 681 immediately before the identified vote—strong evidence of an intended, viable floor measure. Its Israel-boycott and academic-access provisions should draw broad Republican support and some Democratic support. But the record supplies neither the floor procedure/threshold nor a whip count; consideration under suspension or a narrow-majority attendance/defection problem leaves a meaningful failure risk.

The August 27 reported bill, committee report, Union Calendar placement, and identified September 3 on-passage motion strongly indicate leadership scheduled an ordinary final vote it expected to win. Foxx–Gottheimer original sponsorship and the anti-boycott subject provide some bipartisan cushion atop likely near-unanimous Republican support. The discussion found no contrary scheduling evidence; the remaining 4% covers the unresolved possibility of a two-thirds suspension threshold or an unexpected attendance/intra-party failure.

Nothing on the board added evidence beyond what I already used: bipartisan Foxx–Gottheimer sponsorship, committee Report 119-780, Union Calendar No. 681 dated 2026-08-27, and a floor vote a week later. The corpus contains no scheduling documents, so the threshold (rule vs. suspension) is unknown — but that ambiguity does not widen the failure tail much, since leadership screens suspension bills for two-thirds just as it screens rule bills for a majority; conditional pass rates are ~93-97% either way. The residual 6% covers the specific scenario where an anti-BDS Title VI funding condition draws organized minority-party opposition under suspension, plus generic surprise. Holding at 94/6.

Converging evidence points strongly to a hold: the June 16 hike to "around 1.0%" was only six weeks before the July 31 meeting, and even the hawkish June opinion framed further hikes as coming "at intervals of a few months," not consecutive meetings. No back-to-back hike has occurred anywhere in this tightening cycle (per board discussion). Fresh June CPI data (headline 1.7%, ex-fresh-food 1.6%, ex-fresh-food-and-energy 1.7%) remains below the 2% target, reducing urgency for an immediate second hike despite firm wage growth (3.3%) and improving Tankan/regional readings. The July meeting's Outlook Report status keeps some non-trivial hike probability alive, but the weight of evidence favors unchanged. Nothing in the corpus points to conditions justifying a cut — growth and inflation trends are stable-to-improving, not deteriorating.

I have raised unchanged from the first ballot because July 31 follows the June 16 1.0% move by only about six weeks. The June opinions characterize subsequent tightening as conditional, including one view that increases should come at intervals of a few months; the June decision also cited some weakness, oil-related uncertainty, and CPI excluding fresh food below 2%. The case for a hike remains material: the June move was 7–1, several members favored further increases conditional on developments, the Tankan’s current readings improved, and all regions were still assessed as recovering or improving. The supplied corpus contains no later market-pricing, consensus, or BOJ-communication evidence to resolve that balance. A reversal below 1.0% immediately after the June hike has little support.

The BOJ had raised the guideline to 1.0% only six weeks earlier, on June 16, and even the hawkish June opinion described possible increases at intervals of a few months. The July 24 release showed June CPI at 1.7% headline, 1.6% excluding fresh food, and 1.7% excluding fresh food and energy, which does not create a clear need for a consecutive-meeting hike. Firm wages, Tankan results, and ongoing price pass-through leave a small upside tail and point toward later tightening. A cut is only a remote shock tail given positive wage growth and broad regional recovery.

Core facts from the frozen corpus: D01 — "The June 16 decision set the uncollateralized overnight call-rate guideline at around 1.0%, effective June 17, by a 7–1 vote." July 31 is the very next meeting, ~6 weeks later. The BOJ has not tightened at back-to-back meetings at any point in this normalization cycle, and D02 records a hawkish member arguing for increases "at intervals of a few months," with other pro-hike opinions explicitly conditional on data. That is a patience signal, not an urgency signal. Inflation reinforces the pause. From CPI_1 (Statistics Bureau June archive, released July 23) I computed June 2026 y/y as ~+1.7% headline, ~+1.5% ex-fresh-food, ~+1.7% ex-fresh-food-and-energy; Panelist 3 cited the published figures as 1.7/1.6/1.7. Either way the freshest print is below 2%, matching D01's description, and the June statement already flagged oil-price drag and "some weakness." The Tankan (D03) shows firms expecting confidence to soften next quarter (large all-industry 29 now vs 23 forecast). Nothing here forces a second hike. I keep ~7% on a hike rather than dismissing it: July is an Outlook Report meeting, a traditional venue for BOJ moves; wages are firm (final May total cash earnings +3.3% y/y); and the corpus contains no market pricing, consensus poll, or post-June-24 BOJ speech, so I cannot rule out a hawkish signal I simply cannot see. That missing-communication gap is the main reason I nudged up a point from 6%. A cut stays at 1% — it would require an unobserved crisis, and the entire board debate is about the pace of further increases, not reversal. Other panelists landed at 14–16% for a hike; their case rests on hawkish rhetoric, which I think is outweighed by the cadence precedent plus sub-target core inflation.

The frozen corpus contains no evidence of a specific technical, weather, or scheduling driver (e.g., no Starliner-style contingency, no forecast tropical system) that would presage a change to the Sept 12 NET target for Crew-13. However, discussion raised a reasonable historical base rate: NET dates for crew rotation missions set ~3-4 weeks out have shifted before launch day in a substantial share of past cases (Crew-4, Crew-5, Crew-7, Crew-8, Crew-9), though several of those were tied to identifiable special causes (Starliner return decision, hurricane landfall) not present in evidence here, while Crew-6, Crew-10, and Crew-11 held their announced dates. Weighing the base rate against the absence of any specific negative signal in the corpus, and noting September is hurricane season (a generic, non-trivial risk factor for a Florida launch), I move my estimate up modestly from my opening 35% to 40%, reflecting genuine uncertainty rather than strong evidence either way.

Final: 40% Yes, 60% No. The frozen record contains the Crew-13 assignment/background material and NASA’s Aug. 3 introduction/update, but no identified technical, vehicle, ISS, or weather issue pointing to a schedule revision. The interval is short and a NET date leaves material operational uncertainty, including ordinary late targeting and September weather; still, this resolves on a public NASA statement explicitly altering the target, not on a delayed liftoff alone. With no mission-specific trigger, I keep No as the more likely outcome.

Recent crew-rotation history suggests that pre-launch NET dates move often enough to put Yes near a coin flip or slightly above, and NASA would normally publish any genuine change. I reduced my initial 64% because the resolution window closes at midnight ET at the start of Sept. 12, excluding launch-day scrubs—a common source of date changes. The Aug. 3 article presents Sept. 12 without a known readiness problem, but its silence five weeks before launch is weak evidence because weather, traffic, and hardware issues often arise only in the final weeks. On balance I retain a modest Yes lean.

Evidence is thin (two NASA items: May 2026 assignment release, Aug 3, 2026 crew-introduction article giving a fresh NET Sept. 12), so this is mostly a base-rate call, and I say so. Base rate: for SpaceX crew rotations, the date standing a few weeks out moved before launch day roughly half to 60% of the time (Crew-4, Crew-5, Crew-7, Crew-8, Crew-9), while Crew-6, Crew-10 and Crew-11 held and only scrubbed on launch day. Panelist 1's "those were special causes" objection double-counts our ignorance: every slip had an idiosyncratic driver invisible weeks ahead, which is exactly what the cross-mission rate averages over. Corpus silence as of Aug 4 is near-zero evidence — it looks identical in slip and no-slip worlds. Discounts that keep me near coin-flip rather than higher: the window closes at midnight ET on Sept. 12, so day-of scrubs and same-date launch-time refinements — a large share of crew schedule changes — do not qualify; and the target was set recently and specifically with no flagged readiness issue. Offsetting factor: Sept. 12 is peak Atlantic hurricane season, the slot that moved Crew-5 and Crew-9, and any such slip would be publicly announced by NASA before launch day, so detection is not a barrier. Net: 53% Yes / 47% No, with wide uncertainty given the sparse corpus.

The corpus's most recent evidence (Aug 7) affirms the 27 August date with a normal-sounding pre-launch campaign, no anomalies reported. Board discussion surfaced concrete Ariane 6 slip precedents (CSO-3 slipping ~1 week, Metop-SG A1 slipping a day) supporting a real but moderate base rate (~20-25%) of pre-launch-day date slips, plus a separate scrub-on-launch-day risk. A useful clarification: Kourou GTO departures are typically evening local time, well inside the UTC window with hours of margin, so ordinary holds of 30-90 minutes would still resolve Yes — only a full scrub-to-next-day or an earlier reschedule would flip to No. Combining these risks nets to roughly 55-60% Yes, consistent with where the panel converged. I finalize at 0.56/0.44, reflecting genuine uncertainty about schedule risk for a novel first-GTO Ariane 6 mission balanced against no negative signal in evidence and a comfortable timing margin within the resolution window.

I retain my initial probabilities. ESA’s 7 August article still explicitly schedules the flight for 27 August and describes normal ongoing launch-campaign checks, with no cited anomaly or postponement. Conversely, those checks were not yet complete, and the resolution is unusually unforgiving: any technical, range, or weather hold that moves liftoff outside that single local calendar day resolves No. ESA also describes VA270 as Ariane 6’s ninth flight but its first mission to GTO, a real though limited added schedule risk. The clean schedule signal and the residual exact-date risks leave No narrowly more likely.

I remain at 70% Yes. ESA reaffirmed the exact August 27 date on August 7, with MTG-I2 already at the spaceport and in an active launch campaign since July; this is a strong, current schedule signal rather than an old manifest entry. The observation that checks remained underway is already reflected in my 30% No allowance, alongside weather, range, payload, and launcher issues; it does not outweigh the near-term official reaffirmation, especially for what is planned as Ariane 6’s ninth flight.

Nothing on the board changed the evidence base: all four of us are working from the same two ESA features (8 July: date to be announced; 7 August: "set to ride into orbit... on 27 August," checks underway). No launcher-side information, no anomaly, no slip report exists in the corpus. My estimate stays a two-stage base rate. Pre-launch-day slip (campaign, launcher, range) ~20-25% — Ariane 6's short record includes multi-day date moves (CSO-3 late Feb to 6 March 2025) and a one-day move (Metop-SG A1, August 2025), and this is the vehicle's first GTO mission and ninth flight, so the profile is new. Launch-day scrub with next-day retry ~15-20%; that is the failure mode the 24-hour window punishes, whereas a routine 30-90 minute hold still resolves Yes since an evening Kourou liftoff sits mid-window. Combining gives ~0.55-0.60. Offsetting factors roughly cancel: late August is Kourou's dry season and this is a priority EUMETSAT/ESA institutional payload with strong incentive to hold the date, against the added uncertainty of a first-of-kind mission profile. I stay at 0.55 yes / 0.45 no, with the honest caveat that the main unknown — launcher readiness in the final two weeks — is simply absent from the frozen evidence.

D03 confirms Roman/Falcon Heavy is "go" after passing the Launch Readiness Review, targeting a single 7:26 a.m. EDT attempt on Aug 30, with SLD-45 forecasting only 60% favorable weather. Given Roman is L2-bound like Europa Clipper/IMAP, the window is likely narrow to near-instantaneous, and the resolution deadline (midnight EDT Aug 30/31) leaves no room for a scrub-to-Monday recycle — this is effectively a single-attempt question. Weighing the ~60% weather forecast (which is a categorical go/no-go call and not necessarily a literal launch-probability ceiling) against the strong technical readiness (fueling complete, LRR passed) and the historical ~80% first-attempt success rate for recent NASA/SpaceX Falcon missions from KSC, I land near the board's converged estimate: roughly 65% probability of liftoff within the window, with the residual 35% driven mainly by the documented adverse-weather risk and the lack of any recycle opportunity before the deadline.

I retain my initial assessment. NASA’s Aug. 29 report says Roman/Falcon Heavy passed the final Launch Readiness Review and is “go” for a 7:26 a.m. EDT Aug. 30 launch, which makes liftoff more likely than not. However, the same contemporaneous report gives only a 60% favorable-weather forecast, and the evidence offers no established backup attempt before the midnight deadline. That mission-specific weather risk plus residual countdown risk supports a substantial No probability.

I remain at 55% Yes. NASA’s contemporaneous update confirms the mission passed its final readiness review and was go for the Aug. 30 morning attempt, but the official weather forecast was only 60% favorable. Residual vehicle, range, and ground-system scrub risk makes liftoff slightly less likely than the weather figure alone, while some chance of conditions improving or being acceptable within the window keeps the estimate near it. Because a retry on Aug. 31 would fall after the deadline, a scrub probably resolves No.

The deadline (Aug 31, 00:00 EDT) makes this a single-attempt bet on the 7:26 a.m. EDT Aug 30 countdown. D03 (NASA, dated at the cutoff) confirms the Launch Readiness Review passed and the mission is "go," with hardware fueled (D02) and the vehicle at LC-39A — so no known technical blocker. Against that, NASA's own published forecast is only 60% favorable weather, and for an L2-bound mission the window is probably short, so a violation cannot reliably be waited out. Balancing: (a) the base rate of prior NASA primary Falcon missions from Kennedy — IXPE, Psyche, GOES-U, Europa Clipper, IMAP — is roughly four of five flying on the first countdown attempt, which argues above 60%; (b) SLD 45 "percent favorable" numbers are categorical rule calls and historically launches beat them somewhat; (c) but residual technical/range scrub risk (~10%) is independent of weather and has no recycle day here. 60% weather-clearance, modestly improved for within-window recovery and the strong readiness signal, times ~0.9 for technical/range, gives ~0.62-0.65. I settle at 0.63. Main gap: the corpus states no launch window duration and contains no post-LRR update, so I cannot rule out a late issue or confirm a long window.

Consensus from the frozen game logs: Rockies were outscored 20-6 across three losses to Cleveland, then dropped the first Washington game 13-3 before salvaging one 3-1 win. Net series scoring in DC favors Washington (14-6 over two games) despite the split result. Combined with home-field and the broader run of poor Rockies form, I'll settle slightly above my initial estimate for the Nationals, but not much higher given no starting-pitcher data and the Rockies' one solid win.

I retain the modest Nationals edge. The available logs show a split in the first two Washington games (Nationals 13–3 on Aug. 24; Rockies 3–1 on Aug. 25), so neither recent head-to-head form nor momentum is decisive. Colorado’s preceding three losses to Cleveland and Washington’s home field support Washington slightly, but the absence of starting-pitcher, roster, and season-strength information keeps this close.

Washington has the moderate edge from home field and likely underlying team strength. The restricted recent record is consistent with that: Colorado was swept by Cleveland 20-6 and split the first two games in Washington while being outscored 14-6, including an eight-walk, two-error collapse. However, the corpus provides neither full 2026 standings nor probable starters, and Colorado won the August 25 matchup 3-1, so I limit the Nationals to 64%. Discussion moved me only one point upward; estimates based on assumed .300/.440 records are directionally plausible but not established by the supplied evidence.

Washington is the home team in the finale of a four-game set. In-corpus form favors them: Colorado was swept at home by Cleveland (outscored 20-6) and outscored 14-6 across the first two games in DC, and was routed 13-3 on Aug 24 with eight walks and two errors. But Colorado took the Aug 25 game 3-1, and Washington's own log in the same window is poor (shut out 0-5 and 0-2 at Texas, lost 6-2 at Miami). I searched for season standings to anchor a log5 estimate and the frozen corpus has none — only per-game stat lines that explicitly disclaim roster, starter and injury information — so my earlier .300 talent estimate for Colorado was an outside prior rather than evidence, and I discount it. That moves me from 0.66 to 0.63: a clear but modest home favorite, consistent with typical MLB moneylines for a weak home team against a weaker road one. With no starting pitcher information and high single-game variance, I don't think anything above ~0.68 is defensible here, nor anything near a coin flip.

Head-to-head on 7/28 favored Texas (4-1, strong pitching), and Texas has been hot recently (3 of 4 vs Seattle, split with Atlanta). Tampa Bay was also 4-2 over its prior six games and holds home field, per the board discussion. With no injury/starter/season-record data available, I keep this close to even with a slight edge to Texas based on the most recent, most relevant data point.

I retain a narrow Texas edge. The strongest direct evidence is Texas’s 4–1 road win over Tampa Bay on July 28 (7–5 hits; Rangers allowed one earned run), but Tampa Bay had a 4–2 recent displayed stretch and home field. With no starters, lineups, injuries, full-season strength, or July 29 outcome in the restricted evidence, one head-to-head result cannot justify a larger lean.

I moved toward Tampa Bay after discussion supplied a broader recent sample: Texas played well against Seattle but struggled in Atlanta, while Tampa swept Cleveland at home but was mixed on the road. That leaves no demonstrated team-strength gap large enough to override Tampa Bay's home-field advantage. Texas's 4-1 win in the July 28 series opener is relevant but only one game; absent starters, injuries, standings, or the July 29 result, the Rays deserve a modest rather than strong edge.

Venue is the only firm fact: G822949 confirms Texas was the away team at Tampa Bay on 7/28, so the 7/30 game is in Tampa. That gives the Rays the standard ~54% home edge for evenly matched teams. Team strength in the restricted record set is essentially a wash (Rangers 3-of-4 vs Seattle but outscored in Atlanta; Rays strong at home vs Cleveland but 1-2 in Toronto and lost the Texas opener), and no starting pitcher, roster, or injury data exists in the corpus. Colleagues leaning Texas rest on the single 4-1 head-to-head, which is worth only a point or two of update and reflects a starter who won't pitch on 7/30. I shade the home prior down slightly for Texas's marginally better recent scoring profile: Rays 52.5 / Rangers 47.5. Low confidence, close to a coin flip by construction.

Consensus across the panel confirms the same core evidence: Baltimore's 13-1 win over St. Louis on Aug 25 is the most relevant data point, but it's a single game and shouldn't be over-extrapolated absent starter/injury info. Surrounding form (Orioles mixed vs Rays, Cardinals losing series to Phillies) gives a modest overall edge to Baltimore. I maintain my original estimate of 56/44, reflecting a real but limited edge rather than strong conviction.

I retain Baltimore at 60%. In the directly relevant Aug. 25 game at St. Louis, Baltimore won 13–1, with a 17–7 hit advantage and one earned run allowed. Both clubs' nearby records include strong and poor results, so that game supports only a modest Orioles edge rather than extrapolating the blowout. St. Louis is at home, and the restricted evidence has no Aug. 27 probable starters, lineups, injuries, or full-season ratings, leaving substantial Cardinals upset probability.

I retain Baltimore at 55%. The Orioles' 13-1 road win over St. Louis two days earlier, plus a modestly better recent profile in the surfaced records, supports an Orioles lean. The discussion added no starter, injury, or full-season evidence that would justify a larger move; St. Louis's home advantage and normal MLB game variance keep the matchup close.

Two forces of similar size, pointing opposite ways. St. Louis is the home team (G823016 shows the 8/25 game as "Baltimore Orioles away at St. Louis Cardinals"), worth about 53% between comparable clubs. Against that, my prior that Baltimore is the modestly better 2026 roster — the Cardinals in an announced organizational reset, the Orioles a young core that underachieved in 2025 — which I flag as outside-corpus knowledge, plus the visible run differentials (St. Louis outscored badly by Philadelphia and then 1-13 by Baltimore, while Baltimore played roughly even with Tampa Bay). Those roughly cancel, leaving a hair in Baltimore's favor. I discount the 13-1 blowout heavily: the document itself warns the stats "do not describe the roster, starting pitcher or injury status for a later game," and one game's margin has almost no carryover to the next start. I also discount the panel's streak framing — the surfaced games are a search artifact, not a clean last-10 sample. No season records, standings or probable pitchers exist in the frozen corpus, and the 8/26 result posts after the cutoff, so nothing supports a confident lean. 51/49 Baltimore, with low confidence; this is a coin flip with a thumb on the scale.

Both teams' recent (~2 week) logged performance is essentially even in win-loss terms, but run differential slightly favors the Giants (24 RS/24 RA vs. Arizona's 25 RS/29 RA, the latter dragged down by two blowout losses). The venue is not directly confirmed in the corpus, but the "away at home" naming convention plus each team's schedule fingerprint (Arizona finishing a homestand 8/22-24, Giants returning home after their Cleveland trip 8/19-20) both point to San Francisco hosting on 8/27. That gives a modest home-field edge on top of the slightly better run differential, landing at Giants 55% / Diamondbacks 45%.

I changed from my initial Arizona lean because I had assigned the venue backwards. The evidence corpus labels matchups as away team first and home team second; applied to “Arizona vs. San Francisco,” that makes San Francisco the likely home club, though the exact-date schedule record was not returned. Recent logged form is broadly even: SF has a 5-0 home win over Cincinnati alongside mixed Colorado/Cleveland results; Arizona has wins at Atlanta and over Cincinnati but a recent 0-7 home loss to Chicago. No starter, injury, or season-strength data are supplied, so the Giants’ inferred home edge is deliberately modest.

The fuller recent-game sample makes form essentially a wash: both teams were about 3-3 over their last six logged games, with volatile results and no reliable starting-pitcher or injury information. The schedule pattern and matchup ordering strongly suggest San Francisco hosts, so I apply a modest MLB home-field edge. I moved from 52% to 54% Giants because the broader Arizona sample erased the slight form advantage suggested by my initially incomplete search.

Unchanged from my last ballot; nothing on the board moved me. The frozen corpus holds only box-score lines through 8/24 — no 8/27 game document, no starting pitchers, no injury or standings context — so only two levers exist. Team strength is a wash. Arizona's logged fortnight (L3-5, W2-0, W10-3 at Atlanta; L5-11, W5-3 vs Cincinnati; L0-7 vs the Cubs, plus the 7-6 Boston win and 9-0 Cincinnati win another panelist surfaced) and San Francisco's (L7-13, W7-1 vs Colorado; W1-0, L2-5 at Cleveland; W5-0 vs Cincinnati) both sit near .500 with essentially level run differential. A 3-1 four-game Arizona window is too small to outweigh that. Venue is the only real edge, and it is inferred rather than confirmed: the corpus names games "Away at Home," matching the question's away-first "Arizona vs. San Francisco," and the schedule fingerprint (Arizona home 8/22–8/24, Giants home from 8/24 after Cleveland) fits a Thursday opener at Oracle Park. Confirmed home field would justify roughly 0.54–0.57 for the Giants; the live possibility the game is in Phoenix, which would flip the sign, trims that back. Giants 0.55, Diamondbacks 0.45 — near a coin flip, and I would not defend anything more extreme.

Consistent with the board discussion: Brewers' recent game logs show a stronger run (swept Rockies 21-9 combined, went 2-2 with a dominant win over Miami) versus Giants' streakier form (split with Angels, lost 2 of 3 at Seattle, lost at Kansas City). Venue for this specific game is not confirmed in the corpus, but even accounting for a possible home/road split, the underlying team strength signal favors Milwaukee moderately. Settling on 58/42 as a defensible, non-overconfident lean.

I reduce Milwaukee from 56% to 54% because the frozen corpus does not establish the July 29 venue; my initial home-field rationale was therefore unsupported. The available logs show only a small, noisy recent-performance distinction and no starting-pitcher, injury, or standings data. Milwaukee retains a modest underlying-strength prior, but this is close to a coin flip given those omissions.

I raised Milwaukee from 52% after the discussion supplied missing recent results: the Brewers swept Colorado 3-0 and outscored them 21-9, while San Francisco's surfaced form was mixed. I discount that sweep because Colorado is weak and keep the edge modest because no probable-starter or injury evidence is available and San Francisco likely has home advantage. Overall, Milwaukee's stronger team prior plus better recent run supports 56%.

No new evidence surfaced in discussion that changes my estimate. From the game logs I verified: Milwaukee took its last series from Colorado at home (L 2-5, W 8-5, W 11-2) and beat Miami 8-6 and 3-1, showing a team that scores in bulk with several strong pitching lines; San Francisco split with the Angels at home (W 7-6, L 3-4), went 1-2 at Seattle and lost at Kansas City, with repeated multi-error games and a streaky offense. That supports Milwaukee as a clearly better club but not a dominant one. Log5 on ~.590 vs ~.495 gives Milwaukee ~.60 on neutral ground, ~.57 if the Brewers are the visitors at Oracle Park and ~.64 if they are home. The corpus contains no document fixing the July 28 venue; I weight roughly 80% on Milwaukee travelling, which averages near .58. Missing starting-pitcher and injury data widens the uncertainty band and caps how far I can deviate from even money, but it does not systematically pull the point estimate toward 50% since team-level form already averages over rotations. Final: Brewers 58%.

Schedule flow in the corpus (Rockies finished at Coors on 7/5, then played at the Dodgers on 7/6) indicates the July 9 game is on Colorado's road trip, likely at Oracle Park rather than Coors Field. This flips home-field advantage to the Giants. The Rockies' strong offensive showings in the frozen data (15 runs and 7 runs vs Giants, 14 runs vs Miami) all occurred at Coors Field's hitter-friendly altitude, while their road output (2 runs, 14 strikeouts at Minnesota) looks far more modest — consistent with the well-known large home/road performance split for Colorado. Oracle Park is one of the most pitcher-friendly parks in MLB, working against Colorado's offense specifically. Combined with the Giants generally being the stronger organization, this points to a clear Giants favorite, though not overwhelming given the sample size limitations and lack of confirmed starting pitchers.

No new evidence changes my initial assessment. San Francisco has the stronger prior and likely Oracle Park home-field advantage. Colorado won two of three in the immediately preceding Denver series, but those results were close except for one Coors Field blowout and are not enough to reverse the venue-adjusted prior. Starting-pitcher and complete current-record information are absent, keeping the Giants below a heavy-favorite probability.

I lower San Francisco from 66% to 62% because the broader sampled results confirm Colorado was genuinely hot, winning four of six from July 1–6 and taking two of three from the Giants. Still, nearly all of that success came at Coors, while the Rockies then lost their road game at Los Angeles; San Francisco's sample was also respectable, including road win at Arizona and a 10–1 home win over Toronto. With no standings, injuries, or confirmed starters in the restricted evidence, I lean on the Giants' stronger team-strength prior and apparent home field but retain substantial upset probability.

Venue is confirmed by schedule flow: SF played at Coors July 3-5, hosted Toronto July 6, and Colorado was at the Dodgers July 6 (per Panelist 1/3's searches), so July 9 is Rockies at Oracle Park. That puts a bottom-tier road club in the league's most run-suppressing park against a decent home team — a market price near -200/-230. The Rockies' 2-of-3 at Coors is a three-game, altitude-inflated sample; it shifts a strength prior by only a couple of points, and their non-Coors at-bats in the corpus (2 runs and 14 strikeouts at Minnesota) look like the real thing. No starter or injury data exists in this corpus, which is the main reason I don't push past ~0.72. I shade a hair down from 0.71 to 0.70 to acknowledge the panel's slightly lower central estimates and genuine uncertainty about how good this year's Giants actually are (their sampled results vs Atlanta were middling). Ties/cancellations excluded per the resolution rule.

Board discussion surfaced two useful facts beyond my initial ballot: (1) venue confirmation — Dodgers played a doubleheader away at the Yankees on 7/19, indicating they are mid-East-Coast-trip, so the 7/21 game is at Citizens Bank Park with Philadelphia as home team; (2) recent-form tallies from the frozen game logs show Phillies 4-2 in their last six games (including an 18-K shutout-quality win and a 14-K two-hitter) versus Dodgers 3-3 with a 3-game losing streak against Arizona heading into this stretch. Neither signal is individually decisive — a 6-10 game sample moves true talent estimates only modestly, and the corpus explicitly lacks starting-pitcher and injury information, which typically dominates single-game pricing. But home-field advantage and the modest form edge both point the same direction (Phillies), so I'm settling slightly off a coin flip rather than favoring the Dodgers as I did in the sealed first ballot, when I hadn't yet found Phillies data or venue information.

I revise to Philadelphia after the board established venue: Dodgers were away at the Yankees on July 19, consistent with this July 21 game being at Citizens Bank Park. I retain a modest Dodgers neutral-talent prior, but Philadelphia home field more than offsets it. Recent records are broadly mixed—Philadelphia split its visible Mets series after winning two at Detroit, while LA split the July 19 Yankees doubleheader—so I give short-run form little weight. No starting-pitcher or injury information is available, which keeps the edge narrow.

I raised Los Angeles from 53% after finding newer results. The Dodgers rebounded from the Arizona sweep by going 2-1 at the Yankees, including an 8-2 win; Philadelphia went 3-3 across series at Detroit and versus the Mets, with mixed run differentials. Los Angeles also appears to have the home/travel advantage and retains the stronger roster prior. With no confirmed starters, injuries, or full-season records in the restricted evidence, the edge remains modest.

Unchanged from my first ballot; the discussion confirmed rather than challenged my two load-bearing facts. Venue: the Dodgers played a 7/19 doubleheader "away at New York Yankees" (G823521, G823523), so they are on an East Coast trip and 7/21 is at Citizens Bank Park — Philadelphia is home, worth ~4 points. Form: the Phillies went 4-2 on their last road trip (G824494/95/96, G824249/50/52) and the Dodgers stumbled at home against Arizona (G823926, G823927) before splitting the Yankees doubleheader — a mild edge to Philadelphia, but ten-game samples move true talent by a point or two at most, so I give it almost no weight beyond the park. Both clubs are near-equal contenders by roster prior, and the records explicitly contain no starting-pitcher, injury or lineup information, which is the single biggest driver of a one-game MLB price and could swing this ±8 points unseen. That argues for staying near the home-field baseline rather than manufacturing confidence. Phillies 53, Dodgers 47.

Board consensus converges on the same read I had: Phillies went roughly 4-2 to 5-1 in their last six logged games with multiple dominant, double-digit-strikeout pitching performances, while the Mets went 2-4 with shaky pitching even in their wins (slugfests) and a bad 12-16 loss to KC. This is a real but noisy signal (six games ≈ one win of information), and venue for 7/16 isn't confirmed in the corpus. Splitting the difference between the moderate form-based edge and the small-sample discount, I'll hold at Phillies 58/Mets 42.

I retain and slightly strengthen the Phillies lean. Philadelphia closed its visible pre-break stretch with 4–2 and 5–0 wins at Detroit; the latter featured two hits allowed and 14 strikeouts. The Mets’ available recent record includes a 3–2 loss to Boston plus high-run pitching losses to Kansas City (16) and Atlanta (14). This is still a restricted, noisy game-level sample with no confirmed starters or injury information, so it supports only a modest edge.

I move Philadelphia up one point because the fuller recent-game tally confirms a meaningful form gap: the Phillies were 5-1 in their last six logged games with several strong run-prevention performances, while the Mets had multiple heavy losses and needed high-scoring games for their recent wins. I keep substantial uncertainty because recent form is a small, noisy sample and the frozen evidence does not establish the starting pitchers, injuries, or even the venue with confidence.

Nothing on the board changed my evidence base — every panelist read the same six box scores, so the convergence is one weak signal counted four times, not independent confirmation. The substance: Phillies 4-2 into the break with strong run prevention (1-0 and 5-0 road wins, repeated 14-18 strikeout games), Mets 2-4 with their wins coming in 10-9 and 7-6 slugfests and a 12-16 home loss to Kansas City. That is about a one-game difference over six games; regressed toward true talent for two NL East contenders it is worth only a couple of points, not ten. The venue is not documented anywhere in the frozen corpus — only completed box scores are indexed. I assume Philadelphia is home from the "away vs. home" title convention, which carries roughly 4 of my points and remains my largest unverified assumption. Starting pitchers and injuries are also unobserved, and they usually move an MLB price more than recent form does. Final: Phillies 57, Mets 43.

Combining recent form (roughly even, slight Dodgers edge in quality of opposition beaten — Phillies and Mariners vs. Boston's weaker Athletics competition) with the plausible home-field read from the game logs (Boston finishing a West Coast trip at Oakland 7/27-29, Dodgers hosting Seattle 7/28-29, consistent with LA hosting on 8/1), I settle on a moderate home-favorite line for the Dodgers. No pitcher/injury data available to sharpen further, so I avoid pushing beyond a standard ~60/40 split.

Final: Dodgers 60%, Red Sox 40%. Late-July box scores indicate broadly similar short-run results—Boston 2–1 at the Athletics July 27–29 and Los Angeles’ available July 29 result a 4–2 win over Seattle—rather than a material current-form separation. The restricted corpus yielded no game-specific venue, probable starter, or injury evidence, including on a direct matchup search. I therefore retain a modest Dodgers advantage based on the general team-quality prior, but reduce it from 62% because the home-field premise cannot be substantiated from the provided evidence.

Los Angeles remains the favorite on the stronger overall team-quality and roster-depth prior, while the recent restricted records are roughly even: Boston was 4-2 over its last six and Los Angeles 3-3. I reduced the Dodgers from my initial 63% because a focused search did not confirm the venue, starters, or injuries; the apparent Dodgers home-field advantage is plausible from both clubs’ travel sequence but not established. With those important game-level inputs missing, 60% is the most defensible modest edge.

Unchanged from my first ballot; nothing on the board moved me. Two signals put the game at Dodger Stadium: the away-first naming convention and the travel sequence (Boston at Oakland through 7/29, Dodgers home 7/28-29). Even discounting that inference to ~85% confidence costs under a point of win probability. The Dodgers are the stronger roster and showed it against quality opposition (took two of three in Philadelphia), while Boston's 2-1 at the Athletics is against a weak club. Colleagues' "recent form is at parity" argument does not pull toward 50-50: a six-game record is noise, not evidence of equality. A ~57-58% neutral-field talent edge plus MLB home field (~54%) lands in the low-to-mid 60s. No starter or injury data exists in the frozen corpus, which is why I stop at 62 rather than higher.

Both teams show mixed recent form with no strong momentum signal in either direction — Dodgers went 3-1 in their last homestand vs SD before that plus a road loss to A's, Rockies had a rough loss to Miami but bounced back with two wins and beat SF on 7/5. Venue for July 8 isn't confirmed in the corpus (Panelist 4's point is well taken), so I'm blending across home/away possibilities rather than assuming full Dodger-Stadium home-field boost. The Dodgers remain a clearly superior roster to the Rockies, and single-game talent gaps of this magnitude typically translate to something in the 70-75% range rather than higher, given game-to-game variance in baseball. I land at 71% Dodgers / 29% Rockies.

Final view unchanged. Colorado’s available recent logs are mixed: it won 2 of 3 at Minnesota and posted notable home wins over Miami and San Francisco, but also lost to Minnesota and San Francisco; Los Angeles went 1–2 in the recent San Diego series. Short-run outcomes and Colorado home conditions support a meaningful upset chance, but no starter/injury evidence offsets the Dodgers’ much stronger underlying roster and historical team-strength prior. Dodgers remain the clear single-game favorite.

I remain at 72% Dodgers. The restricted June 26–July 5 results I found have Los Angeles 5–3 against San Diego and the Athletics, while Colorado was 4–4 against Minnesota, Miami, and San Francisco; that modestly supports the much larger underlying organizational/team-strength prior favoring Los Angeles. Colorado’s recent home wins and ordinary single-game baseball variance leave a substantial upset chance. Venue, probable pitchers, and injuries were not reliably established in the corpus, so I would not push the favorite above the low 70s.

Nothing on the board changed my view. The corpus gives game logs only: Dodgers roughly 7-4 over their last eleven (2-1 at San Diego, 2-1 at the Athletics, 3-1 hosting San Diego July 2-5) with several big offensive games; Rockies about .500 in the same window (2-1 at Minnesota, 2-1 vs Miami, a 7-6 win over San Francisco) but with a 3-14 blowout loss mixed in — volatile, consistent with a weak team having a decent fortnight. No standings, odds, probable starters, or venue are in the evidence; my search for a July 6-7 head-to-head record returned nothing, so Coors vs. Dodger Stadium stays unresolved (worth ~5 points either way). So I fall back on the prior: an elite Dodgers team against Colorado prices around -250 to -320, i.e. ~72-76%, a touch lower at altitude. Blending venues gives ~73%. I deliberately don't go to 80%+: single MLB games are noisy, one starter can flip anything, and the Rockies' recent scoring shows they're not a pushover at home this season. Final: Dodgers 73%, Rockies 27%.

Consistent with the board discussion: Yankees won both recorded meetings this series (9-5, 3-2), while White Sox recent form is mediocre (lost 2 of 3 to Rangers, lost to Astros). No starter/injury data available, so I keep a moderate but not overwhelming edge for the Yankees, slightly nudged up from my initial estimate given panel agreement on the same evidence.

I retain the initial estimate. In the two latest recorded games of this series at Chicago, New York won 9–5 and 3–2, giving it the clearest direct performance edge. Chicago has home field and baseball game-level variance, and the restricted evidence provides no confirmed starters, injuries, or complete standings; those omissions prevent a stronger Yankees probability.

I remain at 66% Yankees. New York is the stronger club and won the two available games in Chicago, while the White Sox's recent record is weak and volatile. The discussion supplied no concrete starting-pitcher, roster, or injury evidence, so I do not move based merely on another panelist's similar prior; home field and ordinary single-game MLB variance leave Chicago a substantial chance.

Unchanged from my prior ballot. The frozen corpus shows this is a Yankees road series in Chicago, with New York winning 7/27 (9-5) and 7/28 (3-2), and the White Sox posting weak, high-variance recent results (0-10 and 3-10 losses at Texas, 1-4 and 5-9 to Houston, one 12-3 blowout win). No starting-pitcher, injury, roster, or standings data exists for the 7/30 game, so the only defensible inputs are team strength and home field. A strong favorite on the road against a bad MLB team prices around -200, roughly two-thirds. The two head-to-head wins are a weak, largely non-independent update and don't justify going higher; single-game baseball variance caps any such edge near 70%. Yankees 0.68, White Sox 0.32.

Boston's recent form is clearly stronger: a 14-2 home blowout of Chicago on Aug 4, plus wins over the Dodgers, indicate a hot streak and likely home-field advantage. Chicago has shown some capability (extra-inning wins vs Yankees) but also weak offensive stretches (shut out by Tampa Bay). Without confirmed starting-pitcher matchups, I maintain a clear Red Sox favorite (~67%) while preserving meaningful upset probability for the White Sox given single-game variance in baseball.

I keep Boston at 69%. It has home field, won the direct Aug. 4 matchup 14–2 with a 15–6 hit advantage and four homers, and had recent road wins over the Dodgers. Chicago's recent results include good performances against Tampa Bay and the Yankees, which supports a meaningful upset chance. No starter, injury, or Aug. 5 information is supplied, so the blowout alone does not justify a more extreme price.

Boston has the home-field baseline plus better recent results: it went 3-1 at Oakland, won 9-4 at the Dodgers, and routed Chicago 14-2 in this park on August 4. Chicago's 6-1 and 9-1 wins at Tampa Bay and consecutive extra-inning wins over the Yankees keep the upset chance substantial, while the prior blowout should regress heavily. With no starting-pitcher, injury, or full-season record evidence, 67% is a moderate rather than extreme Boston edge.

Boston is the home team and the stronger club in this evidence set: it beat Chicago 14-2 on 2026-08-04, won a series at Oakland, and per other panelists beat the Dodgers in early August. Chicago is a weaker road club but not inert — 9-1 and 6-1 wins at Tampa Bay and extra-inning wins over the Yankees on July 29-30. With no starting pitchers, injuries, or standings in the corpus, the defensible price is the structural one: a contending home team vs. a weak road team is roughly 62-68%. The single blowout regresses hard and doesn't push me past that band. Boston 0.67 / Chicago 0.33.

The frozen corpus shows Boston on a 5-0 run over their last five games (July 7-12), allowing only 4 total runs, against White Sox and Mets. Tampa Bay went 2-1 over their last three vs. Seattle, including a 2-8 loss on July 12. No venue, starting pitcher, or injury data for the July 18 game is confirmed in the corpus (panelist search for schedule/venue came back empty), so I'm not assuming home-field for either side. The panel converged on a modest Boston edge from the recent-form differential, tempered by the small sample size (5-6 games) and unknown opponent quality/starters for the actual game. I'll finalize close to my opening estimate, slightly moderated toward the consensus.

I retain the initial view. Boston’s July 7–9 sweep at Chicago (8–1, 5–0, 2–1) provides a slight recent edge, but Tampa Bay was also 2–1 against Seattle July 10–12, a more formidable recent opponent, and is at home. With no confirmed starters, injuries, or broader standings in the restricted evidence, this supports only a narrow Boston advantage.

Boston’s five-game winning run is the clearest available signal: wins of 8-1, 5-0, 2-1, 4-0, and 3-2, with particularly strong run prevention. Tampa’s 2-1 series against Seattle was also encouraging and came against plausibly stronger opposition, so I keep the forecast close. A targeted corpus search did not establish venue, starting pitchers, injuries, or season standings; I therefore do not count a home-field edge and limit Boston to 55%.

The corpus contains only box-score lines through July 12 — no starters, no standings, no injuries, and (per my own search) no schedule document naming the host for July 18. So venue stays genuinely uncertain: the question's "Rays vs. Red Sox" ordering mildly suggests Boston is home, but Panelist 2 asserted the opposite without a document ID, and I could not verify either way. Blending over that uncertainty leaves roughly zero net home-field edge. The only real signal is form: Boston went 5-0 into the break (8-1, 5-0, 2-1 at Chicago, then 4-0 and 3-2 over the Mets, ≤2 ER in four of five), while Tampa Bay was uneven (7-2 and 6-1 over Seattle but 2-8 with two errors, and 1-5 to the Yankees). That is a small sample against partly weak opposition, worth only a few points in a sport where single games are near coin flips. Hence 0.55 Boston / 0.45 Tampa Bay — down from my initial 0.58 because I could not confirm the home-field assumption that supported it.

The frozen box-score evidence shows a consistent talent gap: Yankees won most sampled August series (Seattle, Atlanta, plus the 8/18 head-to-head 3-1), while Orioles lost more often than they won (Texas, Minnesota, Tampa Bay stretches). This is box-score only evidence with no starter/injury data, so I treat it as a team-strength signal, not a pitching-matchup read. A clearly stronger road team is typically priced 55-60%; Baltimore's home field pulls a few points back the other way. Net: Yankees ~57%.

I retain the initial estimate. The directly relevant restricted record is New York’s 3–1 road win at Baltimore on Aug. 18, and the displayed recent Yankees results are broadly positive. Baltimore’s home field and the absence of season-level strength, confirmed starters, and injury information prevent a stronger edge; a single MLB game remains high variance.

I remain at 56/44 Yankees. The available game records indicate broadly similar recent form, but New York won the Aug. 18 matchup in Baltimore 3-1 while limiting the Orioles to four hits, and I give the Yankees a small roster-strength prior. Baltimore's home field and the absence of probable-pitcher, injury, full-standings, and Aug. 19 information make this only a modest edge; the discussion added no evidence requiring a change.

No new evidence emerged in discussion; the board converged on the same reading I reached independently (55-57% Yankees), which is reassurance rather than new information, so I keep my number. Basis: the corpus is box-score only and explicitly excludes rosters, starters and injuries. Within it, the Yankees look like a solid club (wins over Seattle 10-5 and 5-4, Atlanta 3-2 and 5-4, 4-3 at Toronto) and the Orioles a below-average one (losses at Texas, two of three at Minnesota, 6-7 at Tampa Bay), and New York took the 8/18 series opener in Baltimore 3-1. That talent gap is real but modest in single-game terms, and Baltimore's home field claws back 3-4 points. Without a starting-pitcher matchup — normally the largest single swing factor — I will not push past the high 50s. Yankees 57, Orioles 43; ties/cancellations excluded per the resolution rule.

Sticking close to my original assessment: Dodgers won 3 straight vs Pittsburgh recently while Braves lost 4 of their prior 5 before beating LA 4-3 on 8/25. Dodgers remain the deeper roster and slightly better recent form overall, tempered by Atlanta's home field and the recent head-to-head result. No pitcher/injury info available in this restricted dataset, so I keep a moderate edge rather than a strong one.

Final: Dodgers 57%, Braves 43%. I retain a modest Dodgers underlying-strength lean, tempered by Atlanta home field and its 4–3 Aug. 25 win over Los Angeles. Atlanta nevertheless entered that game having lost five of six against Minnesota and Milwaukee, whereas Los Angeles had recent wins over Colorado and Pittsburgh. These restricted records omit probable pitchers and injuries, so the appropriate edge remains small rather than decisive.

Los Angeles gets a small edge from the stronger underlying-team prior and somewhat better recent sequence, but Atlanta is at home and won the Aug. 25 opener 4-3. I moved only slightly from my initial ballot: the discussion's claim that all three Pittsburgh wins were one-run games conflicts with the frozen Aug. 23 record (Dodgers won 4-0), so I do not heavily weight that characterization. Missing starting-pitcher and injury information keeps this close.

Holding essentially my opening number. The corpus establishes the venue (G824881: "Los Angeles Dodgers away at Atlanta Braves," Braves 4-3 on 8/25), so 8/27 is a road game for LA. Form favors the Dodgers: three straight wins over Pittsburgh 8/21-23 (5-4, 4-3, 4-0) versus Atlanta losing five of six before the 8/25 opener (swept at Minnesota, 1-2 at Milwaukee) while scoring four or fewer in six of seven. That plus the standing prior that the Dodgers are a top-tier roster gives them a clear but not large edge. Discounts: Atlanta's home field is worth roughly four points; the 8/25 head-to-head went to the Braves; short streaks against Pittsburgh are weak evidence; and the records explicitly exclude starting pitchers and injuries, which is the biggest single-game input. I also never located the 8/26 result. Panelists 1-3 landed in the mid-50s to 58 for LA on the same records, which is consistent with my read and gives me no reason to shift materially. I nudge one point down from 58 to 57 to respect the missing pitcher information rather than the room's opinion.

Two consecutive $100 increases (Fold5→6→7) plus a severe May 2026 DRAM cost shock (LPDDR4X/5X ASPs up 70-83% QoQ) tilt toward another price increase. Countervailing: the $1,999.99 price already sits at a psychological "under $2,000" threshold, and the next round step ($2,099.99) forfeits that framing — a real marketing cost that didn't apply to the prior increases. Storage-tier trimming is not a credible lever (256GB is already the practical floor for a flagship), so any cost absorption would come via RAM/margin compression rather than raising minimum storage, which somewhat reduces the mechanical case for "above" via that specific channel. Weighing the trend and cost-shock evidence against the round-number stickiness argument, I land close to my prior estimate: above modal at 55%, same a strong second at 38%, below a small residual at 7% given no historical precedent for Samsung cutting the Fold's starting price.

Fold7’s official US announcement set a $1,999.99 starting price. A cut is least likely given Samsung’s reported strong Fold7 US demand and unusually sharp 2026 mobile-memory cost pressure. Those cost estimates do increase the risk of an MSRP rise, but they do not establish Samsung’s realized bill of materials or retail strategy; importantly, this resolves on the lowest entry configuration, which Samsung can keep at $1,999.99 through storage/configuration or margin choices even if a premium variant rises. I therefore retain a price hold as the modal outcome, with a substantial increase tail.

I moved probability from below and slightly from same to above after explicitly incorporating the recent MSRP sequence: Fold5 $1,799.99, Fold6 $1,899.99, and Fold7 $1,999.99. Two consecutive $100 increases, strong reported Fold7 demand, and sharply rising 2026 mobile-memory costs make another increase marginally more likely than a hold. Exact $1,999.99 remains close because it is a salient psychological threshold and Samsung can absorb or offset component costs; a cut lacks specific supporting evidence.

No new evidence emerged in discussion — every panelist is working from the same two corpus documents (the July 2025 Fold7 release stating "$1,999.99" with 256GB/512GB/1TB, and the May 14, 2026 TrendForce note on mobile DRAM ASPs up 70-83% QoQ). The corpus contains no Fold8 leak, so this stays a base-rate-plus-cost-shock judgment. For "above": the Fold entry price rose $100 in each of the last two generations ($1,799.99 → $1,899.99 → $1,999.99), and the 2026 memory shock lands squarely on Fold8 sourcing. A low-volume, thin-margin foldable is the hardest place to absorb it, and the storage-trim escape hatch is weak here specifically — 256GB is the practical floor for a $2K halo device, and moving the base tier up to 512GB would itself resolve "above." For "same": $1,999.99 is deliberately set just under $2,000, so the next step ($2,099.99) forfeits the "under two grand" line — a discrete marketing cost the Fold6→Fold7 step didn't incur. Samsung held $1,799.99 for three straight years, and Fold7 demand was reportedly ~50% ahead of its predecessor, giving a reason to protect the working price point by cutting RAM (16GB→12GB, exactly the industry response TrendForce forecast) and compressing margin. "Below" needs either a price cut during a severe component-cost spike or a cheaper book-style variant announced at the same US event; there is no corpus evidence for either, so it stays near 7%. I moved one point from "above" to "same" — Panelist 1's framing that the psychological threshold argument deserves real weight alongside the trend is fair — but not further, since nobody produced evidence, only reframing. Uncertainty remains high: the announcement lies past the cutoff and no pricing leak exists in the frozen record.

Consensus among panelists confirms the core reasoning: Apple's Pro-tier pricing is historically sticky (five years flat at $999 before the jump to $1,099 for iPhone 17 Pro), making a second consecutive increase atypical and favoring "same" as the plurality outcome. However, the contemporaneous May 2026 TrendForce data showing severe LPDDR4X/LPDDR5X cost inflation (70-83% QoQ) plus ongoing tariff pressure is a genuinely unusual cost shock relative to prior cycles, keeping "above" a substantial possibility rather than a tail risk. A nominal price decrease remains highly unlikely given Apple's uninterrupted history of never cutting Pro starting prices. No direct evidence of an actual announced successor price exists in the corpus, so this stays a base-rate-anchored judgment with cost-pressure adjustment upward from a naive "same" prior.

I move toward same after weighing the relevant pricing base rate: the non-Max Pro reportedly held a $999 entry price from iPhone 12 Pro through 16 Pro, and $1,099 was only introduced with iPhone 17 Pro. A further immediate increase is therefore less typical. Above remains a large minority outcome because the May 2026 TrendForce-based evidence indicates exceptional LPDDR5X cost pressure (78–83% QoQ), although it is industry-level rather than evidence that Apple will pass costs through. A nominal Pro entry-price cut remains unlikely.

Exactly $1,099 is the base-rate favorite because Apple usually holds a Pro entry price for multiple generations, while consecutive annual increases are uncommon. The entry-price resolution matters: the 17 Pro’s $1,099 price already accompanied a base-configuration/storage repositioning, so prior $999 continuity does not imply another immediate $100 increase. I retain substantial upside probability because the frozen evidence reports exceptional 2026 LPDDR5X price pressure, but that is sector-level rather than Apple-specific and Apple may absorb or offset it. I shifted five points from above to same after discussion clarified the storage-insensitive resolution and the weakness of inferring retail pass-through from component estimates. A nominal cut remains very unlikely.

No new evidence appeared on the board — nobody produced an announced or leaked iPhone 18 Pro price, so this stays a base rate plus one documented shock. What moved me slightly: Panelists 2 and 3 are right that the 17 Pro's jump to $1,099 came bundled with a 256GB base, i.e. a configuration repositioning rather than a pure sticker hike. That weakens my earlier "Apple has shown it will move the number" framing, so I trim "above" from 53 to 50. What I did not concede: the $999 freeze from 2019 to 2024 spanned years of stable-to-falling memory pricing. That reference class describes Apple's behavior under benign BOM conditions and says little about 2026, where the only cost document in the corpus (TrendForce, May 14, 2026) shows LPDDR4X ASPs +70–75% QoQ and LPDDR5X +78–83% QoQ, with high-end phones pushed toward 12GB. Treating "consecutive increases are rare" as decisive is conditioning on the wrong years. The resolution rule is also asymmetric. It is explicitly an entry-price, not same-capacity, comparison, so multiple Apple playbooks land on "above": a straight $1,149/$1,199 increase, or a capacity/RAM repositioning sold as more value for a higher entry number. "Same" requires Apple to eat an industry-wide cost shock entirely in margin while holding both the price and a defensible spec — plausible, since Apple's Pro margins can absorb tens of dollars and it prizes headline-price stability, but it is one path against several. "Below" stays near-dead at 4%: Apple has never nominally cut a Pro entry price, and doing so into cost inflation would be perverse; the residual covers an odd lineup reshuffle (e.g. Pro repositioned under a pricier foldable tier, or base storage reverting to 128GB). Final: above 50, same 46, below 4 — deliberately close to a coin flip between the top two, because the decisive fact (Apple's actual pricing decision) is simply not in the frozen evidence.

Converging with the board's discussion: the corpus contains no Pixel 11-specific leak, so this remains a structural judgment. Historical base rate for the standard numbered Pixel shows price increases in 2 of the last 4 generational transitions and flat pricing in 1 (never a cut), which by itself would favor "above" or "same" roughly equally with "below" a clear long-shot. The countervailing 2026-specific evidence is the sharp DRAM cost shock reported by TrendForce (LPDDR4X/LPDDR5X ASP +70-83% QoQ in Q2 2026), landing right before a plausible Pixel 11 launch — real upward cost pressure. But the resolution rule explicitly measures entry price "even if minimum storage changes," giving Google an easy lever to preserve the $799 sticker by trimming base RAM/storage instead of raising price, which is exactly the kind of margin-protection move component-cost shocks usually trigger before headline price hikes. The one 2026 Google pricing decision we can observe (Pixel 10a holding at $499, flat vs Pixel 9a) came after the memory run-up started, weakly supporting price stickiness, though A-series historically absorbs cost pressure differently than the flagship line. Weighing historical precedent for increases against Google's demonstrated 2026 preference for holding price points plus the storage-substitution escape hatch, I land on a near coin-flip between "same" and "above," with "same" no longer clearly behind. "Below" stays low but not negligible.

I retain my initial distribution. Pixel 10’s official $799 price followed Pixel 9 at the same entry price, so maintaining the familiar $799 headline remains the single most likely pricing choice. A rise is nearly as plausible: the corpus’s May 2026 TrendForce digest projects LPDDR5X ASP growth of 78–83% quarter-on-quarter, and the longer standard-Pixel history has price increases and no year-over-year cut. But this is an industry forecast, not evidence that Google will pass costs through rather than protect its entry price or alter configuration. A below-$799 launch remains a tail outcome.

I keep my initial forecast. Google's revealed behavior makes $799 the modal result: the standard Pixel 10 retained Pixel 9's entry price despite hardware changes, and flagship prices are sticky at salient $100 increments. The unusually sharp 2026 LPDDR5X cost increase reported in the frozen TrendForce digest creates a substantial chance Google moves to $899, but it is industry-level evidence rather than Google's contracted bill of materials and may be absorbed through margins or configuration choices. A price cut would conflict with the line's recent premium positioning. The discussion supplied no independent evidence that changes these weights.

Nothing on the board moved me. All four panelists are working from the same five-document corpus, which contains no Pixel 11 price leak, no Google cost pass-through statement, and no competitor pricing; my targeted search for those came back empty, so this stays a structural judgment. Two forces, roughly balanced. Upward: TrendForce (May 14, 2026) puts Q2 mobile DRAM ASP growth at 70–75% QoQ for LPDDR4X and 78–83% for LPDDR5X, a real BOM shock hitting just before a likely Aug/Sept 2026 launch, and Google's standard line has taken +$100 steps twice in four generations ($599→$699, $699→$799). Downward on that pressure: the only observable 2026 Google pricing decision, Pixel 10a at "just $499" (Feb 19, 2026), is flat versus Pixel 9a and already postdates the start of the memory run-up; $799 is strategically sticky against the base iPhone; and the resolution rule measures the entry price even if minimum storage changes, so Google can absorb the shock by trimming RAM/storage and still resolve "same." That last point is why I hold "same" a hair above "above" rather than below it, against Panelist 1's lean. A decrease has no precedent in the modern standard line and no supporting evidence, so it gets only tail weight for an aggressive share-grab or a repositioning of the tier. Conditional on an unambiguous successor announcement: below 5, same 48, above 47. Confidence is low; the honest statement is near coin-flip between hold and a $50–100 rise.

The Sept 2025 CRL was manufacturing/inspection-specific (Catalent Indiana), with no cited efficacy or safety deficiencies, and the resubmitted BLA was accepted with a Sept 30, 2026 PDUFA date that incorporates a second US fill-finish facility as a hedge. By May 2026, FDA had already completed a reinspection of Catalent Indiana, which is itself meaningful evidence of CAPA progress (FDA doesn't typically schedule reinspections unless remediation looks credible), with classification expected within 90 days — plausibly resolving by early August, leaving a workable buffer before the deadline. The dual-facility structure means the failure mode requires both paths to fall short, not just one to be unconfirmed. Against this: no document in the corpus confirms an actual VAI/NAI classification or completed pre-approval inspection for either site as of the cutoff, this program already had one manufacturing-related CRL on this same facility, and CMC/inspection timelines are historically a common source of slippage even when the underlying clinical package (SAPPHIRE: significant pooled HFMSE effect, p=0.019, though single-dose result was NS) is not in serious question. Balancing the favorable base rate for CMC-only CRL resubmissions and the redundant-facility hedge against the absence of confirmed clearance and the prior stumble, I settle at 0.65.

Unchanged at 68% Yes. The accepted resubmitted BLA has a fixed September 30 PDUFA action date, and the controlled SAPPHIRE result supports efficacy in the principal pediatric nonambulatory group (pooled HFMSE difference 1.8 points, 95% CI 0.30–3.32) with no apparent safety discontinuations. The substantial remaining risk is not the clinical file but CMC: the prior CRL was linked to Catalent Indiana, whose post-reinspection classification had not been reported by July 1, and the newly added US fill-finish source was only expected to begin supply in Q3. Those facts support a meaningful chance of another manufacturing-related failure or delay, but an accepted remedy-focused resubmission with two facilities makes approval by the stated date more likely than not.

The balance favors approval because FDA accepted the resubmission, the prior CRL was reportedly limited to fill-finish inspection findings, Catalent had already been reinspected by May 7, and the application added a second U.S. fill-finish site. The stated 90-day classification window, even measured from May 7, ends around August 5 and therefore leaves time before September 30; commercial supply from the second site was also expected in early Q3. I retain 20% for an adverse or delayed facility classification, deficiencies at the backup site, or an extension/second CRL, since neither site's clearance was confirmed by July 1 and the account of no clinical concerns is sponsor-supplied. SAPPHIRE's pooled primary comparison was statistically positive but modest, with the 20 mg/kg comparison alone nonsignificant, so clinical risk is low but not zero.

Unchanged at 70/30. The CRL was inspection-only at Catalent Indiana (no efficacy, safety, or drug-substance deficiencies per the sponsor's account), second-cycle approval after a CMC-only CRL has a high base rate (~75-85%) and resubmission goal dates are usually met, FDA had already completed a reinspection before May 7, 2026 with classification expected around early August, and a second US fill-finish site is in the accepted filing, so failure requires both paths to miss. Against that: no confirmed VAI/NAI classification or completed PAI for either site exists in the frozen corpus — all favorable timing is sponsor expectation, not regulatory determination; this same facility already produced one CRL; second-site supply was only expected "early Q3," leaving little slack; and the resolution is strict, so even a short slip past Sept 30 resolves No. Small residual clinical risk from SAPPHIRE's nonsignificant 20 mg/kg dose comparison (p=0.11) against a positive pooled primary (p=0.019), which is unlikely to resurface in a CMC cycle. Nothing in the discussion produced new facts; Panelist 1's move to 0.65 reflects the same evidence weighted slightly more conservatively, which is within my own uncertainty band.

The panel converged on the same core facts: standard-review sBLA accepted with a firm Aug 30, 2026 PDUFA date and no filing issues; ropeginterferon already has an established US safety profile via its PV approval; SURPASS-ET showed a large, statistically robust effect (durable modified-ELN response 43% vs 6%, p=0.0001) with fewer high-grade/serious adverse events than anagrelide; EXCEED-ET provides North American bridging data; Taiwan already approved the ET indication in June 2026; and no advisory committee or review-issue signal appears in the corpus. Base rates for standard-review efficacy supplements on already-marketed drugs with a clearly positive phase 3 trial clearing first-cycle are historically fairly high (~80%+), tempered here by real discount factors: an open-label trial, a 96%-Asian pivotal population, and a composite surrogate endpoint rather than hard clinical outcomes, any of which could prompt a narrowed label (still Yes under the resolution rule) or, less likely, a delay/CRL (No). Weighing the strength of the efficacy signal and lack of negative regulatory signals against the generalizability/endpoint risk, I settle slightly above my initial estimate, consistent with the group's independent convergence around 70-75%.

I retain 78% Yes. This is an accepted standard-review adult-ET sBLA with an Aug. 30 target, not an early filing-stage forecast, for a drug FDA already approves in PV. Its pivotal randomized evidence showed a large durable modified-ELN response advantage over anagrelide (39/91 versus 5/83), and the cited North American phase 2b program plus Taiwan’s ET approval modestly reduce concern over relying on one study. The main reasons not to put this higher are timing risk and possible FDA concern about a 174-person, open-label trial that was 96% Asian and measured a surrogate composite response rather than clinical thrombotic outcomes. Those concerns could produce a delay or nonapproval, but a restricted adult indication makes approval by the stated date substantially more likely.

I remain at 79%. FDA accepted a complete sBLA for standard review with an August 30 target, and SURPASS-ET showed a large randomized efficacy advantage over anagrelide (39/91 versus 5/83 durable modified-ELN responses) with no apparent comparative safety penalty. Prior US approval in PV lowers CMC and product-level uncertainty, while a restricted label would still count. The residual 21% reflects the small, open-label, 96%-Asian trial, reliance on a response endpoint rather than clinical events, the narrow hydroxyurea-intolerant/resistant population, and ordinary risks of a CRL, information request, or review delay beyond the fixed deadline. The discussion supplied no evidence warranting a change.

Base rate first: FDA acts by the goal date in roughly 90% of reviews, and an efficacy supplement for an already-marketed product (BESREMi approved in PV, so the safety database and manufacturing are known to FDA) carrying a clearly positive randomized phase 3 is approved on the first cycle at roughly 80%. Corpus specifics move me slightly up from that blend. FILING_01: accepted for standard review with no filing issues, Aug 30, 2026 goal. TRIAL_01: SURPASS-ET durable modified-ELN response 39/91 vs 5/83 on anagrelide, +36.5 pts (95% CI 25.4–47.7, p=0.0001), with fewer grade 3+ and serious adverse events than the active comparator — an effect size that is hard to argue away. TAIWAN_01, dated June 10, 2026, still cites the Aug 30 target, which retires much of the three-month-extension risk since extensions from major amendments are normally granted and disclosed well before the goal date. No advisory committee appears anywhere in the corpus, a mild positive. Remaining No paths: a CRL on generalizability (96% Asian pivotal, with only single-arm North American EXCEED-ET bridging), discomfort with an open-label composite surrogate endpoint at ~12.5 months rather than thrombosis reduction, a facility/CMC problem, or action slipping days past a fixed calendar date. Note that a narrowed label — high-risk ET after hydroxyurea failure — still resolves Yes, which removes the most likely "partial" failure mode from the No column. The honest residual uncertainty is that every document here is sponsor-sourced; we have zero FDA-side signal. 77% Yes.

Final position unchanged from my opening ballot. Evidence: Capricor's deramiocel BLA is a resubmission following an earlier CRL, now supported by HOPE-3 Phase 3 data that met its primary endpoint (PUL v2.0) and all Type I error-controlled secondary endpoints — directly addressing what appears to have been an efficacy-based deficiency. FDA set and has retained the August 22, 2026 PDUFA date, with the May 2026 update describing the BLA as under "active FDA review" and labeling discussions "expected to commence soon," and no disconfirming news (no second CRL, hold, or extension) through the June 27 disclosure. This is a moderately bullish, on-track profile. Countervailing risk, reinforced by discussion: this is an allogeneic cell therapy with a recent CRL history, and CMC/manufacturing-facility inspection risk is real and undocumented in the corpus — the company's own disclosure that its facility has a "second-floor expansion well underway" is a concrete risk factor for a pre-license inspection to not go cleanly, and the question's fixed-deadline rule means any extension (even for a minor amendment) resolves No regardless of eventual approval. Labeling discussions "expected to commence soon" is weaker than confirmed labeling negotiations already underway, so I don't over-weight that signal. Balancing the resolved efficacy risk against real residual CMC/inspection/timing risk under a hard deadline, I hold at 70% Yes / 30% No, consistent with where the panel converged (roughly 70-74% Yes) without any new disconfirming evidence emerging in discussion.

I retain my initial view. The active BLA review, unchanged August 22 action date, anticipated labeling discussions, and reported positive controlled HOPE-3 primary and multiplicity-controlled secondary results support a modestly-better-than-even chance of approval on time. FDA/endpoints alignment after the prior CRL further reduces clinical-efficacy risk, but it is not an FDA finding of approvability. A repeat CRL, CMC or inspection issue, or review extension remains a substantial risk for this cell therapy and resolves No under the fixed-deadline rule.

I remain at 74% Yes. The decisive positive evidence is that, after the prior CRL, FDA and Capricor aligned on the pivotal HOPE-3 endpoints and the randomized Phase 3 trial met its primary and all Type I error-controlled secondary endpoints; the BLA was under active review in May, and June disclosures reported no new safety signal. I give little extra weight to labeling because the sponsor only said discussions were expected, not underway. The 26% No probability covers CMC or inspection problems inherent to an allogeneic cell therapy, another CRL, or a review extension that would fail this fixed-date resolution even if approval eventually follows.

Unchanged in substance after discussion, nudged up one point. The positive case: the July 2025 CRL's efficacy deficiency was addressed by HOPE-3, which met its primary endpoint (PUL v2.0) and all Type I error-controlled secondaries on endpoints FDA had agreed to at the September 2025 Type A meeting; the resubmission was accepted with an August 22, 2026 PDUFA date; the May 12, 2026 update describes active review with labeling discussions expected to begin; the June 26, 2026 release shows reinforcing 5-year HOPE-2 OLE data with no new safety signals and no hint of extension, hold, or second CRL. Class 2 resubmissions with the cited deficiency remedied are approved roughly 70-80% of the time, and FDA meets PDUFA dates in the large majority of cases. Panelist 3's caution that "expected to commence soon" is not confirmation that labeling talks began is fair, and I give that signal only modest weight. What I added, and what keeps me slightly above the room's apparent center: by July 1 the Federal Register lead time makes an advisory committee before August 22 nearly impossible, and no major amendment or three-month extension has been disclosed. That closes two of the three usual routes to a No. The remaining 25% is concentrated in one channel: CMC/pre-license inspection risk for an allogeneic cell therapy manufactured at a facility Capricor describes as still expanding, plus the demonstrated willingness of CBER to issue a surprise CRL on this exact product in 2025. The corpus gives me no dated evidence that inspection is complete and classified, so I cannot go higher.

Consistent with the board's converged view. Established facts: BLA accepted Feb 23, 2026 with Priority Review, PDUFA date Aug 23, 2026, pivotal support from a randomized, double-blind, placebo-controlled Phase 3 (GlucoGene) showing meaningful cornstarch reduction and improved glycemic/PGIC outcomes, plus RMAT/Fast Track/orphan/Rare Pediatric Disease designations — a solid efficacy package that removes "inadequate pivotal evidence" as the dominant risk. The corpus contains no post-February signal of an AdCom, inspection failure, extension, or CRL for DTX401 specifically. The credible residual risk is generic to first-cycle AAV gene therapy BLAs manufactured at a newly built facility (Bedford, MA): a pre-license inspection is essentially required, and PLI findings are a common cause of missed goal dates or CRLs for AAV products industry-wide. The forward-looking-statement boilerplate mentioning "the complete response letter" is ambiguous, unconfirmed for DTX401 in the actual release body, and any outside claim about a different Ultragenyx program (UX111) is explicitly unverified in the frozen corpus, so I give it only slight weight rather than treating it as a confirmed disqualifying fact. Net: good odds of approval, discounted by real but not extraordinary manufacturing/inspection timeline risk and the general base rate that some fraction of PDUFA dates slip past the goal date even when eventual approval follows.

I raised Yes from 58% after verifying the BLA-acceptance release: the package includes 52 treated patients with up to six years’ follow-up and a randomized, double-blind, placebo-controlled Phase 3 study reporting meaningful cornstarch reductions with maintained glycemic measures. FDA accepted the BLA, granted Priority Review, and set August 23, making an on-date action the central case. The remaining one-third No probability reflects that these efficacy claims are sponsor-reported, plus material AAV durability/safety and CMC risk—especially manufacture at a new Bedford facility—and the possibility of an extension or CRL, both of which miss this fixed deadline.

I raise Yes from 68% because the full acceptance release materially strengthens the evidence beyond the small open-label early study: the BLA covers 52 treated patients, up to six years of follow-up, and a randomized, double-blind, placebo-controlled phase 3 reported significant cornstarch reductions while maintaining glycemic control. Priority Review, RMAT designation, high unmet need, and no disclosed extension or review setback by July 1 favor action by the original date. I retain 26% for an efficacy/safety dispute or, especially, a CMC or inspection-related CRL/extension because this is an AAV therapy whose commercial supply is tied to a new manufacturing facility, and the available pivotal findings are sponsor-described rather than an FDA assessment.

In-corpus facts: FDA accepted the DTX401 BLA on Feb 23, 2026 with Priority Review and a PDUFA date of Aug 23, 2026; the application rests on 52 treated patients with up to six years' follow-up and a randomized, double-blind, placebo-controlled Phase 3 (GlucoGene) showing significant reductions in cornstarch quantity and frequency with maintained glycemic control and PGIC improvement; DTX401 holds RMAT, Fast Track, orphan and Rare Pediatric Disease designations; and commercial product "will be manufactured entirely within the U.S. at the new Ultragenyx gene therapy manufacturing facility in Bedford, Massachusetts" (ACCEPT_01). That is a strong efficacy and regulatory package for a rare-disease AAV therapy, so I moved up from my opening 0.60 after reading the full release — the pivotal support is controlled, not the 12-patient open-label phase 1/2 in the corpus. Remaining risk is mostly chemistry/manufacturing and timing, not efficacy. A brand-new manufacturing site makes a pre-license inspection near-certain, and PLI findings are the leading cause of AAV BLAs missing a goal date. ACCEPT_02's safe-harbor language referring to "the observations in the complete response letter" indicates an actual, identified CRL the sponsor is working to resolve on some program; which program and which deficiency is not in the corpus, so I weight it as a mild negative on sponsor-FDA CMC friction rather than a decisive one. The corpus contains nothing after Feb 2026 — no AdComm notice, no extension, no reaffirmed guidance — so the post-acceptance period is simply unobserved. Decomposition: P(first-cycle approval) ~0.78; P(action on or before Aug 23 | approval) ~0.82-0.85, allowing for three-month major-amendment extensions and actions slipping days-to-weeks past the goal date, which the resolution rule counts as No. Product ~0.63.

Final position after discussion: The NDA carries strong positive procedural signals — Breakthrough Therapy Designation, Priority Review, an accepted filing with target action date matching the question's deadline exactly, and a statistically significant positive interim MRD-negativity readout from the pivotal EXCALIBER-RRMM trial. These favor approval as the modal outcome and argue against no_action, since FDA historically resolves PDUFA dates on time in the large majority of cases. However, the discussion surfaced an important caveat I didn't weight heavily enough initially: this filing rests on a still-immature dual-primary-endpoint trial where PFS/OS data are not yet mature, and my own follow-up search found no corpus evidence of established FDA precedent for MRD negativity alone supporting accelerated approval in RRMM. That makes the regulatory basis somewhat novel rather than a well-trodden pathway, raising genuine CRL risk (FDA could ask for more confirmatory data, a REMS, or additional PFS follow-up) beyond generic base rates. Breakthrough Therapy Designation itself explicitly "does not change the standards for approval," per BMS's own filing language. Weighing procedural momentum (favoring timely approval) against endpoint novelty risk (favoring CRL), I land at approval 68%, CRL 18%, no_action 14% — modestly less approval-confident than my opening ballot, reflecting the surrogate-endpoint risk raised in discussion, while still keeping approval as the clear single most likely outcome.

I remain at 72/14/14. The accepted exact NDA has Priority Review, Breakthrough Therapy Designation, and a specific Aug. 17 PDUFA date, making an on-time approval the modal outcome. The release also expressly says the filing rests on planned MRD-negativity analysis while PFS remains ongoing; that unresolved surrogate-evidence question supports nontrivial CRL and delay/extension risk. Project Orbis is concurrent-review logistics, not independent evidence of FDA’s ultimate evidentiary judgment.

Approval remains most likely because the randomized phase 3 trial met its planned MRD-negativity endpoint, safety was described as consistent with prior studies, and FDA granted Breakthrough Therapy on these data plus Priority Review and Project Orbis review. Those are strong signs of prior FDA engagement with the filing strategy. But PFS remains immature and the frozen corpus provides no precedent establishing MRD as a routinely accepted RRMM surrogate, leaving substantial CRL risk for efficacy, safety, or CMC reasons. I assign a smaller no-action probability because an extension or unfinished review maps there under the rule, although priority applications generally receive a substantive action by PDUFA.

Essentially unchanged from my first ballot; the discussion produced no new corpus evidence, only a reweighting I mostly disagree with. What the corpus establishes: the exact application is filed ("FDA has accepted a New Drug Application for iberdomide combined with... daratumumab + dexamethasone"), with Breakthrough Therapy Designation granted "based on these data" (the MRD analysis), Priority Review, Project Orbis concurrent review, and a target action date of August 17, 2026. The filing rests on a planned MRD-negativity analysis with EXCALIBER-RRMM ongoing for PFS. No ODAC scheduling, major amendment, safety signal or CMC/inspection issue appears anywhere in the corpus. Two panelists moved toward ~18% CRL because a corpus search turned up no precedent for MRD as an accelerated-approval surrogate. I nudged CRL up only slightly (0.08 to 0.09) and no further, for two reasons. The corpus is two press releases — failing to find FDA guidance in it is uninformative. And outside the corpus, ODAC voted 12-0 in April 2024 that MRD negativity is reasonably likely to predict clinical benefit in multiple myeloma and is suitable for accelerated approval; I flag that as unquotable here, so I discount it, but it means the surrogate is not unadjudicated. Corpus-internally, FDA granting BTD on the MRD data itself and filing under priority review means the agency declined two cheap off-ramps if it thought the endpoint inadequate. The risk I weight above the room is timing, not rejection. The window closes on the PDUFA date with no buffer, so a three-month major-amendment extension, a late-added advisory committee (plausible for a first-of-kind surrogate approval), Orbis coordination drag, or a routine days-to-weeks miss all resolve as no_action. I put that at 0.13 versus a ~6-8% historical PDUFA-miss base rate. Base rate for first-cycle approval of a BTD/priority-review oncology NDA with a positive randomized phase 3 is ~85-90%, discounted for the surrogate novelty and the timing exposure: approval 0.78.

NDA accepted Nov 13, 2025 with a firm standard-review PDUFA date of Aug 28, 2026; no priority review, breakthrough designation, or advisory committee is disclosed. The pivotal Phase 3 COMPETE trial was randomized, active-controlled (vs. everolimus), and met its primary endpoint with a large, statistically significant PFS benefit (23.9 vs 14.1 months, p=0.022), and the mechanism/class has an approved precedent (Lutetium-177 radiopharmaceuticals in NETs). As of the most recent corpus item (June 2, 2026), the product is still described as "pending review" with no disclosed extension, CRL, or inspection issue. Conditioning on a strong, well-powered randomized trial with a large effect size, the CRL base rate should be below the generic all-comers rate — supporting a higher approval probability than my initial 50%. However, ITM is a first-time FDA sponsor with EU-based radiopharmaceutical manufacturing, and pre-approval inspection/CMC issues are a real, largely efficacy-independent risk channel for CRLs and extensions that we have no visibility into either way. I therefore land between the more bullish (~70% approval) and my original (~50%) estimates: approval 0.60, CRL 0.25, no_action 0.15, reflecting genuine uncertainty about manufacturing/inspection outcomes not resolved by the strength of the clinical data alone.

I retain my initial distribution. FDA accepted ITM’s initial NDA on November 13, 2025 and assigned the fixed August 28, 2026 PDUFA goal; the submission is supported by the positive randomized Phase 3 COMPETE result. Those facts make approval the modal first action. The latest pre-cutoff sponsor material still identifies ITM-11 as pending FDA review and provides no disclosed extension or adverse regulatory signal, but that absence is weak evidence: late-cycle CMC, inspection, labeling, or other review issues can still produce either a CRL or an extension. Under the stated rule, the latter is no_action.

Approval remains the clear favorite. The accepted NDA rests on a 309-patient randomized active-control trial with median PFS of 23.9 versus 14.1 months (p=0.022), significantly higher ORR, and reported favorable safety; an already approved related Lu-177 somatostatin-receptor therapy lowers class-level uncertainty. I raise approval slightly after verifying those trial details. The principal remaining risk is application-specific CMC, manufacturing inspection, or dosimetry trouble at a smaller sponsor, supporting an 18% CRL probability. Most PDUFA reviews end in approval or CRL on time, while the absence of an announced extension 57 days out is only weak evidence, so I retain 7% for no action by the fixed deadline.

Unchanged after discussion. Established facts: NDA accepted Nov 13, 2025 with a standard-review PDUFA goal of Aug 28, 2026; still described as "pending review by the FDA" in ITM's June 2, 2026 release, with no disclosed advisory committee, extension, or inspection problem anywhere in the corpus. Conditioning on a randomized, active-controlled Phase 3 that met its primary endpoint with a large effect (23.9 vs 14.1 months mPFS), an approved in-class precedent (Lutathera), and successful filing, the first-cycle approval probability is well above the all-comers rate. Panelist 1's 25-33% CRL draws on the generic novel-NDA CRL rate, which is inflated by applications with far weaker evidence packages; and the modern therapeutic radiopharmaceutical NDAs I know of (Xofigo, Lutathera, Azedra, Pluvicto) were all first-cycle approvals despite comparable isotope/manufacturing complexity and, for Lutathera, a European site and a sponsor new to FDA. Residual risk is mostly CMC/pre-approval inspection and it splits between a CRL and a three-month major-amendment extension; the latter resolves no_action under this rule, as would any missed goal date from FDA workload disruption. Nobody produced dated evidence of an AdCom, extension, or inspection finding, so I hold at approval 0.70 / CRL 0.12 / no_action 0.18. Main unquantified gap: no visibility into ITM's inspection status or FDA review correspondence.

Discussion confirmed the key facts without new information: the CRL stemmed from an FDA leadership override of its own review team's favorable view on contribution of effect, and the resubmission (accepted as Class 1, with an adcomm only in late July before an Aug 2 goal date) does not appear to bring materially new data to resolve that core dispute. This is a genuine toss-up with a slight lean toward "no" given that leadership already overruled favorable reviewer sentiment and strong advocacy once. I maintain 40% yes / 60% no.

I remain at 42% yes. FDA accepted a complete Class 1 response and set an August 2 goal date, so a timely decision is the central expectation. However, the April CRL concerned whether the single-arm IGNYTE evidence could support accelerated approval; the sponsor said it disagreed with FDA’s scientific judgment. The accepted resubmission still seeks accelerated approval on IGNYTE, and FDA expects a late-July advisory committee, leaving the core evidentiary dispute live close to action. I therefore judge another no-action/negative outcome by the original date modestly more likely than approval.

I lower approval from 68% to 48% after reading the full disclosures. The April 2026 CRL was itself a rejection of the response to the July 2025 CRL, and it concerned the core adequacy of the single-arm IGNYTE evidence and RP1's contribution to nivolumab—not a minor administrative defect. The rapid Class 1 resubmission contains no new controlled trial capable of removing that concern. FDA's late-July advisory committee provides a credible route to reversal, supported by the 34% response rate, 24.8-month median response duration, unmet need, and favorable clinical-reviewer/expert sentiment; acceptance and the short goal date also make timely action plausible. But leadership has already maintained its negative position despite those arguments, and a split or unfavorable vote—or any timing slippage with only days before August 2—resolves No. Overall this is close, with a slight edge to no approval by the deadline.

Evidence base: April 10, 2026 CRL over contribution-of-effect from the single-arm IGNYTE trial, with the company disclosing that FDA's clinical team favored the applicant but leadership did not (D001). Then on June 26, 2026 FDA accepted the resubmission as a "complete, class 1 response with a goal date of August 2, 2026" and told the company to "expect an advisory committee meeting in late July" (D003). Two forces pull opposite ways. Pro-approval: FDA was not obliged to move at all, yet within ~7 weeks of a leadership-level rejection it declared the response class 1 (an affirmative finding that remaining deficiencies are minor), set the shortest possible clock, and scheduled a public adcomm inside that window. That sequence reads as leadership looking for external cover to reverse its own April decision, not as a setup for a third denial. Anti-approval: the underlying dataset cannot have changed materially in seven weeks, the adcomm confirms risk/benefit is still genuinely contested, FDA leadership has already overridden its own reviewers once on this exact question, and a "late July" meeting leaves only days before August 2 — so a split vote, a rescheduled meeting, or a post-vote CRL all resolve No. Decomposition: P(favorable adcomm) ~0.68 given strong melanoma-community support, 34% ORR with 24.8-month median DOR in anti-PD-1-refractory disease, and high unmet need; P(approval action by Aug 2 | favorable) ~0.85 given the compressed window; P(approval | unfavorable) ~0.07. That yields ~0.60. I moved down from 0.72 because the adcomm disclosure materially raises the chance the third cycle ends in another nonapproval or a slipped date; I did not move to the room's ~0.42-0.50 because I think FDA's voluntary choice of the fastest route is evidence of intent, not merely of reviewability.

Priority review with a firm September 22 PDUFA date is intact through at least late June 2026 (per the Recordati licensing release), with no corpus evidence of an advisory committee, complete response letter, or major amendment/information request. Alexander disease is ultra-rare and fatal with no approved disease-modifying therapy, and Ionis has a strong track record bringing ASOs to approval (nusinersen, tofersen), which supports FDA flexibility on statistical bar in this context. The pivotal trial met its primary analysis (33.3% LS-mean difference in 10-Meter Walk Test, age ≥5, 50mg cohort, p=0.041) with supportive nominal secondary/exploratory findings (GMFM-88 in younger children, plasma GFAP reduction) and a favorable safety profile (fewer serious TEAEs in treatment vs. control). The age-stratified endpoint structure (walk test for ambulatory ≥5, GMFM for younger non-ambulatory children) looks like a standard pediatric-trial design choice rather than post-hoc subgroup mining, which eases my concern about the ≥5 slice being cherry-picked. Countervailing risk: this rests on a single trial of only 54 participants, the primary p-value (0.041) is unadjusted for multiplicity and close to the conventional threshold, and there's an unreconciled 53-vs-54 participant discrepancy between releases suggesting some data-package looseness. These are exactly the features that sometimes trigger a CRL requesting confirmatory evidence, even in rare-disease contexts, and a partial-label approval still counts as Yes under the resolution rule (which removes one failure mode but not the CRL/extension risk). Weighing the strong precedent for priority-review approval in ultra-rare pediatric neurodegenerative disease against the genuine statistical fragility, I set my probability at 68%, modestly above my opening 65% given the board discussion clarified the age-stratified design isn't obviously post-hoc, but not as high as the base-rate-only view because the marginal, unadjusted p-value keeps meaningful CRL risk on the table.

I retain 68% approval. The FDA's priority-review acceptance with a September 22 target establishes that a complete application is actively under review and makes an on-time decision likely. For an ultra-rare, serious disease without a disease-modifying therapy, the randomized pivotal-cohort walking-speed result (reported 33.3% advantage; p=0.041) and supporting clinical/biomarker data provide a plausible approval basis. But the entire package is small (~54 participants), the reported margin is thin, and key pediatric and biomarker findings are nominal and unadjusted. Undisclosed safety, CMC, data-review, or deadline-extension issues could still produce a CRL or no qualifying action by the fixed date.

I remain at 68% Yes. FDA accepted the NDA for priority review, no extension or review disruption is evident by the July 1 cutoff, and the small randomized pivotal study reportedly met its key walking-speed endpoint (33.3% LS-mean advantage, p=0.041), with supportive functional and biomarker signals. Severe ultra-rare disease, no approved disease-modifying therapy, and FDA precedent for flexibility with neurologic antisense drugs favor approval, potentially for a narrower age subgroup. The substantial No probability reflects a single ~54-patient study with a borderline result, unclear multiplicity and analysis details, nominal secondary findings, and limited public visibility into safety, CMC, and FDA review issues; any extension beyond the fixed deadline also resolves No. The discussion did not supply evidence strong enough to change my initial estimate.

Unchanged at 74%. Nothing on the board moved me: the other panelists raised the same two caveats I already priced (borderline p=0.041 on the ≥5 slice of the 50 mg cohort; nominal, multiplicity-unadjusted pediatric and GFAP results), and nobody produced evidence of an advisory committee, an FDA information request, a major amendment, or CMC trouble. For Yes: priority review accepted March 23, 2026 with a fixed September 22 goal date; a genuinely randomized, double-blind, controlled pivotal trial (n≈54, 2:1, 60 weeks, 13 sites, 8 countries) in a fatal ultra-rare disease with zero approved therapies; Ionis's ASO manufacturing track record; the June 25 Recordati ex-US deal still describing September 22 as the live action date. Most importantly, safety looks favorable — serious TEAEs 37.5% on pooled 25/50 mg versus 47.1% on control, most events mild/moderate — and rare-disease CRLs far more often stem from safety or CMC than from a thin p-value. A narrow label (ages ≥5) still resolves Yes, closing the most likely partial-win failure mode. Base rate for first-cycle approval of priority-review NDAs in this profile is ~75-85%. For No: a single small trial with p just under 0.05 and an analysis plan the corpus does not let us inspect; an unreconciled 53 vs 54 denominator (minor); and pure timing risk — a major amendment or three-month extension resolves No here even if approval follows. I weight the timing/extension path at roughly 8-10% and residual CRL risk at roughly 15%, landing at ~0.74.

The Q1 FY2026 release explicitly set Q2 FY2026 guidance at "net sales growth of 2% to 4%," which is exactly the "within" bucket. Since the actual Q2 release isn't in the frozen corpus, this remains a forecast, not a lookup. Board discussion sharpened two points I now weight more heavily: (1) the resolution uses the published rounded percentage, so "within" effectively spans roughly 1.5%-4.5% unrounded — a wide landing zone for guidance set just three weeks into the quarter with EMEA weakness (down 10%, Hollister flat) already visible and presumably priced in; (2) the "beat-and-raise" argument for extrapolating a large upside surprise doesn't hold up well against the evidence we actually have — Q1's EPS beat came from margin/cost execution while total sales growth was only 2%, and the maintained 3%-5% full-year guide alongside the 2%-4% Q2 guide implies management is signaling H2 acceleration, i.e., Q2 is intentionally the softer bridge quarter, not one primed for a sales-line beat. This leaves "within" as the clear modal outcome given the wide rounding-adjusted band and management's demonstrated informational advantage in setting the range around known headwinds. "Above" retains real but reduced weight (APAC +24%, Abercrombie brand momentum could still push a print to just above 4%, especially with rounding tolerance). "Below" retains meaningful risk given EMEA/Middle East conflict is unresolved and could deepen further into the summer selling season for Hollister.

I retain my initial probabilities. The official May 27 Q1 release fixes the original Q2 total-company sales guide at 2%–4%, inclusive. Q1’s reported 2% growth, including EMEA -10% amid conflict-related demand softness and flat Hollister, supports material risk below the range; Americas +3%, APAC +24%, and management’s maintained 3%–5% full-year outlook support meaningful upside. The guide itself remains the most likely published outcome, but there is no additional evidence establishing a Q2 result or changing the balance of those risks.

The official Q1 release set Q2 total-company net-sales growth guidance at 2%-4% after management had already observed Q1's 2% growth, flat Hollister sales, and a 10% EMEA decline. Because the result is resolved at the published whole-percentage precision, the inclusive within bucket effectively captures a broad unrounded interval of about 1.5%-4.5%, making it clearly modal. I reduced my initial upside probability because the documented Q1 beat was in EPS rather than sales and the frozen corpus does not establish a recent pattern of sales beating guidance; maintained 3%-5% full-year guidance also appears to place more expected acceleration in the second half. Above remains somewhat likelier than below due to healthy Abercrombie/APAC growth and the possibility of conservative guidance.

Benchmark is quoted verbatim in the only relevant corpus document (D001, May 27, 2026): "Second quarter outlook of net sales growth of 2% to 4%." Context from the same release: Q1 net sales $1.1B "up 2%", comparable sales (1)%, Americas +3%, APAC +24%, EMEA -10% on Middle East conflict softness hitting Hollister, Hollister brands flat, full-year outlook maintained at 3%-5%. Three things drive my numbers. (1) Rounding widens the middle bucket: any unrounded result from ~1.5% to ~4.5% prints as 2%, 3% or 4%, a ~3-point landing zone against a range management set three weeks into the quarter with EMEA weakness already visible. (2) The "A&F always beats" case is outside recollection, not corpus evidence — my search found only the six parts of this one release — and in this quarter the beat came from margins (EPS "exceeding outlook range") while sales merely landed at +2%. Sales guidance is harder to beat than EPS guidance. (3) Maintaining a 3%-5% full-year guide alongside a 2%-4% Q2 guide implies the required acceleration sits in H2, i.e. management is framing Q2 as the soft quarter, which caps the upside tail without eliminating it. Downside is real and specific (negative comps, flat Hollister, an unresolved conflict that could deteriorate further), so "below" gets nearly as much as "above." Discussion didn't move me materially; Panelist 1 conceded the beat-history premise, which slightly reduced my "above" weight. Final: within 0.60, above 0.21, below 0.19, with the caveat that no post-May data exists in this corpus.

Consensus with other panelists confirms the facts: Q2 FY2026 guidance is $4.8-4.9B net sales from continuing operations, based on 2.5%-3.5% comp growth, and Q1 actual comp growth hit the top of that assumed range (3.5%) with 7.2% total net sales growth. This is only one data point of momentum, not direct Q2 evidence, and guidance ranges are typically calibrated to be hit. I slightly increase weight on "within" relative to my first ballot given the panel's reasonable caution that one quarter of top-of-range performance doesn't guarantee a breakout above the following quarter's guide, while keeping "above" elevated above base rate due to the demonstrated momentum and raised full-year EPS outlook. "Below" remains least likely given no evidence of deceleration.

I retain my initial distribution. The May 28 Q1 release’s original Q2 outlook is $4.8–$4.9bn in continuing-operations net sales, premised on 2.5%–3.5% comparable-sales growth. Q1’s 3.5% comp growth and $4,970.5m sales provide modest positive momentum, hence upside exceeds downside, but they are not direct evidence of Q2 sales after July 1. With no later company trading update or demonstrated guidance hit-rate in the evidence, the stated range remains the modal result.

No discussion evidence materially changes my initial view. The May 28 guide was recent, explicitly on the required continuing-operations net-sales scope, and sales are generally more predictable than earnings, so the stated $4.8-$4.9B range remains the clear modal outcome. Q1 comps were 3.5%, at the top of the Q2 comp assumption, while Q1 sales grew 7.2% and square footage 4.9%; that creates an upside skew, but it is not direct Q2 quarter-to-date sales evidence, so I keep above as a meaningful minority outcome and below as least likely.

No one posted anything that changes my read, and the frozen corpus contains only the six parts of the May 28, 2026 Q1 release — there is no Q2 FY25 comparative in it, so my base-year arithmetic is inferred, not verified. Anchor facts: guidance is "net sales from continuing operations for the second quarter will range from $4.8 billion to $4.9 billion, based on comparable store net sales growth in the range of 2.5% to 3.5%" (D002). Q1 FY26 actual net sales were $4,970.5M vs $4,636.5M a year earlier (D003), +7.2% total on a +3.5% comp, implying roughly 3.5-3.7pp from net new square footage. Applying that same non-comp tailwind, the $4,900M ceiling corresponds to a comp of roughly 3.7-3.8% — just above the top of management's own comp guide. So the band is modestly generous on the downside (it tolerates a comp near 1.5%) and tight on the upside: a repeat of Q1's 3.5% comp lands essentially at the ceiling. That is why "above" carries real weight despite the company guiding conservatively. Offsetting the upside: Q2 FY25 was a strong quarter (comp around +6.5% on trade-down and multi-price momentum), a harder compare than Q1's, and management deliberately guided Q2 comp below Q1's realized rate. Typical retailer hit-rate inside a self-set ~2%-wide quarterly sales band is 60-70%, but the top-end tightness here shaves that. Downside below $4,800M needs a genuine demand break with no sign of it in the evidence — a real but small tail. Final: within 51%, above 35%, below 14%.

Confirmed from the frozen corpus (D001, Q1 FY2026 release, June 4 2026): original Q2 FY2026 guidance is net revenue of $2.450B-$2.475B, "representing a decline of 3% to 2%," issued alongside a cut to full-year guidance ($11.000-$11.150B) and language that the company has "more recently" been navigating headwinds. This is a guide set about a month into the 13-week quarter (with May actuals presumably informing it), alongside a downward full-year revision — consistent with an active negative-revision cycle rather than a stable, easily-beaten guide. Structural point: the band is only $25M wide (~1% of revenue), so even an unbiased central estimate implies a large share of outcomes fall outside it — "within" is a narrow target, not a natural majority outcome. Directional tilt: Q1 2026 showed Americas revenue -3% (comps -5%, -6% cc) and gross/operating margin compression, with management explicitly citing headwinds it has "not fully sized" (guidance excludes "future unknown impacts, including tariffs and macroeconomic trends"). This supports a modest skew toward "below" over "above." However, I discount the claim floated by one panelist that "lululemon's recent Q2s have come in at or slightly under the low end of its own guide" — this could not be verified in the frozen corpus (confirmed by two independent searches returning no historical guidance/actual comparison data), so I do not weight it as evidence, only as an unsupported assertion. International's +22% growth and a ~200bp FX tailwind in Q1 provide a real offset to Americas weakness, keeping the upside case from being negligible. Net: I keep "within" as the modal outcome given it's the company's own central estimate freshly set with recent data, but with a real skew toward "below" over "above" reflecting the ongoing negative-revision momentum and unresolved tariff/macro risk that management flagged as unpriced.

I retain below as the modal outcome, but reduce it modestly because no evidence in the frozen record establishes a systematic miss or a worsening Q2 revenue run-rate beyond management’s own contemporaneous range. The official Q1 release reports Americas revenue down 3%, Americas comparable sales down 5%, and says more recent headwinds prompted a full-year outlook reduction—real downside signals for a $25m-wide Q2 range. International revenue growth of 22% and the possibility that guidance already incorporates the headwinds support meaningful within-range and upside probabilities. No historical guidance-hit-rate evidence was available in the corpus searched.

I reduced the upside probability because the frozen corpus does not substantiate my initial appeal to a recent guidance-beat pattern. The June 4 guide was issued after management saw new headwinds and simultaneously cut full-year revenue expectations, giving the narrow Q2 range some near-quarter visibility. Still, the guide already assumes a 2%–3% year-over-year decline despite Q1 growth and strong international sales, so it appears partly de-risked and leaves above as a slight favorite. The range spans only about 1% of revenue, keeping considerable probability on both outside outcomes; weak Americas comps create the principal downside risk.

Confirmed from the frozen corpus (D001, June 4 2026 release): Q2 FY2026 guidance is $2.450–2.475B, "representing a decline of 3% to 2%," issued alongside a cut to full-year guidance ($11.0–11.15B, "now expects") and management's statement that "more recently, we have been navigating headwinds." Q1 actual was $2,471,603 thousand, +4% reported but only +2% constant dollar, with Americas revenue -3% and Americas comps -5% (-6% cc), offset by International +22%. Two structural facts drive my numbers. (1) The "within" band is only $25M wide, ±0.5% of revenue. To put 40%+ on it you need a forecast standard deviation under ~$25M for a quarter that was roughly two-thirds unelapsed when the guide was set, and where the company explicitly says the outlook "does not incorporate future unknown impacts, including tariffs and macroeconomic trends." With an sd of $35–50M, "within" prices at roughly 20–28%. I take 28%. (2) The direction of revision skews the tails: this is a company in an active negative-revision cycle, guiding to a y/y decline with Americas comps deeply negative, which makes further slippage somewhat more likely than a reversal to upside. Offsetting the "below" skew: a guide cut a month into the quarter with May actuals in hand is normally set to be cleared, FX was a ~200bp tailwind in Q1 and is not obviously reversing, and International momentum (+22%) is a genuine upside lever. I also flagged on the board that my recollection of lululemon missing its Q2 guide in 2024 and 2025 is memory, not corpus evidence — the frozen record contains no historical hit-rate, so I discount it to a weak prior rather than treating it as established. Result: a modest tilt to "below" over "above," with "within" materially under the naive assumption that companies usually land inside their own narrow ranges. Confidence is low; this is close to a three-way split with a small negative skew.

Q2 FY27 guidance (from the May 21, 2026 release) is net sales growth of 4%-5% cc — the exact "within" band. Q1 FY27 actual consolidated net sales (cc) growth was 5.7% (distinct from the 5.9% total-revenue cc figure, per the reconciliation table), already above that range, showing strong momentum (26% eCommerce growth, 37% ad growth, positive traffic/units). That argues for a real chance of another beat above 5%. But the company simultaneously reiterated an unchanged full-year net sales cc guide of 3.5%-4.5%; since Q1 alone ran at 5.7%, hitting that full-year band arithmetically requires the remaining quarters, starting with Q2, to decelerate below Q1's pace — meaning management's own guidance embeds a real expected slowdown, not mere sandbagging. That tempers the case for "above" and supports "within" as at least as likely. "Below" remains a low-probability tail requiring a sharper-than-signaled demand deceleration within weeks of the guide being issued, with no such catalyst disclosed in the frozen evidence. Balancing the momentum evidence against the FY-guide arithmetic, I keep "within" slightly ahead of "above," with "below" a small residual.

I retain my initial distribution. The initial Q1 release’s reconciliation reports consolidated Q1 net-sales growth in constant currency of 5.7% (not the 5.9% total-revenue cc figure), demonstrating strength, but management set its Q2 net-sales cc range at 4.0%–5.0% after seeing that result and left full-year cc net-sales guidance at 3.5%–4.5%. That makes an in-range reported percentage the modal outcome. Q1 momentum supports a substantial above-5% tail; ordinary forecast error and a clear deceleration embedded in the company outlook leave downside risk as well.

Walmart’s official reconciliation shows Q1 consolidated net-sales growth of 5.7% in constant currency, above its Q2 guidance range of 4%–5%. Strong Q1 underlying indicators—26% global e-commerce growth and 10.1% international net-sales growth in constant currency—plus Walmart’s tendency to guide conservatively make an above-range result my plurality outcome. I trim the initial above probability slightly because the relevant Q1 figure is 5.7%, not the 5.9% headline revenue figure, and management explicitly guided for deceleration. A reported 5.0% resolves within while only 5.1% or higher resolves above, so rounding leaves substantial probability within; below 4% would require a much sharper slowdown.

Benchmark confirmed from the source: Walmart's May 21, 2026 release guides Q2 FY27 consolidated "Net sales (cc): Increase 4.0% to 5.0%", matching the option bounds exactly. Jump-off point: Q1 FY27 consolidated net sales were $175,684M, +7.1% reported, and the reconciliation gives net sales (cc) ~$173.3B, +5.7% (not the 5.9% headline, which is total revenues cc). So the guide embeds 0.7-1.7pp of deceleration. Drivers that produced the 5.7% are sticky over one quarter: global eCommerce +26%, International cc net sales +10.1% (reported +18%, with an apparent inorganic/expansion component), U.S. net sales +4.5% on comps +4.1%. Counterweight, which is why I'm not higher on "above": in the same release Walmart left FY27 cc net sales guidance unchanged at 3.5-4.5%, which arithmetically implies ~3.0-4.2% for the remaining three quarters. Management set the 4-5% Q2 band knowing the Q1 result, and only ~0.7pp of slowdown lands the print at 5.0%, inside the band. A tougher prior-year base ($175.8B Q2 FY26) and fading tariff-related price inflation both point that way. On the other side, my prior — which I could not corroborate in this frozen corpus, which contains only this one release — is that Walmart habitually sets a conservative 100bp quarterly cc band and prints above the top of it more often than not, and holds annual guidance early in the year before raising later. Low tail: printing ≤3.9% requires ~1.8pp of deceleration below a range just set with near-complete information, with no disclosed Q2-specific headwind; that is a genuine but small tail, ~6%. Net: above 59%, within 35%, below 6%. Residual uncertainty is mainly about how much of Q1's International strength was one-off versus recurring, which I could not resolve from the available documents.

Converging with the board discussion: LINK is already hardware-complete and integrated onto its Pegasus XL launch vehicle (as of the June 6 update), which sharply reduces the OSAM-1-style programmatic cancellation risk that dominated my earlier, more pessimistic estimate. The main remaining uncertainty is flight risk in the launch-rendezvous-capture-boost chain. Recent RPO/servicing flight heritage (MEV-1/2, ADRAS-J, ELSA-d) shows rendezvous and proximity operations succeeding fairly reliably now, and Swift is a comparatively favorable target (live, attitude-controlled, non-tumbling) versus dead rocket bodies these other missions approached. The genuinely unflown step is grapple/rigidize capture via robotic arm on a non-prepared target, which keeps real uncertainty in play. There's also a mild reporting asymmetry (clean announcement on success vs. possible "assessing" delays on failure), partly offset by NASA's demonstrated pattern of frequent, transparent public updates on this mission, including on setbacks. Netting these considerations, I land close to even with a slight lean toward a completed boost being reported first.

I retain the initial assessment. NASA’s May 27 forecast said Swift’s drag-mitigation operations were likely to keep it above the 300-km critical altitude into early fall, and LINK had reached Wallops integration by June 5; thus imminent decay or pre-launch cancellation is not the dominant case. But a successful resolution still requires a Pegasus launch and an end-to-end first-of-kind rendezvous, capture of an uncooperative aging spacecraft, and orbital boost. The hardware test milestones are encouraging but do not demonstrate that chain. OSAM-1 is a cautionary (though not directly comparable) servicing-program failure, while the explicit-abandonment resolution rule means a non-successful mission is likely eventually to resolve abandonment. I therefore keep abandonment modestly favored.

I moved modestly below 50% after separating launch readiness from full mission success. LINK had reached Pegasus integration and had passed environmental testing, so cancellation before flight looks unlikely. But NASA itself called this a “fast, high-risk, high-reward” attempt completed on a schedule of under a year and described it as pioneering a new servicing capability; the available evidence identifies no prior flight heritage for LINK’s three-arm capture system. Launch, commissioning, rendezvous, novel capture of 21-year-old Swift, and sustained coupled-stack thrusting must all succeed before Swift’s declining orbit closes the recovery window. The rule’s allowance for recoverable problems helps, but I judge the compounded first-of-kind operational risk slightly more likely to end in explicit abandonment than in a reported boost.

No new evidence emerged after my last ballot; the board converged rather than adding facts, so I hold at 57/43. Basis: as of the frozen cutoff, LINK had cleared thermal-vac testing at Goddard (three ion thrusters fired, one arm deployed), arrived at Wallops on June 5, 2026 for Pegasus XL integration, and Swift's decay had been slowed by drag-reducing pointing changes, keeping it above the 300 km "critical height" longer than the January forecast. Pre-launch cancellation risk is therefore nearly spent, and the question reduces to flight execution. My chain gives roughly 0.43 for clean end-to-end success (Pegasus return-to-flight ~0.9, commissioning/rendezvous on a sub-12-month build ~0.8, capture of a target with no grapple fixture with retries ~0.7, mated low-thrust boost ~0.85). I add a few points for NASA plausibly declaring a completed boost at a partial altitude gain and a few for the reporting asymmetry — success is announced promptly while several failure modes linger as "under assessment," and silence never resolves abandonment. I keep that asymmetry small because with no calendar deadline, Swift's continued decay eventually forces an explicit stand-down or reentry statement. Offsetting: NASA's own team calls this "fast, high-risk, high-reward" with schedule dictating accepted risk, and no end-to-end capture rehearsal is documented. Supporting: recent RPO missions (MEV-1/2, ADRAS-J, ELSA-d) show rendezvous and close approach generally work, and Swift is a live, attitude-controlled, non-tumbling target. Net a slight lean to boost, with wide uncertainty because the corpus ends before launch.

Board consensus converges on high confidence in 'unchanged' (80-88% range across panelists), grounded in: June MPC held 3.75% 7-2 with both dissenters wanting a hike (not a cut), so no cut sentiment existed on the committee as of June. Since then, June CPI eased to 2.6%, core held at 2.6%, services at 3.6%, and labour market softened modestly (unemployment 4.9%, weak payrolls). This data neutralizes the hawkish dissent (making a hike harder to justify) without being severe enough to flip five hold-voters to a cut. The structural asymmetry noted by others is valid: a hike only needs one more vote to join two existing hawks, while a cut needs a much larger swing from the five holders. But the recent disinflationary data trims the hike tail somewhat. I settle slightly higher than my initial hike estimate reduction, landing at 82% unchanged, with hike modestly above cut reflecting the residual hawkish dissent structure.

I increase the hold probability from my initial ballot. The relevant change since June is disinflation rather than an evident escalation: June CPI was 2.6%, core CPI 2.6%, services 3.6%, and private-sector regular-pay growth 2.9%; payroll employment also weakened. This makes it plausible that the two June hawks join the seven-member hold majority. A hike remains more likely than a cut because two members already preferred 4.0% and the Bank stressed energy-price volatility and persistence risk. But a cut would require a far larger reversal from the June 7–2 hold, so it remains a small tail.

I retain 93% on unchanged. The June 7–2 hold is a strong near-term anchor, and subsequent data—CPI down to 2.6%, services inflation easing to 3.6%, private regular-pay growth at 2.9%, and weaker payrolls—do not support assembling a majority to hike. They also show gradual softening rather than the abrupt deterioration needed for five or more members to reverse into a cut at the next meeting. I shifted the small directional tails toward higher because two members already favored 4%, so a hike requires fewer vote changes than a cut, while leaving room for intervening releases or energy-risk judgments.

Anchor: the June MPC held Bank Rate at 3.75% on a 7-2 vote with both dissents for a HIKE to 4%, and the June Market Participants Survey median expected Bank Rate unchanged over the following year (D01). No easing was being signalled, and the MPC almost never moves without first steering expectations. Data since then are two-sided and neutralising rather than move-forcing: June CPI eased to 2.6% with core 2.6% and services 3.6% (D02, published July 22), and the labour market is loosening (unemployment 4.9%, regular pay 3.4%, private-sector pay 2.9%, falling payrolls and vacancies, D04). That undermines the hawks' case for a hike, but the committee expects energy-driven inflation to rise later in the year and firms' price/inflation expectations remain elevated (DMP 4.1% own-price, 3.7% year-ahead CPI, D05), which blocks an immediate cut. Tail asymmetry: vote arithmetic favours the upside slightly — a hike needs three of seven holders to join two existing hawks, a cut needs about five members to reverse — so "higher" edges "lower" despite the softer prints. Hold at ~88% reflects the low base rate of unsignalled single-meeting surprises plus the absence of any documented intervening shock in the corpus. Residual uncertainty: the frozen corpus has no post-July-22 market pricing or pre-meeting MPC communication.

Two consecutive months of elevated headline CPI (April +0.6%, May +0.5%) plus May PPI showing energy still surging (final demand energy +10.7%, gasoline +23.4% at producer level) support continued above-0.2% momentum into June. However, the discussion surfaced good countervailing evidence: (1) May core was exactly 0.2%, right at the bin boundary, not comfortably above it; (2) the March energy spike (+10.9%) already partly unwound by May (+3.9%), showing these swings can reverse fast; (3) the June jobs report shows cooling labor market (payrolls +57k vs +172k, wage growth 3.5% y/y), consistent with core staying at ~0.2%/month rather than accelerating; (4) there is zero June-dated price data in the corpus, so the top-bin case rests entirely on extrapolating May's PPI momentum forward one more month. Given core is sitting right at the 0.2% boundary and the outcome hinges entirely on whether energy adds any incremental push in June (an unresolved, genuinely uncertain forward-looking question), I shade my probability down from my initial 0.83 to align with the more evidence-disciplined view that emerged in discussion. A modest tail for negative remains, since energy reversals of this magnitude have historically been able to produce flat-to-negative headline prints, though a full negative print still requires an outright energy/goods price decline.

I retain my initial distribution. Official May producer-price evidence showed broad, unusually large price pressure—final demand rose 1.1% m/m, with stage-3 goods inputs up 3.5% and gasoline/diesel among the cited contributors—so the modal June headline outcome is a rounded 0.3% or higher. PPI is an imperfect and lagged guide to consumer prices, and the 0.2% rounding cutoff leaves substantial probability in the middle bin; the available evidence does not establish the sharp June energy decline that would make a negative reading likely.

I keep above 0.2% as the favorite because upstream inflation was unusually broad and strong immediately before June: final-demand PPI rose 1.1% in both April and May after 0.7% in March, and May stage-3 intermediate demand rose 1.9%, with gasoline, diesel, freight, chemicals, and food inputs contributing. May core CPI at 2.9% y/y and shelter at 3.4% indicate that consumer inflation had not already become very soft. I accept the discussion correction that the year-over-year core rate is not a monthly 0.2% floor, and PPI-to-CPI pass-through is noisy; those facts, volatile energy, and one-decimal rounding leave a substantial 0.0%-0.2% probability. A negative print would require a much larger offset and remains unlikely.

No new evidence on the board changed my arithmetic. The frozen corpus gives: May CPI (released 2026-06-10) headline +0.5% SA after +0.6% in April, energy +3.9%/+3.8%/+10.9% over May/April/March and accounting for over 60% of the May increase, core +0.2%, shelter +0.3%, food +0.2%; May PPI (2026-06-11) with final demand energy +10.7% and producer gasoline +23.4%, implying wholesale pressure still feeding into retail; and the only June-dated data, the 2026-07-02 Employment Situation (payrolls +57k, unemployment 4.2%, AHE +0.3% m/m, 3.5% y/y), which shows a cooling labor market consistent with core continuing near 0.2% rather than accelerating. Mechanically, non-energy contributions supply about 0.2pp, so the headline clears 0.2% unless energy is flat to negative; with an energy weight near 6-7%, a ~4-5% energy drop is needed to reach zero and more to go negative. PPI momentum makes a positive June energy contribution more likely than a sharp reversal, but the corpus contains zero June price or crude/gasoline data, and spikes of this magnitude do unwind quickly, so I cap the top bin well short of certainty. Panelist 2's point that 2.9% y/y core is not a monthly floor is correct and is already reflected: May core printed exactly 0.2%, at the boundary, which is the main route to the middle bin via rounding. Final: 0.67 above 0.2%, 0.27 in 0.0-0.2%, 0.06 negative.

Confirmed by board discussion: April revised down to +148k, May revised down to +129k, June first print +57k — a clear deceleration trend with a combined -74k revision to the prior two months. This lowers the predictive center for July's first estimate without mechanically biasing its noise distribution (as Panelist 3 correctly noted — revisions inform the trend, not the specific bias of an unrevised first read). Centering the July first-print estimate near June's +57k level with modest upward drift allowance (~70-90k) and a typical first-release standard deviation of ~70-80k yields most mass in the under-100k bin, meaningful mass on negative and 100-199k, and a small tail on 200k+ given the clear cooling trajectory across three consecutive months.

I retain my initial distribution. June’s first-vintage gain was +57,000, and the July 2 BLS release revised April to +148,000 and May to +129,000, 74,000 lower combined than earlier reports. That lowers the center of the near-term employment-growth outlook and makes 0–99,999 the modal bin. These revisions are evidence on underlying momentum, not a mechanical predictor of the direction of July’s unrevised first estimate; normal establishment-survey and seasonal noise leaves substantial 100–199k probability and nontrivial tails.

I shift slightly toward the two lowest bins after confirming that April and May were revised down by a combined 74,000, leaving a sequence of +148,000, +129,000, and June's first estimate of +57,000; the production/nonsupervisory workweek also declined in June. This indicates genuine cooling rather than relying only on one weak headline. Still, revisions do not mechanically predict July's first estimate, and monthly payroll estimates are noisy, so 100,000–199,999 retains substantial probability. A negative print is plausible but not the base case, while 200,000-plus would require a sizable rebound.

Evidence base is thin but clear. The 2026-07-02 release: June first print +57,000, unemployment 4.2%, with April revised from +179k to +148k and May from +172k to +129k ("employment in April and May combined is 74,000 lower than previously reported"). Current-vintage trend is 148k / 129k / 57k — decelerating, three-month average ~111k. The key modeling point, which the board did not fully absorb, is that this question resolves on the FIRST print. The last three first prints were +179k, +172k, +57k, and the first two were each revised down 30-43k. If first prints systematically run ~30-40k above their settled values, the expected July first print is the underlying July trend plus that bias — which pushes the center above the naive read of June's +57k. I set the center near +80k, allowing for genuine deceleration but not assuming June's weak print is the new trend level rather than partly noise. Spread: BLS notes ~122,000 is the threshold for a statistically significant over-the-month establishment-survey change; realized month-to-month first-print volatility is roughly 70-85k. Using center +80k and SD ~80k gives approximately 16% below zero, 42% in 0-99k, 32% in 100-199k, 10% at 200k+. I round the top bin slightly down because nothing in the evidence suggests a re-acceleration and the sector detail (financial activities -107k from peak, transportation/warehousing -92k from peak) is one-sided. Stated uncertainty: the frozen corpus contains no July-2026 information whatsoever — no ADP, no claims, no strike or federal-workforce events. This is trend-plus-noise extrapolation only, so I keep the distribution wide rather than concentrating on the modal bin.

Consensus across the panel confirms and strengthens the case from the frozen May 2026 PPI release: headline SA final demand rose 0.7%/1.1%/1.1% in March-May, and critically the breadth is not just energy-driven — final demand less foods, energy, and trade services (a core measure) rose 0.8% in May, its largest gain since March 2022, with 5.1% y/y growth. That core reading alone would need to roughly halve to keep June's headline at or below 0.2%. The counterargument (goods were ~80% of May's gain, raising reversal risk) is real but doesn't change the base case, since a full unwind to zero or negative would require an unusually sharp commodity/energy correction with no supporting June-dated evidence in the corpus. I settle close to my prior, nudging slightly toward "above 0.2%" given the corroborating breadth argument from other panelists, while keeping the negative tail modest since no data points to an actual price collapse.

I retain my initial probabilities. In the May first-vintage release, final-demand PPI rose 1.1% after 1.1% in April and 0.7% in March. The signal was broad as well as commodity-led: services rose 0.3%, and final demand less food, energy, and trade services rose 0.8%, its largest increase since March 2022. This makes a June result above 0.2% substantially more likely than either low bin, though PPI’s monthly volatility and lack of direct June producer-price evidence leave a meaningful 0.0–0.2% chance.

The latest vintage shows unusually strong and broad momentum: headline final-demand PPI rose 0.7%, 1.1%, and 1.1% in March–May, while May final demand excluding food, energy, and trade services rose 0.8%. That makes a June result above 0.2% the clear favorite. The principal downside risk is that May was goods-heavy and gasoline surged 23.4%, accounting for over half the goods rise; a sharp energy reversal could pull the headline into either lower bin. No June-specific energy evidence was available in the frozen corpus, so I retain meaningful reversal uncertainty and stay near my initial 80%.

Evidence base: the 2026-06-11 PPI release (May 2026) shows final demand +0.7% (Mar), +1.1% (Apr), +1.1% (May), 6.5% y/y — the hottest since Nov 2022 — with final demand less foods, energy, and trade services up 0.8% (largest since Mar 2022) and, per another panelist, stage-3 intermediate demand +1.9%. Broad pipeline pressure, not a single-line artifact, so the central case is another print well above 0.2%. What moved me off 86%: the composition detail that May final-demand energy rose 10.7% and gasoline 23.4%, over half the goods increase. Final demand energy is roughly 5-6% of the index, so energy contributed about 0.6pp of the 1.1%; the ex-energy run rate was ~0.5%. A spike that size is typically a supply shock that partially unwinds, and a June energy giveback of similar magnitude could pull the headline to near zero or slightly negative even with a firm core. That makes the low bins materially more than a rounding tail. I have no June-dated price evidence in the frozen corpus (June CPI publishes after the 7/8 cutoff), so this is trend persistence and composition arithmetic only. Final: 0.78 above 0.2%, 0.13 in 0.0-0.2%, 0.09 negative.

The most direct and station-relevant evidence is the Suffolk MA (Boston/Logan) zone forecast issued 2026-07-14 11:04Z: "WEDNESDAY...Partly sunny. A chance of showers in the morning. Hot with highs in the mid 90s...Chance of rain 30 percent." This is the official NWS PoP for the exact target date and zone, and PoP is defined as probability of measurable (≥0.01") precipitation at a point in the zone — a close match to our resolution criterion. The companion AFD corroborates this: NBM guidance leaned toward nil PoPs, the forecaster manually added up to 30% due to lingering instability from an overnight frontal passage, described timing/coverage as "scattershot" and low-confidence, but did single out KBOS in the aviation discussion as having the greatest chance of any impacts from early Wednesday convection. Weighing the official 30% quantitative PoP against the slight upward nudge from the aviation-specific note and the low 0.01" threshold (which is easier to clear than higher thresholds), I land at approximately one-third probability of wet, consistent with the converged view on the board.

I revised from the initial 65% wet after the station-relevant Suffolk County forecast evidence: the Wednesday rain chance was only 30%, limited to morning, with dry Wednesday night. The 11:27Z AFD says convection timing and coverage were “scattershot,” NBM had nil PoPs, and the forecaster manually introduced up-to-30% PoPs as a low-confidence possibility. KBOS was identified as having the greatest terminal-impact chance, and 0.01 inch is a low threshold, so I place wet modestly above the literal PoP but still clearly below even odds.

The station-relevant 7:03 AM Suffolk County zone forecast gives a 30% chance of rain Wednesday morning and dry conditions Wednesday night. The full AFD says the NBM initially had nil PoPs and calls convective timing and coverage scattershot, but its aviation section identifies KBOS as having the greatest chance of impacts, potentially from 07Z Wednesday—inside the target day. I shade wet slightly above the rounded zone PoP because a convective shower hitting Logan would likely exceed 0.01 inch, while retaining dry as the clear favorite.

The operative station-level forecast is the Suffolk County ZFP issued 703 AM EDT Tue Jul 14 (D030): "WEDNESDAY...Partly sunny. A chance of showers in the morning. Hot with highs..." — a morning-only shower window with a Heat Advisory still running through 8 PM Wednesday. Panelists 1 and 3 supplied the AFD detail I lacked: the NBM carried nil PoPs, the forecaster manually inserted "up to 30% PoP along the MA/NH/VT border between 4-7 AM Wed, then slowly sagging southward," and called timing/coverage "scattershot." That anchors the ZFP wording at the bottom of the "chance" band (30%) and puts the maximum risk well north of Logan, with the activity weakening as it sags toward the coast during the day. Timing also matters for resolution: the "strong thunderstorms" headline is aimed at "early overnight tonight," much of which falls on July 14 and would not count toward the July 15 CLI day. A 30% zone PoP for a decaying, sagging convective feature implies less than 30% for measurable rain at a single gauge, and part of the remaining probability lands on a trace, which resolves dry under this rule. Offsetting slightly upward: the aviation section singles out KBOS for the greatest impact chance, and the threshold is only 0.01". Net 28% wet / 72% dry. Main uncertainty is that convective nowcast situations are genuinely low-confidence in both directions, and I have no post-cutoff observation.

The most recent (0750 AM EDT Jul 14) NWS Miami Area Forecast Discussion explicitly forecasts the target day: "Conditions become even drier on Wednesday as the SAL intensifies... POPs/Wx coverage drops to single digits for most coastal areas, and 20-30 percent for western interior areas as sea breezes push inland." KMIA is a coastal Miami-Dade site, squarely in the single-digit POP zone, with supporting factors (Saharan Air Layer intensifying, modest PWATs 1.5-1.8", high pressure dominating) all pointing toward suppressed convection reaching the coast. This is same-day-issued, location-specific guidance rather than generic July climatology, so it should dominate over the ~50% seasonal base rate. I weight it heavily but keep some cushion above a literal single-digit-percent reading since it's qualitative language, a forecast rather than an observation, and stray evening cells occasionally clip coastal stations even on suppressed days.

I revised sharply toward dry after the Wednesday-specific KMFL forecast. The 04:27 EDT Jul 14 AFD (D017) says Saharan air intensifies Wednesday, conditions become even drier, and coastal PoP/coverage falls to single digits; the subsequently available 11:50Z AFD (D019) retains that forecast, while the Miami point forecast was 10% Wednesday and 10% Wednesday night. KMIA is in the coastal east-metro area. I retain 16% wet because the CLI reporting-day can span both forecast periods and isolated summer convection can still produce measurable rain at the airport.

I revised sharply toward dry after reading the full latest pre-cutoff KMFL AFD. It explicitly says the Saharan Air Layer will make Wednesday even drier, with precipitation coverage in the single digits for most coastal areas, while its point table gives Miami 10% PoP for both Wednesday and Wednesday night. KMIA is in the east-coast metro regime rather than the 20–30% western-interior regime. I retain 14% wet because combining day and night periods and allowing for forecast error or a stray localized cell makes the full CLI-day risk somewhat higher than a literal single-period 10% PoP.

Two independent NWS products issued the morning before the target date point the same way. The 420/750 AM EDT Jul 14 AFDMFL: "Conditions become even drier on Wednesday as the SAL intensifies... POPs/Wx coverage drops to single digits for most coastal areas, and 20-30 percent for western interior areas." KMIA is a coastal east-metro station, east of the inland sea-breeze convergence. The 346 AM EDT ZFPMFL carries no PoP line at all for Wednesday in the SE Florida coastal zones ("WEDNESDAY...Sunny"), whereas Today and Friday-Monday carry explicit 40-60% chances — NWS drops the PoP wording below ~20%, so Wednesday is being forecast as essentially rain-free rather than merely low-chance. Physical support: Saharan Air Layer intensifying, PWATs 1.5-1.8", surface high, weak gradient. July climatology (~50% measurable days at KMIA) is strongly overridden by this specific 1-day-lead signal. I keep 8% for a stray sea-breeze cell drifting to the coast late day or an evening shower inside the CLI midnight-to-midnight window, plus the small chance the forecast busts. Gap: I did not read the Metro Miami-Dade zone paragraph verbatim, relying on the AFD's coastal characterization and adjacent coastal zones.

Consensus among panelists reinforces the core evidence: the Jul 14 0626 CDT KLOT AFD forecasts upper-90s at O'Hare for Tuesday and explicitly expects similar conditions ("peak values around 100 [heat index] today and Wednesday") into Wednesday July 15, with lake cooling confined to within 1-2 miles of shore (not reaching ORD) and no frontal/convective relief expected until Thursday. This is a strong, specific, near-term forecast for a ridge-driven heat event, so I weight ge90 as most likely (~65%), with residual probability on 80-89 (~30%) reflecting ordinary day-ahead forecast miss risk, and minimal probability on cooler outcomes.

I retain ge90 as the dominant outcome. The Jul 14 06:26 CDT KLOT AFD specifically places O'Hare among the locations with upper-90s readings in play under the ridge, describes similar air temperatures for the following hot day, and says lake cooling should be limited to the immediate shore. The 100-degree statement is for heat index rather than temperature, so I retain a nontrivial 80–89 F tail for temperature/mesoscale forecast error; cooler bins are very unlikely in this synoptic setup.

I raised ≥90 after the discussion surfaced an earlier LOT AFD explicitly calling Wednesday the hottest day of the week, with warmer low-level temperatures, stronger capping, and lake cooling confined to within a few miles of shore. O’Hare is well inland, and the later AFD separately put upper 90s in play at O’Hare Tuesday and expected similar air temperatures on Wednesday. The 7.7% 80s tail covers cloud/smoke debris, unexpectedly broader lake influence, or ordinary day-ahead forecast error; sub-80 outcomes would require a major unforecast disruption.

Two independent AFD cycles point to the same answer. The 1152 PM CDT Jul 13 KLOT AFD (D020) calls Wednesday July 15 "the hottest day of the week," with stronger capping, added evapotranspiration and warmer low-level temps, heat index peaking 100-105 and lake relief "confined to within only a few miles of shore." With forecast dew points low-to-mid 70s (mid-upper 60s in the urban core), a 100-105 heat index requires air temps near 92-96. Panelists 1-3 add the 0626 AM CDT Jul 14 AFD (day-1 lead), which puts "upper 90 degree readings" at the deeply-mixed urban corridor "including Midway and O'Hare" for Tuesday with similar air temperatures the following day, and keeps lake cooling within 1-2 miles of shore. That moved me up from 0.85: the central estimate is ~95-97, and a fresher, station-specific, day-1 statement is stronger evidence than my day-2 heat-index inference. For the 80-89 bin to verify, the forecast has to bust cool by roughly 6-8 F. Under a near-stationary 600 dam ridge with capping suppressing convection and no front advertised until Friday, day-1 MaxT errors at a major ASOS are typically 2-3 F; busts that large are a single-digit-percent event, driven mostly by unforecast cirrus/MCS debris or an early backdoor frontal push (the backdoor is mentioned only for Thursday). I hold 8% there. Below 80 requires a regime failure with no textual support: 1% combined. I take Panelist 2's caveat that the "confidence in peak values around 100" line is about heat index, not air temperature, which is why I stop at 0.91 rather than going higher. Remaining gap: I never saw an explicit MaxT digit for ORD on 7/15 in zone/grid text, only AFD prose.

KPHX mid-July normal high is ~106-107°F, and the 2026-07-14 AFD confirms a typical monsoon pattern with "seasonably hot temperatures" persisting through midweek, with no synoptic cooldown signal for 7/15. Even the wettest monsoon days at Sky Harbor rarely push max temps below the mid-90s; a sub-90 July max is essentially unprecedented in the modern record. Small residual mass to 80-89 accounts for tail risk of an exceptional widespread outflow/cloud event, with lt70/70-79 negligible.

I retain ge90 as effectively certain. The 14 July KPSR AFD forecasts worsening heat on Wednesday into Thursday, with 110–113°F highs in the western deserts, while placing the more impactful cloud/rain period on Thursday–Friday. The board also identifies the complete 13 July KPHX CLI maximum as 108°F despite 0.38 inch of rain and strong convection. Thus even a materially cooler-than-forecast Wednesday should remain far above 90°F; residual probability covers an exceptional unforecast daytime convective/cloud event.

KPHX’s July 13 complete CLI showed a 108°F maximum against a 107°F normal even with 0.38 inch of rain and a 53 mph convective gust. The latest AFD still calls for seasonably hot conditions through midweek, with the more favorable disturbance for widespread storms later in the week. A July 15 maximum below 90°F would therefore require an extraordinary roughly 18°F negative departure and unusually early/persistent convection; I retain only a very small freak-weather or first-report tail below 90.

KPHX mid-July normal high ~107 F; the 7/14 AFD forecasts a typical monsoon pattern with "seasonably hot temperatures" through midweek and 110-113 F western-desert highs Wed-Thu, with the heavier cloud/rain disturbance arriving Thu-Fri rather than on the 15th. The completed 7/13 CLI showed 108 F even with 0.38" rain and a 53 mph gust, demonstrating convection does not push Phoenix maxima near 90 F. Sub-90 July maxima are effectively absent from the modern KPHX record. ge90 = 0.99, with the small residual in the 80s for an implausible all-day washout; a missing value voids rather than resolves to a bin.

The most recent AFD (330 AM PDT Tue Jul 14 2026, D018) keeps an upper ridge over the region through Wednesday, explicitly stating "warm and dry conditions" with highs in the 80s, and assigns the shower/thunderstorm threat from the incoming upper low to "around Thursday," with onset "very late Wednesday night and Thursday morning." The contemporaneous Seattle zone forecast carries no PoP for Wednesday, calling it partly sunny becoming sunny. This means the target CLI day (July 15) is forecast to fall almost entirely within the dry ridge period, with the wet system's leading edge arriving at or after the day boundary. July is also climatologically Seattle's driest month, reinforcing a low base rate. I allow a modest residual probability for a faster-than-modeled onset (the AFD noted models had "a shaky start" on the incoming system) clipping precipitation into the July 15 reporting day before local midnight, but this is a narrow window and the panel discussion converged on similarly low wet probabilities (7-17%). I settle at 11% wet / 89% dry.

I retain the initial forecast. The latest pre-cutoff KSEW AFD kept high pressure, warm/dry conditions through Wednesday Jul 15 and deferred a shower/thunderstorm threat to Thursday; the corresponding Seattle zone forecast called Wednesday partly sunny then sunny. Thus KSEA’s first complete CLI for Jul 15 is very likely to show less than 0.01 inch. The 4% wet tail reflects an earlier-than-expected arrival or isolated precipitation, plus ordinary point-observation uncertainty.

Wednesday daytime is strongly forecast dry, but the latest Seattle zone forecast adds “a slight chance of rain after midnight” Wednesday night, and the AFD says the low begins moving inland very late Wednesday night before widespread Thursday rainfall. Because SEA’s complete CLI timing is consistent with a midnight-LST cutoff (about 1 AM PDT in summer), only a narrow part of that onset window can count toward the July 15 reporting day. I raise wet from 2% to 4% for this explicit overlap, while keeping dry overwhelmingly favored.

No new evidence emerged in discussion; all four panelists worked from the same two documents. The 330 AM PDT Tue Jul 14 AFDSEW keeps the upper ridge in place "today and again Wednesday," with lower-to-mid 80s and 50-80% Moderate HeatRisk probabilities along the Seattle-Tacoma corridor — the target day is a hot ridge day, not a marginal one. The coastal upper low "will begin to move inland very late Wednesday night and Thursday morning," and the widespread rain plus 15-25% thunder probabilities are assigned to Thursday afternoon/evening. The 236 AM Tue Seattle zone forecast carries Wednesday as partly sunny then sunny with no PoP, which in NWS practice means below 20% and effectively zero here. The only route to wet is the CLI climate day running midnight-to-midnight LST (1 AM PDT to 1 AM PDT), catching about one hour past local midnight, combined with a faster onset than forecast. The AFD's "shaky start" caveat concerns model disagreement on convection on Thursday, not an argument for earlier arrival, so I do not inflate that tail the way a 10-17% figure would. A trace also fails to resolve wet, which further trims the probability. I stay at 7% wet, and would only move if a later product showed Wednesday-night PoPs at SeaTac.